

WO 03/068169

PCT/US03/04711

Stabilized Synthetic Immunogen Delivery Systems

FIELD OF THE INVENTION

[0001] The present invention relates to a stabilized immunostimulatory complex and a method for preparing the stabilized immunostimulatory complex. More specifically, the present invention provides stabilized synthetic immunostimulatory complexes that are useful in vaccine delivery systems with improved immune responses *in vivo*. These immunostimulatory complexes are also useful for preparing vaccine formulations designed to function as a depot for controlled release of the immunostimulatory complex. The immunostimulatory complex may also be incorporated in formulations designed to target specific cell types to synergistically improve the quality of the immune responses elicited.

BACKGROUND OF THE INVENTION

[0002] Vaccines have been successfully employed for many years in prophylactic compositions for the prevention of infectious disease and more recently in therapeutic compositions for the treatment of cancers and non-infectious diseases.

[0003] Traditionally vaccines have been derived from attenuated or killed viral or bacterial pathogens and have proven to be very effective against diseases such as polio virus and *Bordetella pertussis*. In spite of these successes, there are growing concerns over the safety of such vaccines. This has led to the development of subunit vaccines derived from components of these pathogens or fully synthetic peptide immunogens.

[0004] Examples of subunit vaccines include Tetanus toxoid and hepatitis B surface antigen. These antigens are often poorly

WO 03/068169

PCT/US03/04711

immunogenic and require adjuvants to improve the immune responses obtained. Well-characterized biologically active compounds such as synthetic peptides are preferred substrates for inducing biological responses, for safety and regulatory purposes. However, these immunogens are not optimal, and induce partial or negligible protective responses in animal models. The synthetic peptides require both stabilization and adjuvantation for the induction of an effective immune response *in vivo*.

[0005] Various methods have been employed to protect synthetic peptide immunogens against degradation *in vitro* and *in vivo*, mediated by various processes including chemical and physical pathways.¹ (The superscript numbers refers to publications, which more fully describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference. The citation of each reference is found at the end of this section).

[0006] Various methods have been employed to improve peptide solubility or protect a peptide against degradation *in vivo*.² These generally include simple procedures like modifying the salt concentration and/or the pH of the solution. Peptides have also been chemically modified by conjugation with water soluble compounds like polyethylene glycol (PEG) or polyethylene oxide (PEO) both to improve their aqueous solubility and circulation time *in vivo*.³ It has been documented that adjuvants derived from PEG or PEO can down regulate the immune system.⁴ Thus, PEG or PEO modified peptides would not be expected to function effectively as adjuvants. The addition of multiple lysines to add charge to a peptide can improve its aqueous solubility but does not generally result in improved immunogenicity.

[0007] The objective of these various strategies is to improve circulation time *in vivo* or minimize or eliminate

WO 03/068169

PCT/US03/04711

immunogenicity problems associated with the physical conditions (e.g. salt, pH, temperature, buffer type) and/or chemical incompatibilities when peptides are employed in a vaccine formulation.

[0008] Polyether block copolymers, comprising polycationic polymers, were disclosed by Kabanov et al., U.S. Patent No. 5,656,611⁵ for stabilizing polynucleotides or oligonucleotides.

The polyether block copolymer-polynucleotide complexes are employed to facilitate the transport of the polynucleotide across a cell membrane for improved biological activity. However, these polynucleotide-polyether block copolymers are not immunogenic and are not suitable as vaccines.

[0009] Allcock et al. US patent No. 5,562,909⁶ describes an immunoadjuvant derived from phosphazene polyelectrolytes. The immunoadjuvant was admixed directly with an antigen in solution and may be prepared as microparticles by spray drying a solution of the polymer and the antigen or by a process described by Cohen in US patent No. 5,149,543.⁷ Although, increased adjuvanticity was shown for these systems, there are difficulties in preparing the microparticulate compositions due to the cumbersome mechanical processes employed, which would be difficult to scale up for commercial production. Furthermore, the stability of the polymer-antigen complex so formed is highly dependent on salt concentration and pH conditions.

[0010] A different approach is described in Moss et al. WO91/04052⁸, wherein a solid vaccine composition is prepared from an antigen, which may be a peptide, a saponin and a polycationic adjuvant such as DEAE-dextran. Vaccines formulated from this combination provided improved longevity, making such combinations suitable for use as implants. However, the antigen must first be chemically conjugated to a carrier molecule and exhaustively purified. The purified

WO 03/068169

PCT/US03/04711

antigen-carrier was then combined with a saponin and a polycationic adjuvant to provide a solid composition. This process provides no control over the physical properties, such as particle size, of the product.

[0011] Numerous adjuvants and/or depot-based parenteral, mucosal or transdermal delivery systems destined for use with human or veterinary vaccines have been developed to enhance the immune response. These include the use of mineral salts, water-in-oil (w/o)-emulsions, liposomes, polymeric microparticles, nanoparticles and gels/hydrogels.⁹ A large number of clinical trials employing various (w/o)-emulsion compositions have been conducted.

[0012] In spite of this vast body of clinical research, typical parenteral formulations, administered subcutaneously or intramuscularly, are prepared with adjuvants derived from aluminum salts, such as aluminum phosphate or aluminum hydroxide. Alum salts are suitable and effective for many vaccines based on attenuated pathogens, killed pathogens and subunit antigens derived from biological agents. However, the aluminum-based adjuvants are often totally ineffective for synthetic peptide-based immunogens because of the large dose of peptide required and the need of much stronger adjuvantation. The combination of a large dose of immunogen with a weakly adjuvanting alum in a vaccine composition is not ideal as it can lead to immunogen tolerance and reactogenicity, i.e., undesired side reactions, such as swelling and redness at the site of injection.

[0013] Freund's complete adjuvant (FCA), a suspension of heat-killed *M. tuberculosis* mycobacteria in mineral oil containing a surfactant, has been recognized as one of the most powerful adjuvants. However, severe adverse reactions, ranging from minor irritation to lesions and sterile abscesses at the site of injection have been documented. Due to these adverse

WO 03/068169

PCT/US03/04711

reactions, FCA has been banned from human and veterinary applications.

[0014] Thus, there is a clear need to develop adjuvants which are safe without the toxicological and/or reactogenic problems associated with alum or FCA and can effectively enhance immunogenicity and prolong the effectiveness of peptide immunogens to avoid the problem of tolerance associated with alum. It is also most desirable to develop compositions and methods, which can both, stabilize a peptide immunogen and adjuvant the immune responses in a single composition.

[0015] Jones et al.¹⁰ have disclosed two specific CpG oligonucleotides that may be co-administered with a peptide-based malaria vaccine in Aotus monkeys to enhance immune responses. In the Jones study, the ionization point (IP) of the peptide used is 5.96. This corresponds to the pH at which the peptide will have a theoretical zero charge.¹¹ By virtue of its amino acid composition, the peptide used would be effectively uncharged at physiological pH in the aqueous solvent selected. Thus, no complexation can take place with the two CpG oligomers. The resultant mixture when formulated in a w/o-emulsion is expected to be transiently adjuvanted. To achieve a useful level of immunogenicity, multiple injections and a large quantity of adjuvant would be required.

Further, the long-term stability of such a composition is questionable. In fact, Jones et al. disclosed that it was necessary to employ a large dose of CpG oligonucleotide, 500 µg per injection. Furthermore, the methods, employed to prepare the w/o-emulsions, cannot be easily scaled up for commercial applications. It is to be noted that Jones et al. taught that different CpG oligomers are useful for different mammalian species. For example, a CpG oligomer, CpG ODN 1826 is mitogenic for mice and a lower primate, but not for chimpanzees or humans and the effect is not predictable.

WO 03/068169

PCT/US03/04711

[0016] Krieg et al., U.S. patent No. 6,194,388 B1¹² describes unmethylated CpG oligonucleotides particularly useful for therapeutic applications based on their ability to stimulate immune responses when mixed with an antigen. Krieg et al., US 6,207,646 B1¹³ further describes the use of unmethylated CpG oligonucleotides to redirect a Th2 response to a Th1 response.

In both, the effectiveness of the CpG oligomers were shown by B-cell stimulation wherein B-cells were cultured with phosphorothioate modified CpG oligomers. There is no disclosure or suggestion on how the CpG oligomers can be used to provide a stabilized immunostimulatory complex or a vaccine.

[0017] Another area of intense interest and research has been focused on methods to formulate synthetic immunogens for alternate delivery routes, such as mucosally, transdermally, or orally. Mucosal immunity is mediated by the induction of secretory immunoglobulin (sIgA) found in external secretions (e.g., intestinal, bronchial or nasal washings). It is believed that transdermal or mucosal delivery of vaccines would be effective against a majority of pathogenic organisms, which gain entry via mucosal surfaces. For example, an orally administered cholera vaccine has been shown to be far superior to the parenterally administered analog.¹⁴

[0018] Friede et al., WO99/52549¹⁵ teaches that vaccine compositions intended for mucosal use can be derived from a combination of an antigen with a polyoxyethylene ether or polyoxyethylene ester as the primary adjuvant. It was suggested that the target antigen might be a synthetic peptide. Friede et al. also suggests the addition of CpG oligonucleotides into the vaccine composition to provide improved responses. They showed that a combination of a polyoxyethylene ether or polyoxyethylene ester with a CpG oligonucleotide could improve mucosal responses when co-

WO 03/068169

PCT/US03/04711

administered with an antigen. However, the results showed a lack of any adjuvanticity from simple mixtures of CpG oligonucleotides with antigen described.

[0019] Transdermally administered vaccines represent an area of recent interest. Ideally, devices, i.e., patches or needle-free jet injectors can be employed to target the intradermal Langerhan cells, i.e., dendritic cells. These specialized cells are responsible for the effective processing and presentation of an immunogen and can be used to directly induce systemic humoral and cellular responses. In some cases, intramuscular immunization was achieved by transdermal methods.¹⁶ For example, a recent paper described a diphtheria vaccine administered as a patch. Systemic antibodies to diphtheria toxoid were found for a variety of compositions when co-administered with adjuvants.¹⁷

[0020] Although the prior art has illustrated the potential of various vaccine formulations, there are a number of practical limitations for the development of synthetic peptide-based vaccine formulations for mucosal or transdermal delivery. These include:

- 1) immunogen degradation by mucosal fluids or secretions and/or proteolytic enzymes at the mucosal surface or within the intradermis;
- 2) negligible adsorption across the mucosal epithelium or through the intradermal layers; and
- 3) dilution of the immunogen to a concentration below that required to induce a suitable level of immune responses.

[0021] Few strategies exist which both stabilize and adjuvant a synthetic peptide-based immunogen in a single vaccine composition. Such a composition would be essential for the

WO 03/068169

PCT/US03/04711

development of highly efficacious parenteral, mucosal or transdermal peptide-based vaccines.

[0022] It is also desirable to prolong the duration of immunogenic responses in order to reduce the number of administrations required. This would result in improved compliance and reduce the overall cost for vaccination.

[0023] Various methods may be employed to adjuvant synthetic peptide-based immunogens, but normally a carrier or depot system is required for effective long-term immunogenic responses. Notable examples include adsorbing the immunogen onto a mineral salt or gel. For example, encapsulating a peptide immunogen within a polymeric matrix (monolithic matrix) or gel, or layering a polymeric material around a peptide immunogen (core-shell) may be an effective strategy. Or, an immunogen may be incorporated in a liposome or vesicular type of formulation, with the immunogen either embedded in the lipid matrix or physically entrapped in the internal aqueous phase. Another strategy may employ a mineral-based, vegetable-based or animal-based oil, with an aqueous solution of the immunogen in various proportions, to prepare a water-in-oil (w/o)-emulsion or a water-in-oil-in-water (w/o/w)-double emulsion¹⁸.

[0024] Diverse particle sizes, morphologies, surface hydrophobicity and residual surface charge are possible formulation dependent variables for consideration. Control of these parameters is known to be important for the phagocytosis of micron-sized particulates via parenteral administration^{19, 20} and for the uptake of particulates at specialized M-cells of the Peyer's Patches within the intestinal tract^{21, 22} for oral delivery. Similarly, these parameters have been shown to be important for access to the nasal-associated lymphoid tissue of the nasopharyngeal tract, a target of intranasal delivery.^{23, 24}

WO 03/068169

PCT/US03/04711

[0025] Krone et al., U.S. Patent No. 5,700,459²⁵ describes the use of polyelectrolyte complexes in microparticulate form derived from polyacids and polybases, in which the complexing agent is a polymer. Various uses for these complexes are described and include vaccine compositions comprising antigens or antigenic peptides. Some of the compositions are controlled release formulations employing potentially biodegradable materials. In one of the examples, a method of incorporating an antigen in polyelectrolyte complex microparticles is described. However, the mechanical process described for preparing microparticles by grinding the mixture of 100 μM size particles to about 1-4 μM , is cumbersome. This would not be easily scaled up for commercial production.

[0026] Eldridge et al.²⁶ developed polymeric biodegradable microspheres manufactured from poly-D,L-lactide-co-glycolide copolymers for the controlled release of an antigen *in vivo*. The polymers disclosed to be useful for encapsulating an antigen into microparticles include poly-D,L-lactide, polyglycolide, polycaprolactone, polyanhydrides, polyorthoesters and poly(α -hydroxybutyric acid).

[0027] Although the controlled release of an antigen was achieved in the prior art, difficulties were encountered when microparticles were manufactured by methods described. The methods described are difficult to scale-up. Moreover, the exposure of biological materials to organic solvents and mechanical processing can lead to denaturation and low to modest encapsulation efficiencies. Furthermore, hydrophilic antigens are inefficiently encapsulated in the processes described.

[0028] Henry, et al., U.S. Pat. Nos. 5,126,141 and 5,135,751^{27, 28} described aqueous, thermally reversible gel compositions formed from a polyoxyalkylene polymer and an ionic polysaccharide for application to injured areas of the body to

WO 03/068169

PCT/US03/04711

prevent adhesion. Rosenberg, et al., WO93/01286²⁹ described the use of the same type of polyoxyalkylene polymers for the local delivery of antisense oligonucleotides to surgically exposed surface of blood vessels for treatment of restenosis.

Neither Henry et al. nor Rosenberg et al. taught or suggest the use of a gel composition as a vaccine.

[0029] Dunn et al., U.S. Patent Nos. 4,938,763 and 5,702,716³⁰,³¹ describe polymeric compositions useful for the controlled release of biologically active materials. A biocompatible solvent was used to prepare solutions or suspensions of antigen for direct parenteral injection, whereupon *in-situ* gelling results in implant formation. Utility for a variety of antigens including small synthetic peptide-based immunogens was claimed. However, Dunn et al., US 5,702,716³¹, stated that the controlled release compositions require up to 15% by weight of a gel rate-retarding agent. The retarding agents were added to modulate the gelling rate and were needed for higher entrapment efficiencies for antigens, which are easily extracted *in vivo*. As the solvent extraction is governed largely by diffusion, this presents more of a problem for small synthetic immunogens than for larger sub-unit or protein-based antigens.

[0030] Neither US 4,938,763³⁰ nor US 5,702,716³¹ taught nor suggested synthetic peptide-based immunogen stabilized as an immunostimulatory complex suspended within a biocompatible solvent. Furthermore, neither US 4,938,763³⁰ nor US 5,702,716³¹ taught nor suggested compositions which are self-adjuvanting and can upregulate immune responses in both the priming and boosting phases.

[0031] It is an object of this invention to develop stable immunostimulatory complexes from synthetic peptide immunogens and stabilizing molecules, which possess self-adjuvanting properties *in vivo*. It is a further object of the present

WO 03/068169

PCT/US03/04711

invention to provide a simple method to stabilize a synthetic peptide immunogen *in vitro* and *in vivo*.

[0032] It is a still further object of the present invention to provide sustained or controlled release delivery vehicles compatible with these stabilized synthetic peptide-based immunostimulatory complexes.

[0033] It is a still further object of the invention to develop formulations using a combination of stabilized synthetic peptide-based immunostimulatory complexes and uncomplexed immunogens in a controlled release delivery system to achieve a synergistic enhancement of the immune response including protective responses.

References Cited

1. Manning MC, et al. Pharmaceutical Research, 1989, 6:903-918.
2. Monfardini C, et al., Bioconjugate Chem., 1998, 9:418-450.
3. Roberts MJ, et al., J Pharm Sci, 1998, 87:1440-1445.
4. Hilbert AK, et al., Vaccine, 1999, 17:1065-1073.
5. Kabanov AV, et al., U.S. 5,656,611, 1997.
6. Allcock HR, et al., U.S. Patent No. 5,562,909, 1996.
7. Cohen S, et al., U.S. Patent No. 5,149,543, 1992.
8. Moss BA, et al., WO 91/04052, 1991.
9. Cox JC, et al. Vaccine, 1997, 15:248-256.
10. Jones TR, et al., Vaccine, 1999, 17:3065-3071.
11. Bjellqvist B, et al., Electrophoresis, 1993, 14:1023-1031.
12. Kreig AM, et al., U.S. Patent No. 6,194,388 B1, 2001.
13. Kreig AM, et al., US Patent No. 6,207,646 B1, 2001.

WO 03/068169

PCT/US03/04711

14. Suharyono, et al. Lancet, 1992, 340:689-694.
15. Freide M, Hermand P., WO 99/52549, 1999.
16. Aguiar JC, et al. Vaccine, 2002, 20:275-280.
17. Scharton-Kersten T, et al. Infect Immun, 2000, 68:5306-5313.
18. Powell MF, et al., Pharmaceutical Biotechnology, Vol. 6, Plenum Press, New York, 1995.
19. Ikada Y, et al., J Bioactive Compat Polym, 1986, 1:32-46.
20. Kreuter J, et al. Vaccine, 1986, 4:125-129.
21. Jepson MA, et al. J Drug Targeting, 1993, 1:245-249.
22. Moldoveanu Z, et al., J Infect Dis, 1993, 167:84-90.
23. Matsuo K, et al. Vaccine, 2000, 18:1344-1350.
24. Higaki M, et al., Vaccine, 1998, 16:741-745.
25. Krone V, et al., U.S. Patent No. 5,700,459, 1997.
26. Eldridge JH, et al., Mol Immunol, 1991, 28:287-297.
27. Henry RL, U.S. Patent No. 5,126,141, 1992.
28. Henry RL, U.S. Patent No. 5,135,751, 1992.
29. Rosenberg RD, et al., WP 93/01286, 1993.
30. Dunn RL, et al., U.S. Patent No. 4,938,763, 1990.
31. Dunn RL, et al., U.S. Patent No. 5,702,716, 1997.
32. Papisov IM, et al., Advances in Polymer Science, 1988, 90, 1988,139-177.
33. Chu RS, et al., J Exp Med, 1997, 186:1623-1631.
34. Akasaka T, et al., Bioconjugate Chem., 2001, 12:776-785.
35. Ballico M, et al., Bioconjug Chem, 2001, 12:719-725.
36. Klinman DM, et al., Vaccine, 1999, 17:19-25.

WO 03/068169

PCT/US03/04711

37. Krieg AM, et al., Nature 1995, 374:546-549.
38. Klinman DM, et al., Infect Immun, 1999, 67:5658-5663.
39. Nagel KM, et al., Pharmacotherapy, 1993, 13:177-188.
40. Weeratna RD, et al., Vaccine, 2000, 18:1755-1762.
41. McCluskie MJ, et al., Vaccine, 2000, 18:231-237.
42. LiCalsi C, et al., Vaccine, 1999, 17:1796-1803.
43. Romera SA, et al., Vaccine, 2001, 19:132-141.
44. Wright JC, et al., J Controlled Release, 2001, 75:1-10.
45. Graham PD, et al., J Controlled Release, 1999, 58:233-245.
46. DesNoyer JR, et al., J Controlled Release, 2001, 70:285-294.
47. Aguado MT, et al., Immunobiol, 1992, 184:113-125.
48. Visscher GE, et al., J Biomed Mater Res, 1985, 19:349-365.
49. Forbes RT, et al., J Pharm Sci, 1998, 87:13161321.
50. Overcashier DE, et al., J Pharm Sci, 1999, 88:688-695.
51. Wang CY, et al., WO 99/67293, 1999.
52. Wang CY, U.S. Patent No. 5,763,160, 1998.
53. Wang CY, U.S. Patent No. 6,090,388, 2000.
54. Ladd AE, et al., U.S. Patent No. 5,759,551, 1998.
55. Wang CY, U.S. 6,025,468, 2000.
56. Wang CY, USSN 09/865,294, 2001.
57. Wang CY, et al., U.S. Patent No. 6,107,021, 2000.
58. Wang CY, USSN 09/747802, 2001.
59. Wang CY, WO 99/66957, 1999.

WO 03/068169

PCT/US03/04711

60. Wang CY, WO 99/66950, 1999.
61. Mascotti DP, et al., Proc Nat Acad Sci, USA, 1990, 87:3142-3146.
62. Kabanov AV, et al., Bioconjug Chem, 1995, 6:7-20.
63. MacDonald RC, et al., Biochim Biophys Acta, 1991, 1061:297-303.
64. Shen F, et al., Vaccine, 1999, 17:3039-3049.
65. Wang CY, et al., Proc. Nat. Acad. Sci., USA, 1999, 96:10367-10372.
66. Hanson CV, et al., J. Clin Microbiol, 1990, 28:2030-2034.
67. Park TG, et al., J Controlled Release, 1995, 33:211-222.
68. www.expasy.ch/tools/pi_tool.html
69. Hakim, I, et al. J Immunol, 1996, 157:5503-5511.
70. Zeng, XY, et al., Theriogenology, 2002, 58:1315-1326.
71. Office International des epizooties (OIE). Foot-in-mouth disease. Manual of standards for diagnostic tests and vaccines. Paris(France): OIE, 1996, p. 47-56 [chapter 2.1.1]
72. Proietti, E, et al., J. of Immunol, 2002, 375-383.

SUMMARY OF THE INVENTION

[0034] The present invention is directed to a stabilized immunostimulatory complex comprising a cationic peptide and anionic molecule or oligonucleotide or polynucleotide and a method for stabilizing a cationic peptide by complexation with an anionic molecule or oligonucleotide or polynucleotide via electrostatic association. The stabilized immunostimulatory complex may be incorporated into a pharmaceutical composition as an immunogen delivery system.

[0035] A "cationic peptide" as described herein refers to a peptide, which is positively charged at a pH in the range of 5.0 to 8.0. The net charge on the peptide or peptide cocktails is calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a -1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for the other amino acid within the sequence. The charge contributions from the N-terminal amine (+1) and C-terminal carboxylate (-1) end groups of each peptide effectively cancel each other when unsubstituted. The charges are summed for each peptide and expressed as the net average charge. A suitable peptide immunogen has a net average positive charge of +1. Preferably, the peptide immunogen has a net positive charge in the range that is larger than +2.

[0035a] In a first aspect of the present invention, there is provided a stabilized immunostimulatory complex comprising a cationic peptide immunogen and anionic CpG oligonucleotide wherein the cationic peptide immunogen has a net positive charge at a pH in the range of 5.0 to 8.0 calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a -1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for all other amino acids in the peptide immunogen and wherein the anionic CpG oligonucleotide has a net negative charge at a pH in the range of 5.0-8.0 and is a single-stranded DNA comprising 8 to 64 nucleotide bases with a repeat of a cytosine-guanidine motif and the number of repeats of the CpG motif is in the range of 1 to 10.

[0036] The peptide immunogens comprise B-cell epitopes and Th epitopes. The Th epitopes may be intrinsic to the peptide or added thereto as described in the prior art. Suitable peptide immunogens are described herein below.

[0037] An "anionic molecule" as described herein refers to molecules, which are negatively charged at a pH in the range of 5.0-8.0. The net negative charge on the oligomer or polymer is calculated by assigning a -1 charge for each

phosphodiester or phosphorothioate group in the oligomer. A suitable anionic oligonucleotide is a single-stranded DNA molecule with 8 to 64 nucleotide bases, with the number of repeats of the CpG motif in the range of 1 to 10. Preferably, the CpG immunostimulatory single-stranded DNA molecules contain 18-48 nucleotide bases, with the number of repeats of CpG motif in the range of 3 to 8.

[0038] More preferably the anionic oligonucleotide is represented by the formula: 5' X¹CGX² 3' wherein C and G are unmethylated; and X¹ is selected from the group consisting of A (adenine), G (guanine) and T (thymine); and X² is C (cytosine)

WO 03/068169

PCT/US03/04711

or T (thymine). Or, the anionic oligonucleotide is represented by the formula: 5' (X³)₂CG(X⁴)₂ 3' wherein C and G are unmethylated; and X³ is selected from the group consisting of A, T or G; and X⁴ is C or T.

[0039] Most preferably, the CpG oligonucleotide is selected from a group consisting of 5' TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3' (CpG1) SEQ ID NO: 1, a 32 base length oligomer, and 5'nTC GTC GTT TTG TCG TTT TGT CGT T 3' (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus a phosphorothioate group (designated as n at the 5' end).

[0040] The resulting immunostimulatory complex is in the form of particles with a size typically in the range from 1-50 microns and is a function of many factors including the relative charge stoichiometry and molecular weight of the interacting species.³² The particulated immunostimulatory complex has the added advantage of providing adjuvantation and upregulation of specific immune responses *in vivo*. Additionally, the stabilized immunostimulatory complex is suitable for preparing vaccine formulations by various processes including water-in-oil emulsions, mineral salt suspensions and polymeric gels.

[0041] The term "stabilize" as used herein may be accomplished by the use of any material, which protects the synthetic peptide immunogen against degradation *in vitro* or *in vivo*. This may be accomplished by virtue of chemical modification and/or physical association. A stabilizer may augment the physiological properties of a synthetic peptide immunogen, an oligosaccharide-modified glycopeptide or a lipidated peptide to provide a more efficacious formulation.

[0042] The term "adjuvant" as described herein refers to any material, which can enhance or upregulate the immune responses

elicited by an immunogen in humans or animals. The adjuvant itself may or may not induce an immunogenic response.

[0043] The stabilizer may also preferably function in a vaccine as an adjuvant, effectively upregulating the immune responses. The stabilizer may act as an adjuvant by actively facilitating the presentation of the immunogen to professional processing cells of the immune system, such as macrophages and dendritic cells. In the present invention, the stabilized immunostimulatory complex ideally remains as an integral unit in solution when administered.

[0044] The stabilized immunostimulatory complex may also be formulated for controlled release and remains as a complex in a concentrated form in a "depot" near the site of administration. These formulations synergistically combine the benefits of a stabilized adjuvanted immunogen coupled with a sustained local release of immunogen to immune effector cells. In some compositions the role of the adjuvant itself may also involve attracting cells of the immune system to the vicinity of the immunogen depot and stimulate such cells to elicit an immune response.

[0044a] In a second aspect of the present invention, there is provided a process for preparing a stabilized immunostimulatory complex as defined above comprising the steps of: (a) dissolving or dispersing the cationic peptide immunogen in an aqueous phase selected from the group consisting of distilled deionized water, saline, PBS and a mixture thereof with the proviso that the pH of the aqueous phase is lower than the ionization point of the peptide immunogen; (b) dissolving the anionic CpG oligonucleotide in an aqueous phase selected from the group consisting of distilled deionized water, saline, PBS and a mixture thereof; (c) adding the CpG oligonucleotide in the aqueous phase dropwise to the solution or dispersion of the cationic peptide immunogen in an amount to form a stabilized immunostimulatory complex of the peptide immunogen and the CpG oligonucleotide in a charge ratio of the cationic immunogen peptide to the CpG oligonucleotide in the range of 16:1 to 1:1.

[0045] An embodiment may relate to a method for preparing a vaccine composition containing an immunostimulatory complex. In a preferred embodiment the immunostimulatory complex has the added advantage of being a stabilized synthetic peptide-based immunogen *in vitro* and at the same time is self-adjuvanting with upregulation of specific immune responses *in vivo*.

[0045a] In third aspect of this invention, there is provided a process for preparing a water-in-oil emulsion comprising an immunostimulatory complex as defined above, comprising the steps of: (a) preparing an immunostimulatory complex in aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline; (b) adding the immunostimulatory complex in the aqueous phase into a continuous oil phase selected from the group consisting of a synthetic oil, a vegetable oil, a mineral oil, a metabolizable animal oil and a mixture thereof; (c) dispersing under mechanical shear the immunostimulatory complex in the aqueous phase into the continuous oil phase to form a homogeneous water-in-oil emulsion.

[0046] Another embodiment may relate to a method for preparing a vaccine composition from the immunostimulatory complex. The immunostimulatory complex or a mixture of the immunostimulatory complex with the uncomplexed immunogen may be formulated as a suspension in solution, a water-in-oil emulsion, a suspension in combination with a

mineral salt suspension or a reconstituted suspension in a biocompatible solution. The immunostimulatory complex alone or in a mixture with uncomplexed immunogens may also be co-formulated in a biocompatible solvent in a polymeric gel.

[0046a] In a fourth aspect of this invention, there is provided a process for preparing a suspension comprising an immunostimulatory complex comprising the steps of: (a) preparing an immunostimulatory complex as defined above in an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline; (b) preparing a suspension of a mineral salt selected from the group consisting of aluminum hydroxide, aluminum phosphate, and calcium phosphate, in an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline; (c) adding the immunostimulatory complex in the aqueous phase into an aqueous phase containing the mineral salt suspension; (d) mixing the immunostimulatory complex with the mineral salt suspension to form a mixed suspension.

[0046b] In a fifth aspect of the present invention, there is provided a process for preparing a suspension comprising an immunostimulatory complex comprising the steps of: (a) preparing a solution of a peptide immunogen selected from the group consisting of SEQ ID NOs: 3-13 in an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline; (b) preparing a suspension of a mineral salt selected from the group consisting of aluminum hydroxide, aluminum phosphate and calcium phosphate in an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline; (c) adding the peptide solution to the suspension of the mineral salt with mixing; (d) adding a CpG nucleotide selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2 with mixing to form a mixed suspension of an immunostimulatory complex and a mineral salt.

[0046c] In a sixth aspect of the present invention, there is provided a pharmaceutical composition comprising a suspension of an immunostimulatory complex as defined above in an aqueous solvent selected from the group consisting of distilled deionized water, saline and phosphate buffered saline.

[0046d] In a seventh aspect of the present invention, there is provided a pharmaceutical composition comprising a gel of an immunostimulatory complex as defined above wherein the gel is formed *in situ* by adding the immunostimulatory complex in dried form to a solution of an *in-situ* gelling biocompatible polymer selected from the group consisting of poly-D,L-lactide-coglycolide copolymer, poly-D,L-lactic acid-co-glycolic acid copolymer, polycaprolactone, polyanhydride, polyorthoester, and poly(α -hydroxybutyric acid) in a biocompatible solvent selected from the group consisting of dimethyl sulfoxide (DMSO), N-methyl pyrrolidine (NMP), triacetin and glycerin.

[0046e] In an eighth aspect of the present invention, there is provided a pharmaceutical composition comprising an aqueous suspension of a mineral salt and an immunostimulatory complex as defined above wherein the mineral salt is selected from group consisting of aluminum hydroxide, aluminum phosphate, aluminum sulphate, calcium phosphate.

[0047] This invention is further directed to the production of useful immunogen delivery systems for administration by various routes, including parenteral, oral, intranasal, rectal, buccal, vaginal and transdermal routes.

BRIEF DESCRIPTION OF THE DRAWINGS

[0048] The present invention is further understood with

reference to the drawings.

[0049] Figure 1 is a schematic showing the complexation process of cationic peptide immunogens and CpG oligonucleotides.

[0050] Figure 2 shows the typical size distribution for the stabilized immunostimulatory complexes prepared from LHRH peptide immunogens and CpG oligonucleotides in various proportions as determined by laser diffraction measurements.

[0051] Figure 3 is a schematic of the process for preparing a water-in-oil (w/o) emulsion employing homogenization or extrusion techniques.

[0052] Figure 4 shows a typical photomicrograph for a w/o emulsion prepared via homogenization from ISA Montanide® 51 and LHRH:CpG immunostimulatory complexes, wherein LHRH:CpG is 4:1 at a fixed final total peptide concentration of 100 µg/mL.

[0053] Figure 5 shows a typical photomicrograph for a w/o emulsion prepared via extrusion from ISA Montanide® 720 and LHRH:CpG immunostimulatory complexes, wherein LHRH:CpG is 4:1, at a fixed final LHRH peptide concentration of 200 µg/mL.

WO 03/068169

PCT/US03/04711

[0054] Figure 6 is a schematic detailing the *in-situ* polymer gel process employing reconstitution.

[0055] Figure 7 shows the serum IgG responses in guinea pigs immunized intramuscularly (I.M.) in accordance with the immunization protocols described in Example 7.

[0056] Figure 8 shows the serum IgG responses in guinea pigs immunized intramuscularly (I.M.) in accordance with the immunization protocols described in Example 7. No sera were obtained for the animals immunized with the immunostimulatory complex derived from CD4 peptides and CpG2 on week 17. This is indicated by an asterisk in Figure 8.

[0057] Figure 9 shows the serum IgG responses in guinea pigs immunized intramuscularly (I.M.) in accordance with the immunization protocols described in Example 7.

[0058] Figure 10 shows the serum IgG responses in guinea pigs immunized intramuscularly (I.M.) in accordance with the immunization protocols described in Example 7. No sera were obtained for the animals immunized with the immunostimulatory complex derived from CD4 peptides and CpG2 on week 17. This is indicated by an asterisk in Figure 10.

[0059] Figure 11 shows the serum IgG responses in guinea pigs immunized intramuscularly (I.M.) in accordance with the immunization protocols described in Example 8.

[0060] Figure 12 shows the serum IgG responses in guinea pigs immunized intramuscularly (I.M.) in accordance with the immunization protocols described in Example 8.

[0061] Figure 13a shows the serum IgG responses and 13b shows the total serum testosterone in male rats immunized intramuscularly (I.M.) in accordance with immunization protocols as described in Example 10.

WO 03/068169

PCT/US03/04711

[0062] Figure 14a shows the serum IgG responses and 14b and 14c shows the total serum testosterone in male baboons immunized intramuscularly (I.M.) in accordance with immunization protocols as described in Example 11.

[0063] Figure 15a shows the serum IgG response, 15b shows the total serum testosterone and 15c shows the average weight gain per group in boars immunized intramuscularly (I.M.) over the trial period in accordance with immunization protocols as described in Example 13.

[0064] Figure 16 is a schematic detailing the process of preparing a mixed suspension of immunostimulatory complex and a mineral salt.

DETAILED DESCRIPTION OF THE INVENTION

[0065] In accordance with a first aspect of the invention, a cationic peptide immunogen is complexed with an anionic single-stranded DNA to form a stable immunostimulatory complex.

[0066] The cationic peptide immunogen is a peptide with a net positive charge at a pH in a range of 5.0 to 8.0. The net charge on the peptide or peptide cocktails is calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a -1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for the other amino acids in the sequence. The charge contributions from the N-terminal amine (+1) and C-terminal carboxylate (-1) end groups of each peptide effectively cancel each other when unsubstituted. The charges are summed for each peptide and expressed as the net average charge. Preferably, the net average charge of the peptide immunogen is at least +2.

[0067] The cationic peptide immunogen may intrinsically have a net positive charge as calculated above based on its amino acid sequence. It may be made to have a positive charge by

WO 03/068169

PCT/US03/04711

the addition of a lysine, an arginine or a histidine or a mixture of these amino acids to the N-terminal or C-terminal of the peptide immunogen. Other synthetic moieties, such as polyethyleneimine or polyamines, which provide a positive charge to the peptide immunogen in aqueous solution, may also be added.

[0068] The cationic peptide immunogen comprises a Th epitope and a target B-cell epitope. The Th epitope may be intrinsic to the peptide or may be synthetically added to a peptide, which functions as a target B-cell epitope. Suitable peptide immunogens include peptides that elicit protective or therapeutic immune responses and are derived from pathogens or proteins known to cause diseases. These include: human or animal IgE peptides for the immunotherapy of allergies, e.g., the IgE peptide immunogens described in WO 99/67293⁵¹; HIV peptides for protective immunity and immunotherapy for HIV infection described in US 5,763,160⁵²; CD4 peptides for protective immunity from HIV and immunotherapy of HIV infection and immune disorders described in US 6,090,388⁵³; Luteinizing Hormone Releasing Hormone (LHRH) peptides for immunotherapy of androgen and estrogen-dependent tumors, contraception and immunocastration, and removal of boar taint described in US 5,749,551⁵⁴ and US 6,025,468⁵⁵; β -amyloid peptides for prevention and immunotherapy of Alzheimer's Disease described in USSN 09/865,294⁵⁶; foot-and-mouth disease virus peptides for protective immunity against foot-and-mouth disease described in US 6,107,021⁵⁷; peptides from bacterial pili for protective immunity from urinary tract infection described in USSN 09/747802⁵⁸; *Plasmodium* peptides for protective immunity from malaria described in WO 99/66957⁵⁹; and somatostatin peptides for growth promotion in livestock described in WO 99/66950.⁶⁰ The specific peptide immunogens named herein are examples for purposes of illustration only

WO 03/068169

PCT/US03/04711

and are not to be construed as limiting the scope of the invention in any manner.

[0069] The "anionic single stranded DNA" is a polynucleotide or oligonucleotide that is negatively charged at a pH in the range of 5.0-8.0. The net negative charge on the polynucleotide or oligonucleotide is calculated by assigning a -1 charge for each phosphodiester or phosphorothioate group in the oligomer. A suitable anionic oligonucleotide is a single-stranded DNA molecule with 8 to 64 nucleotide bases, with a repeated CpG motif and the number of repeats of the CpG motif is in the range of 1 to 10. Preferably, the CpG immunostimulatory single-stranded DNA molecules contain 18-48 nucleotide bases, with the number of repeats of CpG motif in the range of 3 to 8.

[0070] Preferably, the anionic oligonucleotide is represented by the formula: 5' X¹CGX² 3' wherein C and G are unmethylated; and X¹ is selected from the group consisting of A (adenine), G (guanine) and T (thymine); and X² is C (cytosine) or T (thymine). Or, the anionic oligonucleotide is represented by the formula: 5' (X³)₂CG(X⁴)₂ 3' wherein C and G are unmethylated; and X³ is selected from the group consisting of A, T or G, and X⁴ is C or T. The CpG oligonucleotide may be modified at the 5' end with a phosphorothiorate or a thiol-acetamido glycopolymer.³⁴

[0071] Most preferably, the CpG oligonucleotide is selected from a group consisting of 5' TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3' (CpG1) SEQ ID NO: 1, a 32 base length oligomer, and 5'nTC GTC GTT TTG TCG TTT TGT CGT T 3' (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus an phosphorothioate bridging group (designated as n at the 5' end).

[0001] Moreover, it is known that the DNA sequences derived from unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes and can enhance a subject's immune

WO 03/068169

PCT/US03/04711

responses, including IL-6, TNF- α , IL-12, IFN- γ responses³³. These molecules represent preferred complementary substrates that can both stabilize the synthetic cationic peptide immunogens and provide a novel immunogen delivery system, based on these findings. The stabilizing immunostimulatory complexes of the present invention also provide self-adjuvantation of the immune responses *in vivo* without significant dilution at the site of injection.

[0073] The formation of discrete immunostimulatory complexes derived from cationic peptide immunogens is principally a function of charge neutralization. It is expected that stable complexes may be formed from CpG-containing immunostimulatory DNA molecules derived from both natural or synthetically modified nucleotide sequences. Furthermore, improvements in the stability of an immunostimulatory complex may be realized by increasing the cationic charge residing on the peptide immunogen. These include extending the peptides with additional lysine, arginine or histidine or other synthetic moieties, which provides a positive charge to the modified peptide in an aqueous solution as described above.

[0074] It is expected that non-CpG containing immunostimulatory sequences (ISS) will be identified and contemplated that these single-stranded DNA substrates would prove to be useful materials to form immunostimulatory complexes from when combined with synthetic cationic peptide immunogens in appropriate aqueous solvents.

[0075] Modified CpG motifs are also envisioned, wherein a defined anionic single-stranded DNA has been chemically conjugated to another biologically functional molecule, such as lectins, sugars or lipids for enhancing cell-specific uptake and targeting, or polymers, copolymers and graft copolymers such as PEG for improved circulation *in vivo*. The chemically conjugated DNA may be polyanionic and may

WO 03/068169

PCT/US03/04711

subsequently be complexed with a cationic peptide immunogen to provide a modified immunostimulatory complex with potentially novel physical or biological properties.^{34, 35}

[0076] It is contemplated that block and graft co-polymers derived from polyanionic oligomers and polyethylene glycol represent another class of anionic molecules, which may also provide improved stability and improved adjuvanticity.

[0077] In another aspect of this invention an immunostimulatory complex may be prepared from a modified CpG oligonucleotide, wherein an additional phosphorothioate or another bridging group has been added at the 5' end of the oligomer for improved complexation.

[0078] Preferably, the immunostimulatory complexes have an average aggregate particle size distribution in the range of about 1 to 50 μ M. More preferably, the immunostimulatory complexes have an average aggregate particle size distribution in the range of about 1 to 30 μ M. Most preferably, the immunostimulatory complexes have an average aggregate particle size distribution in the range of about 1 to 15 μ M.

[0079] There is evidence that the number of CpG motif repeats influences the degree of intrinsic adjuvanticity and immune stimulation, with a minimum number of CpG repeats being required. Moreover, there is strong evidence that the selection of flanking nucleotide bases adjacent to the CpG is very important, as this appears to directly impact the adjuvanticity in a species-specific manner.^{10, 36} For example, it was demonstrated by Kreig et al.¹³ that enhanced immunostimulatory activity of human cells occurred when oligonucleotides containing CpG motifs are represented by the formula $X^1X^2CGX^3X^4$ where C and G were unmethylated, and X^1X^2 were selected from the groups GpT, GpG, GpA and ApA and/or X^3X^4 were selected from the groups TpT, CpT and GpT.

WO 03/068169

PCT/US03/04711

[0080] Although CpG oligonucleotides can function as B-cell mitogens³⁷ and are useful adjuvants, it has been shown that the immune responses generally peak 2 weeks after administration for an antigen mixed with CpG oligonucleotides in a soluble form. This necessitates multiple repeat injections to maintain high antibody titers to ensure protection.³⁸ Thus, a method for effectively delivering constructs with these oligonucleotides in a controlled release formulation is strongly desired.

[0081] With respect to stability, the phosphodiester bonds in the CpG backbone are sensitive to degradation by nucleases *in vivo*³⁹. Thus to improve the duration of the immune response, the phosphate groups may be modified to phosphorothioate groups.

[0082] The immunostimulatory complex of the present invention may be formulated for delivery by numerous pathways including parenteral, mucosal and transdermal. The immunostimulatory complex of the present invention is particularly desirable for vaccine formulations in that the CpG oligonucleotides in the complex are useful adjuvants for upregulating both parenteral and mucosal responses *in vivo*.^{40, 41}

[0083] The results of our experiments show that the aggregate particle size of the immunostimulatory complex varies based on the ratio of the peptide immunogen to the CpG oligonucleotide. The intrinsic stability of the immunostimulatory complex and the ability to control the size of the composition increases the potential for phagocytosis by a parenteral route.¹⁹ Mucosal immunization by targeting specific cells, such as M-cells located on Peyer's Patches via oral route²¹ or the nasal-associated lymphoid tissue (NALT) via intranasal route²³ is similarly facilitated by the use of the stabilized immunogen of the present invention.

WO 03/068169

PCT/US03/04711

[0084] The immunostimulatory complex of the present invention is prepared by a controlled self-assembling process wherein the anionic CpG oligonucleotide in aqueous solution is added to an aqueous solution of the cationic peptide immunogen. Suitable aqueous solutions for the preparation of an immunostimulatory complex is selected from the group consisting of distilled deionized water (DDW), normal saline (NS) or phosphate buffered saline (PBS). Distilled deionized water and normal saline typically exhibit a pH of about 5.5, whereas in PBS, the pH is controlled in a range of 7.2-7.4. The complexation process is a function of the charge ratios, the molecular weight of the interacting electrolytes, pH and ionic strength of the medium.³²

[0085] Multiply charged anionic molecules, such as the short CpG oligomers possess a net negative charge when the pH is in the range 5.5-7.4 in aqueous solutions. The net charge on the peptide immunogen is dependent on the amino acid composition of the peptide and may be affected by the pH of the aqueous solution. Thus, the aqueous medium is selected to ensure a net positive charge for efficient complexation. An examination of the ionization point (IP) or point of zero charge for the individual peptides can guide the selection process. In general, the IP is determined by the motion of the molecule through a pH-gradient in an isoelectric focusing experiment.¹¹ To ensure a peptide is positively charged, the pH of the selected aqueous medium should be less than the isoelectric point for the peptide in question.

[0086] To prepare an immunostimulatory complex the following steps are followed. Firstly, the average molar positive charge contribution is determined for a desired peptide immunogen or for a cocktail of peptide immunogens based on the molar ratios of peptides mixed together and the charge contribution from each peptide component in the final vaccine

WO 03/068169

PCT/US03/04711

composition. Secondly, the molar negative charge contribution is determined for the complexing oligonucleotide based on the molar ratio of oligomer and the charge contribution from this component in the final vaccine composition. Thirdly, the amount of peptide immunogen, based on total average molar positive charge, is dependent on the amount of oligonucleotide employed for complexation and the total molar negative charge thereof. This relationship is used to define the relative amounts of peptide immunogens and oligonucleotides to be combined in an aqueous solvent to form an immunostimulatory complex. An excess of the cationic immunogen peptide may be employed to provide a mixture of the immunostimulatory complex and an excess of the uncomplexed peptide. Or, an excess of the oligonucleotide may also be employed to provide an excess of the oligonucleotide. The relative amounts of the peptide immunogen and the oligonucleotide selected are based on the vaccine formulation desired.

[0087] Finally, the calculated amount of anionic oligonucleotide in a compatible aqueous solvent is added with mixing to the calculated amounts of cationic peptide immunogens similarly dissolved in a compatible aqueous solvent. The amount in nmol of the cationic peptide immunogen used is generally in a range to provide 8 positive charges to 0.5 positive charge to the amount in nmol of the anionic oligonucleotide to provide one negative charge. This is referred to as the charge ratio. Where the charge ratio is 8:1, there is a large excess of the peptide immunogen. Where the charge ratio is 1:2, there is a moderate excess of the anionic oligonucleotide. The complex forms spontaneously in the form of a suspension in solution. Estimation of the residual amounts of peptide immunogens or oligonucleotides can be made by separating the complex from the solution and assaying the supernatant solutions by ultraviolet

WO 03/068169

PCT/US03/04711

spectrophotometry (UV) or by reverse phase high performance chromatography (RP-HPLC).

[0088] The immunostimulatory complex as prepared as a suspension may be used as a vaccine composition. If the immunostimulatory complex is to be injected parenterally, the aqueous solvents are selected such that the final vaccine composition is isotonic and suitable for such a purpose. In cases where the complex is first formed in distilled deionized water, aqueous buffers of suitable salt concentration are added to ensure the final vaccine composition is isotonic.

[0089] The immunostimulatory complex prepared as a suspension or solution may be lyophilized. The lyophilized composition may then be reconstituted and incorporated into different vaccine formulations in accordance with the desired mode of delivery. The immunostimulatory complex of the present invention may also be formulated as a water-in-oil emulsion, in combination with a mineral salt suspension or a biocompatible polymeric gel.

[0090] In accordance with a further aspect of the invention, the invention describes a process for isolating the stabilized immunostimulatory complexes as stable particles via lyophilization. Reconstitution of the stabilized immunostimulatory complex as a suspension in aqueous solvents or biocompatible solvents shows essentially no changes in the particle size distribution or *in vivo* potency. This represents an important advantage over formulations requiring refrigeration to maintain efficacy, such as Alum-based vaccine compositions. This feature extends the potential utility of these systems to include direct reconstitution prior to immunization and alternative modes of delivery which require stable solid state dosage forms, such as a dry powder aerosol or nebulization for pulmonary or intranasal delivery.⁴²

[0091] In accordance with a further aspect of the present invention, the invention provides various processes for preparing stable water-in-oil emulsions⁴³ comprising the stabilized immunostimulatory complex of the present invention.

In such an emulsion, preferably the aqueous phase comprises the immunostimulatory complex or a mixture of the immunostimulatory complex with the uncomplexed peptide immunogen; and the continuous oil phase comprises a synthetic, mineral, animal or vegetable oil. Additionally, the oil phase may also comprise an immunostimulatory emulsifier, a biocompatible or a metabolizable component.

[0092] In particular, the oils useful for preparing the water-in-oil emulsions of the present invention include, but are not limited to, synthetic oils (e.g. isopropyl myristate), vegetable oils (e.g. peanut oil), mineral oils (e.g. DrakeolTM or MarcolTM), metabolizable animal oils (e.g. squalene or squalane), and a mixture thereof. The mineral oils are preferred. The oil-based emulsifiers useful for stabilizing the emulsions include, but are not limited to, the family of mannide oleates and derivatives thereof.

[0093] The relative amount of emulsifier required is a function of the hydrophile-lipophile balance (HLB) and the intrinsic stability of the water-in-oil emulsion produced under specified conditions. Methods for selecting oils and combinations of emulsifiers are well known to those skilled in the art.

[0001] The w/o-emulsion may comprise between 10 v/v% and 80 v/v% water in the internal aqueous phase. For most purposes, the optimal water concentration is in the range of 30 v/v% and 50 v/v%. The internal aqueous phase is characteristically comprised of very fine droplets with sizes typically in the

WO 03/068169

PCT/US03/04711

range of 1-10 μM , preferably 1-5 μM . The preparations are stable when maintained at room temperature or refrigerated.

[0095] Other stabilizing agents may also be used to prepare the emulsion. These include surfactants, colloidal particles, proteins, and other polymerizing and stabilizing agents known to those skilled in the art.

[0001] The w/o-emulsion may further comprise at least one oil-soluble lipophilic adjuvant such as 3-O-desacyl-4'-monophosphoryl lipid A (MPL), N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), Dimethyldioctadecylammonium bromide (DDA), N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl) propanediamine (Avridine), N-(2-Deoxy-2-l-leucylamino- β -D-glucopyranosyl)-N-octadecyl-dodecanoylamide hydroacetate (BAY-1005), 3 β -[N-(N,N'-dimethylaminoethane)-carbonyl] cholesterol (DC-Chol), NAc-Mur-L-Thr-D-isoGln-sn-glycerol dipalmitoyl (Murapalmitine) and mixtures or derivatives thereof. The w/o-emulsion may also comprise in the dispersed phase at least one water-soluble adjuvant, e.g., poly[di(carboxylatophenoxy)]phosphazene(PCPP), *Quillaja* saponin (QS-21), Cholera Holotoxin (CT) or Cholera Toxin B subunit(CTB), heat labile Enterotoxin from *E. Coli* (LT) or heat labile Enterotoxin B subunit from *E. Coli* (LTB) and cytokines such as Interleukin-1 β (IL-1 β), Interleukin-2 (IL-2), Interleukin-12 (IL-12), interferon- γ (IFN- γ) and mixtures and derivatives thereof. The water-soluble adjuvant may be synthetic or natural. The presence of a water soluble adjuvant with film forming properties, such as an oligomer or polymer, can additionally serve to stabilize the emulsion. The w/o-emulsion can facilitate presentation of the immunogens to the immune system to provide a more efficacious vaccine.

[0097] A water-in-oil emulsion comprising an immunostimulatory complex, or a mixture thereof with uncomplexed immunogen may

WO 03/068169

PCT/US03/04711

be prepared as follows. Firstly, an immunostimulatory complex is prepared from a peptide immunogen and an oligonucleotide in a ratio to ensure the formation of the immunostimulatory complex alone or in a mixture with excess residual peptide immunogen in an aqueous solution. Secondly, the aqueous solution is mixed with an oil containing emulsifiers and homogenized to provide a water-in-oil emulsion wherein the aqueous phase is dispersed in a continuous oil phase. The water-in-oil emulsion as such is suitable for parenteral injection.

[0098] Emulsification of the aqueous and oil phases can be accomplished by homogenization or by transfer between two syringes or by extruding the components through a membrane filter of a controlled pore size. The low-energy semi-manual methods are rapid. However, because there is considerably less shear than other processes, the emulsion produced is not as fine as that produced using high shear mechanical systems.

Examples of high-shear systems include rotostators, microfluidizers, and sonifiers. Other devices similar to these high-shear systems that are well known for emulsification may also be employed.

[0099] In accordance with a further aspect of the present invention, the invention provides various processes for preparing physiologically acceptable suspensions of mineral salts comprising the stabilized immunostimulatory complex of the present invention. In such a mixed system, the aqueous phase comprises a combination suspension of mineral salt and immunostimulatory complex, which may additionally contain residual, unbound peptide immunogens in solution.

[00100] In particular, the mineral salts useful for preparing the full aqueous-based suspensions of the present invention include, but are not limited to, Aluminum hydroxide (e.g., Alhydrogel®, Rehydrgel HPA®, Rehydrgel LV®), Aluminum

WO 03/068169

PCT/US03/04711

phosphate (e.g., Adju-phos® or Rehyraphos®) or calcium phosphate (e.g., Calphos®), and mixtures thereof.

[00101] Methods for selecting mineral salts and determining the preferred concentration of mineral salt to employ or combinations thereof are well known to those skilled in the art.

[00102] Other stabilizing agents may also be used to prepare the mineral salt suspension. These include surfactants, anti-oxidants, physiological acceptable buffers, tonifiers, preservatives and other agents known to those skilled in the art.

[0001] The mineral salt suspension may further comprise at least one additional adjuvant (e.g. MPL, MDP, DDA, N,N-Avridine, BAY-1005, DC-Chol, Murapalmitine, PCPP, QS-21, CT or CTB, LT or LTB and cytokines such as IL-1 β , IL-2, IL-12, IFN- γ and mixtures and derivatives thereof). The mineral salt can facilitate presentation of the immunogens to the immune system in the form of a depot or attract specific cells of the immune system by a process known as chemotaxis.

[00104] A mineral salt suspension comprising an immunostimulatory complex, or a mixture of immunostimulatory complex in combination with residual uncomplexed immunogens may be prepared as follows. Firstly an immunostimulatory complex is prepared from a peptide immunogen and an oligonucleotide in a charge ratio to ensure the complete complexation of all peptide immunogens and the oligonucleotide in solution. Alternatively, an immunostimulatory complex is prepared from a peptide immunogen and an oligonucleotide in a charge ratio to ensure partial complexation of the peptide immunogens and oligonucleotide components in solution; Secondly, the aqueous suspension is combined with a mineral salt suspension with mixing to provide a full aqueous

WO 03/068169

PCT/US03/04711


suspension of all components. The suspension combination as such is suitable for parenteral injection.

[00105] In a complementary method, a mineral salt suspension comprising an immunostimulatory complex, or a mixture thereof with uncomplexed peptide immunogens may be prepared as follows. Firstly, peptide immunogen is mixed with a mineral salt suspension. Depending on the physical properties of the mineral salt, peptide immunogens and aqueous buffer various proportions of immunogen may be absorbed directly by the mineral salt at this stage; Secondly, to this suspension is added an oligonucleotide with stirring. Partial or full complexation of the residual unbound peptide immunogens in solution results. The suspension combination as such is suitable for parenteral injection. In Figure 16, both methods of preparation are shown.

[00106] In accordance with another aspect of this invention, there is provided a process for preparing an *in-situ* gelling biodegradable polymer in which a stabilized immunostimulatory complex or a mixture of a stabilized immunostimulatory complex and uncomplexed immunogen is dispersed. The immunostimulatory complex may be dispersed either in solution or as a suspension within a biocompatible solvent. The biocompatible solvent may further comprise a soluble adjuvant that is synthetic or natural. The solution or suspension in the biodegradable gelling polymer is designed for the delivery of the immunogen to a host. The *in-situ* gelling polymer is biodegradable and is a copolymer of poly-D,L-lactide-co-glycolide (PLG) and poly-D,L-lactic acid-co-glycolic acid (PLGA) with a molecular weight in the range of about 2,000 to about 100,000 daltons and an inherent viscosity of about 0.2 to 1.0 dl/g. The formula of the in-site gelling polymer is:

WO 03/068169

PCT/US03/04711



wherein R1 is OH or alkoxy having 1 to 5 carbons and R2 is H;
 x:y is the ratio of each monomer unit of the copolymer with
 x+y=1.

In the case of PLG, R1 is alkoxy and the monomer units are
 lactide and glycolide and in the case of PLGA, R1 is OH and
 the monomer units are lactic acid and glycolic acid.

[00107] The stabilized immunostimulatory complex or a mixture
 thereof with the uncomplexed immunogen with the *in-situ*
 gelling polymer may be prepared as a single phase or as a
 suspension in a biocompatible solvent.

[00108] The biocompatible solvent useful in the present
 invention is selected from the group consisting of dimethyl
 sulfoxide (DMSO), N-methyl pyrrolidine (NMP), triacetin and
 glycerin. DMSO is preferred. DMSO has a high capacity for
 solubilizing a large quantity in weight percent of the
 polymer. It has been widely used as a solvent for *in-situ*
 gelling of polymers. DMSO may be also be used to prepare a
 suspension of the stabilized immunostimulatory complex of the
 present invention.

[00109] Importantly, it has been demonstrated in animal models
 that there is a high tolerance for DMSO when used in small
 amounts.⁴⁴ Thus, toxicity concerns are minimal when
 compositions comprising DMSO are administered via a parenteral
 route.

WO 03/068169

PCT/US03/04711

[00110] The biodegradable polymers suitable for the present invention include, but not limited to, the PLA or PLGA family of polyesters. These materials can be dissolved in various biocompatible solvents at a concentration in a range of 5 w/w%-50 w/w%. Several physical factors can influence the practical amount of polymer, which may be dissolved in the biocompatible solvent. These include the constitution, molecular weight, intrinsic viscosity and crystallinity of the polymer. For the PLG/PLGA series of copolymers, these factors are highly variable. For example, homopolymers of poly D,L-lactic acid (PLA) or poly D,L-lactide (PL) and copolymers of PLG or PLGA with long blocks of the lactic acid monomer component are highly crystalline materials with relatively high intrinsic viscosities.

[00111] The relative weight percentage of these crystalline materials which can be solubilized is distinctly lower than the amorphous PLG or PLGA analogs, wherein the ratio of the lactic acid to glycolic acid components are approximately equal, 1:1. It is contemplated that the difference in the total amount of polymer, which may be administered by injection, will have a dramatic impact on the matrix degradation rate and affect the release kinetics for encapsulated immunogens. It is envisioned that it is possible to vary the blends of physically compatible polymers and copolymers with varying physical properties in biocompatible solvents to achieve novel biological effects.

[00112] Other biodegradable polymers suitable for the present invention are contemplated and include, but are not limited to, polycaprolactones, polyanhydrides, polyorthoesters and poly(α -hydroxybutyric acid). These polymers can be solubilized in biocompatible solvents at useful weight percentages and provide useful matrix-forming substrates.

[00113] In accordance with the present invention, a controlled or delayed release vaccine preparation in stable form is provided together with a method of making such a vaccine preparation. The gel matrix of the controlled or delayed release vaccine composition comprise a biodegradable polymer selected from the group consisting of poly-D, L-lactide-co-glycolide (PLG) and poly-D, L-lactic acid-co-glycolic acid (PLGA), polycaprolactones, polyanhydrides, polyorthoesters and poly(α -hydroxybutyric acid), a biocompatible solvent and a stabilized immunostimulatory complex.

[00114] The polymeric gel may further comprise at least one additional adjuvant, e.g., MPL, MDP, DDA, *N,N*-Avridine, BAY-1005, DC-Chol, Murapalmitine, PCPP, QS-21, CT or CTB, LT or LTB or a cytokine such as IL-1 β , IL-2, IL-12, IFN- γ and mixtures and a derivative thereof.

[00115] Advantages of the controlled released composition of the present invention include:

- (a) a fully biodegradable and biocompatible gel formulation;
- (b) a sustained release of the immunogen for presentation to the immune effector cells resulting in improved immunogenicity;
- (c) a high loading of the gel with a desired immunogen in a stable composition; and
- (d) a flexible mode of delivery including a suspension of a stabilized immunostimulatory complex that is self-adjuvanting.

[00116] The molecular weight and crystallinity of the polymer directly impacts the entrapment efficiency *in vivo*. The polymeric gelling material is miscible in polar aprotic solvents such as DMSO. However, upon intramuscular or

WO 03/068169

PCT/US03/04711

subcutaneous injection, DMSO is extracted into the surrounding body tissues with water reversibly penetrating the polymer rich solution. This process serves as the primary mechanism controlling *in-situ* gel formation. The rate at which this process proceeds directly affects the initial burst of release of the immunogen during the time interval when the biocompatible solvent is actively extracted into body tissue and exchanged with physiological solutions and before the entrapment of the immunogen by the formation of the gel.⁴⁵ It is known that controlling the crystallization process is an important key mechanism by which the retention of immunogens within the gel can be improved.⁴⁶ This is intimately connected to the internal morphology of the gel formed which limits the diffusional pathways by which immunogens may be released.

[00117] The entrapped or retained immunostimulatory complexes are subsequently released from the gel in limiting amounts in a sustained fashion with a larger boost released when the bulk of the matrix forming polymer is eroded. This varies depending on many of the same conditions that influence gelation, such as molecular weight, degree of crystallinity, constitution, hydrophobicity, and the presence of additives.

[00118] The potential for an adverse toxicological response to the solvent DMSO has been addressed in a recent study⁴⁴ wherein a device containing a peptide hormone suspended in DMSO was surgically implanted subcutaneously in a dog and in a human. The volume of DMSO employed in the study was 150 μ L. The implant was designed to release the peptide over the course of 1 year and surgically removed at the end of the study. In neither the dog or the human were any adverse tissue reactions observed. The controlled release of the peptide/DMSO mixture from the implant into physiological tissues is useful as a model for evaluating potential toxicity concerns for a fully biodegradable *in-situ* gelling polymeric composition. It is

WO 03/068169

PCT/US03/04711

contemplated that the amount of DMSO useful in the present invention is essentially the same as that used in the study.

[00119] It is expected that there is an initial extraction of the immunostimulatory complex in DMSO into body tissue before the solubility limit of the polymer is exceeded.

Solidification takes place, retarding the release of the stabilized immunostimulatory complex. Subsequently, the stabilized immunostimulatory complex is released along with DMSO by diffusion-controlled pathways or retained in the gel with a release rate that is a function of the polymer properties. It is apparent that the diffusivity of these molecules within the gel is governed by several factors, such as the internal gel morphology and porosity, the degree of penetration by water into the gel and the hydrolysis of the bulk of the polymer.⁴⁵

[00120] In the case of the stabilized immunostimulatory complex of the present invention, which is dispersed as a suspension throughout the gel, the initial extraction is largely that of DMSO with a small quantity of the immunostimulatory complex located near the gelling front. Thus, the small amount of the immunostimulatory complex, not effectively entrapped during the initial gelling phase, would be responsible for the initial priming of the immune response *in vivo*. Thereafter, it is expected that DMSO would continue to be released by diffusion, with the bulk of the immunostimulatory complex remaining entrapped in the gel matrix until the bulk of the polymer has sufficiently been hydrolyzed to result in a full release of the encapsulated immunostimulatory complex.

[00121] Specifically, polymeric gels formulated from higher molecular weight and more crystalline polymers derived from α -hydroxy acids degrade over a longer period of time than lower molecular weight amorphous analogs. This phenomenon, is known

WO 03/068169

PCT/US03/04711

to be related to the accessibility of water to the hydrolytically unstable ester bonds.⁴⁶

[00122] It has been established that random amorphous copolymers composed of 50% D,L-lactide and 50% glycolide with a molecular weight in the range of from 8,000-50,000 daltons exhibit the highest degradation rates. 50% by weight or less of the polymer remains after approximately 6-8 weeks, when immersed in a PBS buffer.⁴⁷

[00123] It is desirable to modify the parameters controlling the rate of gellation, the kinetics of immunogen release and the internal gel morphology. Specifically, use of various pore forming agents, plasticizers, and stabilizers such as surfactants, sugars, proteins, polymers and other excipients known to those skilled in the art are useful for this purpose.

[00124] The preparations are stable when refrigerated or at room temperature. The vaccine composition of the present invention employing DMSO will freeze when refrigerated since the freezing point of DMSO is about 18°C. It has been found that thawing does not cause a change in the efficacy of the vaccine *in vivo*.

[00125] In accordance with the present invention, the *in-situ* gelling biodegradable polymer and the stabilized immunostimulatory complex may be formulated separately. The *in-situ* gelling polymer may be solubilized in a biocompatible solvent in one vial, and the stabilized immunostimulatory complex in dry form in a separate vial. The immunostimulatory complex in dry form may be prepared by spray-drying, or preferably, lyophilization.^{48, 49} The dried immunostimulatory complexes can then be reconstituted in a biocompatible solvent, and dispensed by syringe either as a solution or as a suspension into the biodegradable polymer solution. The

WO 03/068169

PCT/US03/04711

mixture is then used immediately or soon thereafter for immunization.

[00126] Employing separate vials has an added advantage of minimizing any potential stability problems. These include polymer degradation in the presence of the peptide immunogen, which may have reactive functional side chains, such as, free amine groups or carboxylate groups,⁵⁰ or the oxidation of selective amino acids, such as cysteine and tryptophan in the peptide immunogen in the presence of DMSO.¹

[00127] To prepare a reconstitutable *in-situ* gelling polymer composition containing an immunostimulatory complex, an immunostimulatory complex is prepared as described above. Then, this aqueous solution is lyophilized to form a dried composition. The dried composition is then reconstituted as a suspension in a biocompatible solvent containing a calculated weight percentage of a biodegradable gelling polymer. The final vaccine composition represents an *in-situ* gelling polymer and is suitable for parenteral injection.

[00128] The compositions of the present invention are contemplated to be useful as vaccines or for therapeutic purposes. Other biological materials which may be modified to possess cationic charge at pH's generally ranging from 4.0-8.0 for efficient complexation with CpG oligonucleotides, may include proteins, protein mimetics, bacteria, bacterial lysates, viruses, virus-infected cell lysates, antigens, antibodies, pharmacological agents, antibiotics, carbohydrates, lipids, cytokines, chemokines, lipidated amino acids, glycolipids, haptens and combinations and mixtures thereof.

[00129] These compositions can be administered parenterally via subcutaneous or intramuscular injection. When administered, parenterally, the immune response may be a cell-mediated response or a local or serum antibody response to provide

WO 03/068169

PCT/US03/04711

neutralizing antibodies. For compositions administered mucosally the immune responses would additionally include a local secretory antibody response.

[00130] It will be readily apparent to those skilled in the art that immunostimulatory complexes may also be admixed in oil-in-water (o/w)-based emulsions. Other possibilities include encapsulation of stabilized immunostimulatory complexes within water-in-oil-in-water (w/o/w) double emulsions, biodegradable polymeric microparticles, lipid vesicles or liposome structures. Most of these delivery systems are attractive for the development of sustained release formulations.

[00131] Preferably, the peptide immunostimulatory complex of the present invention may be employed in w/o-based emulsions employing SEPPIC's oil-based adjuvants, in combination with mineral salts such as Aluminum hydroxide, Aluminum phosphate and Calcium phosphate or in a single-dose controlled release *in-situ* gelling formulation based on biodegradable poly-D,L-lactide-co-glycolide (PLG) or poly-D,L-lactic acid-co-glycolic acid (PLGA) copolymers.

[00132] Most preferably, the vaccine compositions of the present invention comprise a stabilized immunostimulatory complex of the peptide immunogen with a CpG oligonucleotide admixed with the uncomplexed peptide immunogen.

[00133] It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of medicine and in particular vaccination, diagnosis and treatment of infections with pathogens including bacteria and viruses. Further uses of the present invention are described below.

Vaccine Preparation

[00134] Immunogenic compositions, suitable to be used as vaccines, may be prepared from an immunostimulatory complex of

WO 03/068169

PCT/US03/04711

the present invention, as a w/o emulsion, as a suspension in combination with a mineral salt suspension or as an *in-situ* gelling polymer or a combination of these systems as disclosed herein. The immunogenic composition containing the immunostimulatory complex is useful for eliciting an immune response by the host to which it has been administered. The immune response includes the production of antibodies by the host.

[00135] The immunogenic composition may be prepared as injectables, as liquid solutions or suspensions, as lyophilized or spray-dried powders or emulsions. The composition comprising the immunostimulatory complex may be mixed with physiologically acceptable buffers or excipients, such as, water, saline, dextrose, glycerol, ethanol and combinations thereof. The vaccine may further contain additional substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants to further enhance the effectiveness thereof. The vaccine may further contain additional biocompatible substances, specifically in conjunction with the *in-situ* gelling polymers such as dimethyl sulfoxide (DMSO), N-methyl pyrrolidine (NMP), triacetin, glycerin, and poly vinyl pyrrolidone (PVP).

[00136] The vaccine of the present invention may be administered parenterally, e.g., by injection subcutaneously, intramuscularly or transdermally. The vaccines of the present invention may be administered mucosally via oral, intranasal, rectal, vaginal or ocular routes.

[00137] The vaccines are administered in a manner compatible with the formulation, and in such amount as to be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject or species to be treated, including, for example, the capacity of the

WO 03/068169

PCT/US03/04711

subject's or species' immune system to synthesize antibodies, and if needed, to produce cell-mediated immune responses.

[00138] Precise amounts of emulsifying oils, mineral salts or gelling polymers and material having biological activity required to be administered for effect depend on the judgement of the practitioner or veterinarian. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms to milligrams. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage of the vaccine may also depend on the route of administration and thus vary from one host or species to another.

EXAMPLES

[00139] The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in the form and substitution of equivalents are contemplated as circumstances may suggest it as necessary to achieve a particular goal. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

[00140] Methods of chemistry, organic chemistry, polymer chemistry, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

Preparation of Immunostimulatory complex

[00141] In general, an immunostimulatory complex of a synthetic peptide immunogen and a CpG oligonucleotide in aqueous

WO 03/068169

PCT/US03/04711

solutions is prepared by the dropwise addition of a stock peptide solution in an appropriate aqueous solvent into a vial containing a gently stirred stock solution of CpG oligonucleotide dissolved in an appropriate aqueous solvent. The reverse mode of addition is equally effective. Compatible aqueous solvents include, but are not limited to, distilled deionized water, normal saline (NS = 0.9% NaCl) or phosphate buffered saline (PBS = 10 mM Phosphate buffer, 0.9% NaCl) or mixtures thereof. The complexation process is largely unaffected by physiologic buffers, providing flexibility when selecting a compatible solvent system for both the synthetic peptide immunogen and the CpG oligonucleotide.

[00142] The complex forms immediately and can be identified visually by the observation of a fine precipitate suspended in solution. The quantity of suspension so formed is a function of the relative amounts of the CpG oligonucleotide to the cationic peptide in solution. The precipitation process is controlled by the electrostatic neutralization of oppositely charged molecules. In a thermodynamically favourable process, the highly charged polyanionic single-stranded DNA binds with the positively charged cationic peptide immunogen.⁶¹

[00143] The CpG oligonucleotide is selected from a group consisting of 5' TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3' (CpG1) SEQ ID NO: 1, a 32 base length oligomer, and 5'nTC GTC GTT TTG TCG TTT TGT CGT T 3' (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus an phosphorothioate group (designated as n at the 5' end). The CpG oligonucleotides were synthesized by Oligo's Etc. (Wilsonville, Oregon), and are obtained in a lyophilized dry state. These materials were reconstituted in the appropriate aqueous solvent prior to use. CpG1 possesses a CpG motif sequestered within a sequence of 8 nucleotide bases and may provide stronger adjuvantation *in vivo* and improved stability by binding cationic peptides with higher

WO 03/068169

PCT/US03/04711

affinities, than shorter oligonucleotides. A phosphorothioate modified group at the 5' end of CpG2 increases the molar negative charge density and potentially promotes improved binding.

[00144] The peptide immunogens were synthesized and the appropriate aqueous buffer used to ensure that the peptide is cationic in solution. This is an important consideration in vaccines where complexation of the peptide immunogen to the CpG oligonucleotide is desired. The ionization point or IP for each peptide immunogen and the pH of the medium is used to guide the selection of the appropriate buffer. The pH for an aqueous mixture of a stock peptide solution dissolved in distilled deionized water or normal saline (NS) was approximately 5.5, whereas in phosphate buffered saline (PBS) the pH of the stock peptide solutions was significantly higher at approximately 7.2. Careful selection of aqueous solvent systems is made to ensure full protonation for peptides derived from amino acids with weakly basic side chains, notably Histidine.

[00145] Table 1 list the physical properties of the synthetic peptide immunogens and CpG oligonucleotides used to form immunostimulatory complexes. Three exemplary peptide immunogen targets are depicted in Table 1. A cocktail of two or three peptide immunogens or in one case a combinatorial library of peptides containing analogs of the peptide have been employed to prepare each vaccine. Each peptide immunogen comprises two segments, a B-cell target epitope and a T-helper epitope. The Th epitope is included to improve the immunogenicity of the peptide immunogen.

[00146] The B-cell and T-help epitopes were selected after screening libraries of peptides in the appropriate animal models. Detailed information regarding the identification and composition of these constructs can be found by referring to

WO 03/068169

PCT/US03/04711

US patent Nos. 6,090,388⁵³, US patent No. 5,759,551⁵⁴ and WO99/67293⁵¹ and US 6,107,021.⁵⁷ SEQ ID NOS: 7-9 in Table 1 comprise the LHRH immunogen peptides and are useful in a vaccine for prostate cancer immunotherapy, designed for hormone ablation treatment. SEQ ID NOS: 10-11 are useful in an anti-IgE immunotherapeutic vaccine for the treatment of allergy. SEQ ID NOS: 4-6 are useful in an anti-CD4 immunotherapeutic vaccine for the treatment of HIV infection. SEQ ID NOS: 12-13 comprise a combinatorial library of FMD peptides and are useful in an anti-FMD vaccine for protective immunity against *foot-and-mouth* disease.

[00147] The immunostimulatory complex of the present invention may be prepared with various ratios of cationic peptides to CpG oligonucleotides to provide different physical properties, such as the size of the microparticulate complexes. Table 2 shows the calculated average molar positive charge and average formula weight for the peptide immunogen in the mixture. Table 2 also provides the calculated average molar negative charge contribution from CpG1 (SEQ ID NO: 1) and CpG2 (SEQ ID NO: 2), respectively.

Example 1: Preparation of Immunostimulatory complex of LHRH Immunogens and CpG1 Oligonucleotides

[00148] This Example illustrates the preparation of immunostimulatory complex from LHRH peptide immunogens and CpG1 oligonucleotides in various proportions. A flow diagram of the process of complex formation as described herein is shown in Figure 1.

[00149] All glassware, stir bars and pipette tips were autoclaved for 40 minutes at 121°C prior to use. All reagents were weighed, dispensed, transferred or added to reaction vessels in a laminar flow hood to prevent contamination.

WO 03/068169

PCT/US03/04711

[0001] A LHRH peptide immunogen stock solution was prepared by mixing a 1:1:1 molar ratio of peptides of SEQ ID NOS: 7-9 at a concentration of 3 mg/mL in distilled deionized water. 33 μ L of the stock solution (100 μ g of the peptide immunogens) was added to each of a series of 2 mL vials equipped with micro stir bars. To this solution was added 0.5 mL of distilled deionized water as a diluent. A stock solution of 2.0 μ g/ μ L of CpG1 oligonucleotide was prepared in distilled deionized water. Various amount of the CpG1 oligonucleotide stock solution was added to each vial to form the immunostimulatory complex. The amount of CpG1 oligonucleotide added to each vial was determined by calculation to provide a charge ratio of LHRH:CpG1 ranging from 8:1, with a large excess of LHRH, to 1:2 with an excess of CpG1. The respective amounts of CpG1 used to prepare these compositions are shown in Table 3. It is to be noted that the ratio of LHRH:CpG1 are represented as molar charge ratios and is based on the calculations shown in Table 3.

[00151] The additions were made at room temperature with continuous stirring and equilibrated for 30 min. In all cases, an immediate clouding of the reaction mixture was observed upon addition of the CpG oligonucleotide stock solution. After complete addition of the CpG1 oligonucleotide, a fine white particulate suspension was observed. The particles gradually settled and could be easily resuspended with gentle shaking.

[0001] The solid microparticulate complexes can be essentially removed after settling and allows the separated supernatant solutions to be analyzed by ultraviolet spectroscopy for residual uncomplexed peptide immunogens (at $\lambda = 280$ nm) or for residual CpG1 oligonucleotide (at $\lambda = 260$ nm). For the immunostimulatory complexes prepared using an excess of LHRH,

WO 03/068169

PCT/US03/04711

wherein LHRH:CpG1 = 8:1, 4:1 or 2:1, excess amounts of peptide were detected.

[00153] The result obtained by ultraviolet spectroscopy is an estimate and may be $\pm 20\%$ of the number obtained for the following reasons. The peptide chromophores have sizeably smaller extinction coefficients as compared to CpG oligonucleotides and the wavelength maxima used to detect the peptides and CpG1 are fairly close to each other. Thus, the estimates for free residual peptide may possibly be exaggerated. Further, a small amount of nanoparticles of peptide CpG complex may be present in the supernatant. The interpretation of these results is further complicated by the observation that increasing the excess amount of the peptide immunogen relative to CpG generally results in complex aggregates with smaller average particle sizes.

[0001] It is observable from Figure 2 that the ranking of LHRH/CpG1 complexes with respect to average aggregate particle size distribution is in the order LHRH:CpG1 2:1 > 4:1 > 8:1. It is expected that the efficiency of the complexation process would vary based on the physical properties of the peptide immunogens and CpG oligonucleotides selected and the relative ratio of each in the vaccine composition. For the LHRH:CpG1 system, the residual levels of uncomplexed peptide as determined by UV spectroscopy range from 60-90% (LHRH:CpG1 = 8:1), 40-80% (LHRH:CpG1 = 4:1) and 25-65% LHRH:CpG1 = 2:1) over the background, respectively. For the LHRH:CpG1 complex prepared at a 1:1 charge ratio there was very little detectable concentration of residual peptide immunogen, ~3%, or residual CpG oligonucleotide, ~2%. The large increase in the aggregate size of this complex coupled with the essentially complete complexation of immunogen is consistent with expected polyelectrolyte behavior at neutral charge. For the immunostimulatory complex LHRH:CpG1 = 1:2 charge ratio, an

excess of CpG1, 48% residual level of CpG1 was found at $\lambda = 260$ nm. This amount of residual CpG1 approximates the quantity of CpG1 expected if the first equivalent of CpG1 was fully complexed with the peptide immunogen in solution.

[00155] The results of the UV method demonstrate that immunostimulatory complex compositions prepared with a high excess of peptide to oligonucleotide (e.g. LHRH:CpG1 = 8:1 charge ratio) results in a significant amount of peptide free in solution. Similarly, immunostimulatory complexes prepared from a moderate excess of oligonucleotide to peptide (e.g. LHRH:CpG1 = 1:2 charge ratio) result in compositions with excess free oligonucleotide. The presence of excess oligonucleotide can serve to stabilize smaller aggregates as shown in Figure 2.

[00156] This example demonstrates that there may be no practical advantages to preparing immunostimulatory complex with a high excess of LHRH, LHRH:CpG1 = 8:1 charge ratio, wherein a significant amount of peptide remains free in solution. Similarly, there is no practical advantage for immunostimulatory complex prepared with a moderate excess of CpG1, LHRH:CpG1 = 1:2 charge ratio, wherein it is reasonable to assume that after complete complexation at the point of electrical neutrality, excess oligonucleotide can serve only to stabilize the aggregates as shown in Figure 2. This result does reveal that compatible anionic molecules and/or polymers may be sequentially added to a preformed 1:1 electrically neutral complex in order to reduce the effective particle size of the composition. This presents a novel strategy for complete immunostimulatory complexation coupled with particle size control.

[00157] It is an object of this invention to effectively bind the peptide immunogens in solution for certain applications to maximize the stability of the vaccine in vivo. Thus

WO 03/068169

PCT/US03/04711

immunostimulatory complex prepared with charge ratios of peptide immunogens to CpG oligonucleotides ranging from 4:1 to 1:1 respectively are preferred. It is another object of this invention to maximize the adjuvanticity of the immunostimulatory complex *in vivo* by using smaller more discrete particles (~10 microns or less) for presentation to the immune system.

[00158] It has been found that the presence of residual free and uncomplexed peptide is more desirable for more complex vaccine formulations such as water-in-oil emulsions or absorption on to mineral salts. In these formulations, adjuvantation of the immune responses may result from immunogens bound as immunostimulatory complex and also from uncomplexed immunogens dispersed within the w/o emulsion or adsorbed on the mineral salt directly. Thus, the immunostimulatory complexes prepared with charge ratios of peptide immunogens to CpG oligonucleotides ranging from 8:1 to 2:1 are found to be useful for these applications.

[00159] More preferably, a combination of maximal peptide complexation for stability and small particle size for improved adjuvanticity is found for immunostimulatory complexes prepared with charge ratios of peptide immunogens to CpG oligonucleotides ranging from 4:1 to 2:1.

[00160] The most preferred immunostimulatory complex are those prepared to possess physical properties, which make them suitable for alternative delivery modalities. Specifically, average particle sizes on the order of 10 microns or less are desirable in particular for rectal, vaginal, oral and nasal delivery.

**Example 2: Quantitation of Peptide Immunogen and
Oligonucleotide Complexation Efficiency by RP-HPLC**

[0001] This Example illustrates a preferable method for determining the complexation efficiency with respect to the peptide immunogen and oligonucleotide vaccine components employing reverse phase high performance liquid chromatography (RP-HPLC). This technique allows the quantitation of each residual uncomplexed individual peptide in a peptide cocktail mixture to be separated and identified (at $\lambda = 226$ nm) and can be used to verify full complexation of the CpG oligonucleotide (at $\lambda = 260$ nm). The solid microparticulate complexes can be separated from the supernatant solution by centrifuging followed by filtration. Two separate RP-HPLC programs are run on supernatant samples to identify and quantitate residual LHRH peptide immunogens and CpG1 oligonucleotides in solution.

[00162] The peptide(s) were resolved by high performance liquid chromatography (HPLC) using the Vydac 4.6 x 250 mm C-18 column, Cat. number 218TP54, with a gradient from 95% of solution A (0.05% TFA in HPLC grade water) and 5% solution B (0.05% TFA in HPLC grade acetonitrile) to 24% of solution A and 76% solution B in 40 minutes at the flow rate of 1 mL/minute. The UV wavelength absorbance was monitored at 226 nm. Peptide identity was determined by retention time, using standard peptides.

[00163] The oligonucleotide(s) were resolved by high performance liquid chromatography (HPLC) using the PerSeptive Biosystem 4.6 x 100 mm Oligo R3 column, Cat. number R330-050, with a gradient from 95% of solution A (0.1 M TEAA in HPLC grade water, pH=8) and 5% solution B (HPLC grade acetonitrile) to 24% of solution A and 76% solution B in 40 minutes at the flow rate of 1 mL/minute. The UV wavelength absorbance was

WO 03/068169

PCT/US03/04711

monitored at 260 nm. Peptide identity was determined by retention time, using standard oligonucleotide.

[00164] Immunostimulatory complexes of LHRH and CpG1 ranging from 8:1 to 1:1 were prepared for this study as described in Example 1 and Example 11. The respective amounts of CpG1 used to prepare these compositions are shown in Table 3 and Table 9. It is to be noted that the ratio of LHRH:CpG1 are represented as molar charge ratios and is based on the calculations shown in Table 3 and Table 9.

[00165] For the immunostimulatory complexes prepared using an excess of LHRH, wherein LHRH:CpG1 = 8:1, 4:1 or 2:1, non-equivalent amounts of residual peptide were detected by RP-HPLC in the supernatant solutions indicating that the complexation process is selective. This technique enables a ranking of LHRH peptide immunogens with preferences for CpG1 oligonucleotide in solution based on binding affinity. In all cases no residual uncomplexed CpG1 oligonucleotide could be detected by RP-HPLC, indicating full complexation of this component.

[00166] For the immunostimulatory complex prepared using an equivalent amount of LHRH to CpG1 oligonucleotide based on charge ratio (LHRH:CpG1 = 1:1), essentially no peptide and no CpG1 was detected by RP-HPLC indicating full complexation of all components.

[00167] The complete set of results for these analyses is depicted in Table 8. It is clear that the binding of LHRH peptide immunogens with CpG1 oligonucleotide may be ranked as p607E > p667 > p500. The three peptides have near identical ionization points and all three are positively charged as calculated in Table 1. The preference of CpG1 oligonucleotide for p607E (+4 charge) over p667 (+5 charge) both of which are preferred to p500 (+4 charge) is likely related to the

WO 03/068169

PCT/US03/04711

molecular weight and the distribution of charges within these peptides.

Example 3: Preparation of Dried Immunostimulatory Complex

[00168] This Example illustrates the procedure used to prepare an immunostimulatory complex in a dry state.

[00169] Suspensions of LHRH/CpG1 complexes, prepared as described in Example 1, in 0.5-1.0 mL in aqueous solvent, distilled deionized water, normal saline or phosphate buffered saline, were placed in a dry ice/acetone bath and frozen for 15 minutes. The frozen samples were then placed on a freeze-dryer (Vertis 25LEZ) and the water removed by sublimation at 200 millitorr over three days. This procedure provided a near transparent glassy finished product in the vial. The appearance of the residual solid recovered depends on the aqueous solvent used and can range from a near transparent glass to a white fluffy solid.

[00170] Reconstitution of the dried materials in the same volume of aqueous solvent regenerated a suspension of discrete particles. The particle size distributions, determined as described in Example 2, showed essentially no change.

[00171] This demonstrated that the drying and resuspension process does not effect the physical properties of the prepared immunostimulatory complexes. Thus, a vaccine composition comprising the immunostimulatory complexes of the present invention may be provided in the form of a suspension, a solid or a dried powder.

Example 4a: Preparation of Water-in-Oil Emulsions Using High Shear Homogenization

[00172] This Example illustrates the process of preparing a water-in-oil (w/o)-emulsion from cationic peptides derived from LHRH peptide immunogens (SEQ ID NOS: 7-9 in a 1:1:1 molar

WO 03/068169

PCT/US03/04711

ratio in solution), IgE peptide immunogens (SEQ ID NO: 10-11 in a 2:1 molar ratio in solution) CD4 peptide immunogens (SEQ ID No: 4-6 in a 2:1:1 molar ratio in solution) or immunostimulatory complex derived from LHRH, IgE or CD4 immunogens and CpG1 or CpG2 oligonucleotides in various proportions using homogenization techniques. A flow diagram illustrating the process of emulsion formation via homogenization as described herein is shown in Figure 3.

[00173] All glassware, stir bars and pipette tips were autoclaved for 40 minutes at 121°C prior to use. All reagents were weighed, dispensed, transferred or added to reaction vessels in a laminar flow hood to prevent contamination.

[00174] The w/o-emulsions were optimized for stability with respect to the volume ratio of the aqueous to oil phases required. For compositions employing Montanide® ISA 720 oils (SEPPIC, Inc) the ratio of water to oil was 30:70 by volume. For compositions employing ISA Montanide® 51 or ISA Montanide® 50v oils (SEPPIC, Inc.) the ratio of water to oil was 50:50 by volume.

Example 4b: Preparation of Water-in-Oil Emulsions from ISA Montanide® 720 and Immunostimulatory complex

[0001] To a 10 mL vessel, was added 3,333 µg of peptide immunogens dissolved in an appropriate aqueous buffer (1,111 µL, 3 mg/mL) or an immunostimulatory complex prepared from 3,333 µg of peptide immunogens dissolved in an appropriate aqueous buffer (1,111 µL, 3 mg/mL) and either CpG1 or CpG2 oligonucleotides. Table 3 and Table 4, shows the calculations for determining relative amounts of each reagent employed.

[00176] Specifically, to prepare an immunostimulatory complex from LHRH peptide immunogens at a 4:1 charge ratio of

WO 03/068169

PCT/US03/04711

LHRH:CpG1, 244 µg CpG1 oligonucleotide (122 µL, 2.0 µg/mL) were used.

[00177] Specifically, to prepare an immunostimulatory complex of IgE peptide immunogens at a 4:1 charge ratio of IgE:CpG1, 387 µg of CpG1 oligonucleotide (193.5 µL, 2.0 µg/µL) were used. To form a 1:1 neutral complex of IgE:CpG1, 1,548 µg of CpG1 oligonucleotide (774.0 µL, 2.0 µg/µL) were used.

[00178] Specifically, to prepare an immunostimulatory complex of CD4 peptide immunogens at a 2:1 charge ratio of CD4:CpG2, 402 µg of CpG2 oligonucleotide (201 µL, 2.0 µg/µL) were used.

To form a 1:2 charge ratio of CD4:CpG2, 1608 µg of CpG2 oligonucleotide (804 µL, 2.0 µg/µL) were used.

[00179] To each of the vessels additional diluent aqueous solvent was added so that the final volume of the aqueous phase was fixed at 3.0 mL for preparation of ISA Montanide® 720 w/o-emulsions respectively.

[00180] For LHRH or IgE peptides normal saline or PBS was found to be suitable for complexation. The calculated IP for each peptide immunogen is greater than 9.0 (Table 1), far greater than the pH of the aqueous solvent selected.

[00181] In the case of CD4 peptides the choice of aqueous solvent proved important. Upon dilution with either normal saline or PBS a solid precipitate was observed to quickly form in solution. This instability would preclude use of this immunogen combination by parenteral routes. An examination of the peptide immunogens revealed that peptide sequence ID No: 6 (Table 1) has a calculated ionization point of 6.91. In PBS (pH ~ 7.2), this peptide would tend to aggregate and be expected to exhibit instability. A solution to this problem was found by first preparing the immunostimulatory complex in distilled deionized water followed by dilution with saline or

WO 03/068169

PCT/US03/04711

PBS of sufficient ionic strength to ensure that the suspension was isotonic and suitable for injection.

[00182] This example demonstrates the advantages of stabilizing immunogens in solution in the form of an immunostimulatory complex of LHRH, IgE or CD4 peptides.

[00183] The diluted aqueous solutions or suspensions were then slowly added to a dry 25 mL reaction vessel charged with 7.0 mL of ISA Montanide® 720. The additions were made while homogenizing (High Shear Laboratory Mixer, Sealed Unit, Silverson) the mixture at low speeds (2,000-3,000 rpm) to generate a coarse emulsion. This processing speed was maintained until the aqueous sample had been completely added and was continued a full 2 minutes to ensure uniform pre-mixing of the aqueous and oil phases. The homogenization speed was then ramped up (5,000-8,000 rpm) and maintained for from 5 to 10 minutes further resulting in the formation of a homogeneous white finely dispersed w/o-emulsion.

[0001] The final concentration of immunogens once formulated as suspensions or in water-in-oil emulsions as described above was 200 µg/mL.

Example 4c: Stability Evaluation for Water-in-Oil Emulsions Prepared by Homogenization Methods.

[00185] The consistency and stability of the w/o-emulsions prepared by homogenization was checked by a variety of methods. To prove that the emulsion was water-in-oil (w/o) and not oil-in-water (o/w) or water-in-oil-in-water (w/o/w), a droplet of the composition was added to a beaker containing distilled deionized water. A droplet of a w/o-emulsion will float on the surface and not disperse into water. Conversely, a droplet from an o/w emulsion will instantly disperse into water and a droplet from a w/o/w double emulsion will disperse both on the surface and into the bulk of the aqueous phase.

WO 03/068169

PCT/US03/04711

Droplets from the emulsions prepared from ISA Montanide® 720 were observed to float on the surface with minimal dispersal and droplets from the emulsions prepared from ISA Montanide® 51 oils were observed to float on the surface with essentially no dispersal. These results indicated that the emulsions were w/o and further that the tendency towards dispersal was higher for the w/o-emulsion prepared from ISA Montanide® 720. This is related to the initial viscosity of the oils themselves and the viscosity of the resultant emulsions. This is an important consideration for maximizing the depot potential of the resultant vaccine formulation.

[00186] The apparent viscosity of the finished emulsions and oils were checked (Brookfield DV-1+ rotational viscometer) for lot to lot consistency and for long-term stability trials. ISA Montanide® 720 had a viscosity of ~15 mPa at 25°C whereas the w/o emulsion prepared from ISA Montanide® 720 had a viscosity of ~45-50 mPa at 25°C. This provided a fairly fluid product, which is desirable for facilitating the handling, and dispensing of the vaccine with a syringe.

[00187] In contrast, ISA Montanide® 51 had a viscosity of ~50 mPa at 20°C whereas the w/o-emulsions prepared from ISA Montanide® had a viscosity of ~ 1,500-2,900 mPa at 25°C. The wide variation in viscosity was found to be a function of buffer selection. (PBS = ~2,900 mPa, NS = ~2,500 mPa and distilled deionized water = ~1,500 mPa) Material of this high viscosity can present some difficulties with respect to transferring and dispensing with a syringe. However, the long-term stability of these compositions was improved. The long-term stability of the emulsion was evaluated by placing 1 mL of each emulsion in a 1.5 mL eppendorf vial and centrifuging the contents under high speed (5,000 rpm) for 10 minutes. These conditions do not simulate actual storage

WO 03/068169

PCT/US03/04711

conditions but can be used to predict the resistance of the emulsion to separation. In the case of ISA Montanide® 720, 5-10% of the volume separated out with a clear or straw yellow oil phase observed on the surface. In the case of ISA Montanide® 51, 0-2% of the volume separated out with a clear or straw yellow oil phase observed on the surface. The higher viscosity of the ISA Montanide® 51 emulsion products accounts for the greater stability to sedimentation and resistance to separation.

[00188] The particle size and distribution for the w/o-emulsion was further characterized by optical microscopy (Nikon DIAPHOT 200). A photomicrograph of each composition was obtained and an estimate of the size range of particles was made using a computer-generated scale. The scale itself is externally referenced against standards of known particle sizes (NIST traceable microparticles - Duke Scientific). For w/o emulsions prepared from either ISA Montanide® 720 or ISA Montanide® 51 and peptide immunogens, the particles sizes were essentially the same (c.a. 1-2 microns) with minimal aggregation or coalescence. For w/o-emulsions prepared from either ISA Montanide® 720 or ISA Montanide® 51 and immunostimulatory complex the particle sizes were slightly larger (c.a. 1-3 microns) with minimal aggregation or coalescence. Figure 4 is a photomicrograph obtained from a w/o-emulsion prepared via homogenization from ISA Montanide® 51 and an immunostimulatory complex derived from 100 µg of LHRH peptide immunogens, with LHRH:CpG1 in a final charge ratio of 4:1.

[00189] The initial average particle size was on the order of 10 microns. The process of homogenizing an aqueous suspension of immunostimulatory complexes under high shear resulted in a smaller average aggregate particle size. A stable w/o-

emulsion with droplets in the size in the range of 1-3 microns was obtained.

Example 5a: General Preparation of Water-in-Oil Emulsions
Using Low Shear Extrusion

[00190] This Example illustrates the process of w/o-emulsion formation from cationic peptides derived from LHRH, IgE or CD4 immunogens or immunostimulatory complex derived from LHRH, IgE or CD4 immunogens and CpG1 or CpG2 oligonucleotides in various proportions using extrusion techniques. Table 3 and Table 4, shows the general calculations for determining the relative amounts of each reagent employed. A flow diagram illustrating the process of emulsion formation via extrusion as described herein is shown in Figure 3.

[00191] All glassware, stir bars and pipette tips and the entire extruder mechanism were autoclaved for 40 minutes at 121°C prior to use. All reagents were weighed, dispensed, transferred or added to reaction vessels in a laminar flow hood to prevent contamination.

[00192] The extrusion process involves repeatedly passing an aqueous phase loaded in one syringe into an oil phase loaded in a second syringe through a narrow bore tube joining the two syringes. Emulsification occurs as the fluids are driven through the narrow bore under pressure, typically 100 psi. By contrast, a homogenizer system typically operates at a pressure that is greater than 1,000 psi. The number of return passages necessary for the above extrusion process often exceeds 20 to 30 before a visually uniform w/o-emulsion is generated. This manual extrusion process cannot generate significant shear and the number of exchanges required to efficiently produce a w/o-emulsion is highly variable. The physical properties of the w/o-emulsions are inconsistent and the overall stability and consequently *in vivo* potency are

WO 03/068169

PCT/US03/04711

typically highly irreproducible. In spite of these problems, there are a number of possible applications for products produced by this process.

[0001] To address these shortcomings an extruder mechanism has been developed (LiposoFast™ Basic, Avestin, Inc., Ottawa, Canada). The device consists of two syringes (0.5 mL or 1.0 mL) fitted via luer locks with a narrow bore passage connected to a holder with a polycarbonate membrane of a defined pore size placed in between the two syringes. The device as originally designed was for the preparation of liposomes of a controlled size.⁶³ The application of such a device with a compatible oil-based product for the preparation of w/o emulsions appears not to have been contemplated. The membrane pore size can be selected (Whatman Nucleopore, 0.05 μM - 10 μM). The smaller pore size allows for the extrusion of dispersions under increased shear. The larger pore size can be selected for formulating wherein the particulates are larger sized. Using this device, the efficiency of emulsification was increased. Fewer return passages were required to provide a more uniform and stable product. The *in vivo* potency of such a preparation would be predicted to be more reproducible. However, there are still limitations due to the small maximum volume, c.a. 1.0 mL, which can be practically employed and the practical restrictions on the choice for the oil component.

[00194] The process works well for the preparation of w/o emulsions derived from ISA Montanide® 720. However, the higher viscosities of emulsions derived from ISA Montanide® 51 results in significant backpressure, precluding the use of this extrusion device. As such, this method can be best viewed as a process for preparing instant w/o emulsions from oils with apparent viscosities of less than 1,500 mPa.

WO 03/068169

PCT/US03/04711

[00195] In particular, where the costs associated with storage and stability of vaccines are of concern or where patient compliance is an issue or application as a palliative medicine is involved, this method of delivery may be cost effective and practical. Ideally, trained practitioners such as doctors or pharmacists can be relied upon for preparing instant w/o-formulations on-site for general use.

[00196] This device and protocol may be used for the preparation of instantaneous o/w, and w/o/w, microemulsions for which controlled shear and extrusion are required, or for the preparation of refined products.

Example 5b: Preparation of Water-in-Oil Emulsions from ISA Montanide® 720

[0001] To a 1.0 mL glass syringe (gas tight), was added 333 µg of LHRH, IgE or CD4 peptide immunogens dissolved in an appropriate aqueous buffer (111 uL, 3 mg/mL) or an immunostimulatory complex (with a 4:1 charge ratio) prepared from 333 µg of LHRH or IgE peptide immunogens or an immunostimulatory complex (with a 2:1 charge ratio) prepared from 333 µg of CD4 peptide immunogens dissolved in an appropriate aqueous solvent (111 µL, 3 mg/mL) and CpG1 or CpG2 oligonucleotides in appropriate ratios as described in Tables 3 and Table 4, respectively.

[00198] Specifically, to prepare immunostimulatory complex from LHRH peptide immunogens at a charge ratio of LHRH:CpG1 of 4:1, 24.3 µg CpG1 oligonucleotide (12.2 µL, 2.0 µg/mL) were added.

[00199] To prepare immunostimulatory complex from IgE peptide immunogens at a charge ratio of IgE:CpG1 of 4:1, 38.7 µg of CpG1 oligonucleotide (19.4 µL, 2.0 µg/µL) were added or to form a 1:1 neutral complex of IgE:CpG1, 154.8 µg of CpG1 oligonucleotide (77.4 µL, 2.0 µg/µL) were added.

WO 03/068169

PCT/US03/04711

[00200] To prepare immunostimulatory complex from CD4 peptide immunogens at a charge ratio of CD4:CpG2 of 2:1, 40 µg of CpG2 oligonucleotide (20 µL, 2.0 µg/µL) were added or to form a complex at a charge ratio of CD4:CpG2 of 1:2, 160 µg of CpG2 oligonucleotide (80 µL, 2.0 µg/µL) were added.

[00201] Additional diluent aqueous solvent was added so that the final volume of the aqueous phase was 300 µL.

[00202] To a second 1.0 mL glass syringe (gas tight), was added 700 µL of ISA Montanide® 720. The syringes were connected via luer locks to an extrusion-housing unit containing a membrane holder and support for the polycarbonate membrane filter. Membrane filters with pore sizes 3 µm or 5 µm were selected for w/o-emulsions to be prepared with peptide immunogens in the aqueous phase. Whereas, membrane filters with pore sizes 5 µm or 10 µm were selected for the preparation of w/o emulsions with immunostimulatory complex suspended in the aqueous phase. The aqueous phase was then first passed through the membrane into the oil phase, typically with great ease. The subsequent exchanges require additional pressure with the increased backpressure generated during the emulsion process. After 8-12 passages the backpressure upon extrusion had equalized and a homogeneous white emulsion was typically obtained.

[00203] The final concentration of immunogens once formulated as solutions or as immunostimulatory complex in water-in-oil emulsions as described above was 200 µg/mL.

Example 5c: Stability Evaluation for Water-in-Oil Emulsions Prepared by Extrusion

[0001] Stability tests similar to those conducted in Example 4c, prepared by the extrusion processes confirmed that these compositions were w/o-emulsion. Droplets placed on the

WO 03/068169

PCT/US03/04711

surface of distilled deionized water were observed to float with minimal dispersal. The viscosities of the resultant emulsions were found to range from ~35-40 mPa, a slight reduction when compared to the high energy homogenized system in Example 4c. The size distribution of the emulsion droplets was larger than the analogous homogenized systems. About 1-3 microns for w/o emulsions prepared from peptide immunogens or 2-5 microns for w/o emulsions prepared from immunostimulatory complex. For comparison, Figure 5 is a photomicrograph obtained from a w/o emulsion sample prepared via extrusion from ISA Montanide® 720 and an immunostimulatory complex derived from 200 µg of LHRH peptide immunogens and CpG1 oligonucleotides in a final charge ratio of LHRH:CpG1 of 4:1.

[00205] In general, the size of the droplets obtained by the low energy extrusion process as shown in Figure 5 were larger and more highly aggregated than the high energy homogenized droplets as shown in Figure 4. Overall, these instant w/o emulsions are sufficiently stable for immediate or same day use.

Example 6a: Preparation of In-situ Polymeric Gels

[00206] This Example illustrates the process of *in-situ* gel matrix formation and encapsulation of immunostimulatory complex derived from IgE or CD4 immunogens and CpG1 or CpG2 oligonucleotides in various proportions using direct reconstitution techniques. A flow diagram showing the process of preparing an *in-situ* gel formulation with either peptide immunogens or immunostimulatory complex via reconstitution as described herein is shown in Figure 6.

[00207] All glassware, stir bars and pipette tips were autoclaved for 40 minutes at 121°C prior to use. All reagents were weighed, dispensed, transferred or added to reaction vessels in a laminar flow hood to prevent contamination.

WO 03/068169

PCT/US03/04711

[00208] In general, varying weight percentages of PLG or PLGA copolymers (Boehringer Ingelheim) were dissolved in biocompatible solvents such as anhydrous dimethyl sulfoxide (DMSO, Aldrich). The solubilization process required vigorous agitation for higher molecular weight polymers with continuous stirring maintained for from 4-6 hours to ensure complete dissolution. The polymer solution was then filtered through an organic solvent compatible membrane of pore size 0.45 microns (Phenomenex, PTFE). To this was added a solution of cationic peptide immunogens or more preferably a suspension of immunostimulatory complex in an appropriate biocompatible solvent. The peptide immunogen or peptide/CpG complex or a mixture thereof was first lyophilized (as described in Example 3) and subsequently dissolved or resuspended in an appropriate biocompatible solvent, such as DMSO.

[00209] The use of polar aprotic solvents, such as DMSO, may present some problems with respect to long-term peptide stability. DMSO is known as a powerful oxidizing agent and peptides containing sensitive amino acids such as cysteine and tryptophan may be chemically incompatible in these solutions.

Thus, peptide immunogens containing these residues may have to be reconstituted on site for immediate use.

[00210] The lyophilized peptide immunogens or immunostimulatory complex or a mixture thereof was reconstituted directly in the vial into a solution of polymer in DMSO at the time of use, thereby avoiding prolonged exposure of the peptide immunogens to DMSO. The dissolution of the peptide immunogen or the resuspension of immunostimulatory complex or a mixture of the immunostimulatory complex with peptide immunogens was rapid, requiring gentle shaking to ensure sample uniformity.

[00211] There are minimal stability and manufacturing issues expected for these generic compositions. The polymer solutions in anhydrous DMSO are not as susceptible to

WO 03/068169

PCT/US03/04711

hydrolytic degradation as compared with peptide immunogens dissolved or suspended in aqueous solutions. The polymer solution may be frozen (DMSO freezes at c.a. 18°C) with no detectable changes in the physical properties upon thawing. The peptide or immunostimulatory complex isolated in the lyophilized dry state would also be expected to exhibit increased stability in the absence of water.

[00212] The mixture of polymer and peptide immunogens or immunostimulatory complex as such constitutes a single-phase solution or a suspension suitable for subcutaneous or intramuscular injection.

[00213] Of importance for either system is the viscosity of the solution or suspension. This directly influences the ability to syringe and inject the compositions by a subcutaneous or intramuscular route.

[00214] The apparent viscosity of these systems is a function of various factors including the constitution, molecular weight, crystallinity and intrinsic viscosity of the PLG or PLGA copolymers. These factors delimit the useful amount by weight for each polymer that can be dissolved while maintaining practical flow characteristics. Table 5 shows the physical properties for selected PLG or PLGA polymers and the corresponding amount in weight percentages that may be dissolved in DMSO to obtain solution viscosities of practical use. The apparent viscosity for these solutions was determined by a Brookfield DV-1+ rotational viscometer.

[00215] 100 mPa was arbitrarily chosen as the upper desired limit for these compositions. In most cases a solution or suspension formulated as an *in-situ* gelling polymer solution with an apparent viscosity less than 200 mPa can be uniformly delivered through conventional syringes.

WO 03/068169

PCT/US03/04711

[00216] A polymer/DMSO solution with polymer to solvent in excess of that required to provide an apparent viscosity of 100 mPa would be of value for delivery by an alternative modality, including conventional syringe or a needleless method. The gelling behavior upon injection and burst release of the immunogen is in part related to the concentration of the polymer in the composition. Consequently, maximizing the rate of gelation and reducing the burst release of immunogen would be two additional design parameters for consideration in the development of an optional single-dose controlled release composition.

Example 6b: Preparation of Polymers Gels from PLGA Resomer® - RG 503H or RG 504H

[0001] To two separate 25 mL flasks equipped with stir bars was added 2,200 mg RG 504H or 2,750 mg RG 503H respectively. To each flask was added 10.0 mL of anhydrous DMSO (1.1 gm/mL) by transfer pipette. The mixtures were vigorously stirred for c.a. 2-3 hours at room temperature after which the copolymers were fully solubilized. After complete dissolution the stock solutions were filtered through a 0.45 μ M organic solvent stable membrane filter (Phenomenex, PTFE). The final weight percent of RG 504H and RG 503H polymer to DMSO solvent was 20% and 25% respectively.

[00218] 10 mL of the polymer/DMSO solution so prepared was then added via syringe into vials containing lyophilized IgE or CD4 peptide immunogens (2,000 μ g) or lyophilized immunostimulatory complex (4:1 IgE:CpG1 charge ratio or 2:1 CD4:CpG2 charge ratio) derived from 2,000 μ g of IgE peptides mixed with 232 μ g of CpG1 oligonucleotide (116 μ L, 2.0 μ g/ μ L) or 2,000 μ g of CD4 peptides mixed with 241 μ g of CpG2 oligonucleotide (120.5 μ L, 2.0 μ g/ μ L). The final concentration of immunogen in solution or in the form of an immunostimulatory complex in suspension

WO 03/068169

PCT/US03/04711

was 200 µg/mL. The immunogen or immunostimulatory complex was immediately reconstituted in solution or suspension with gentle shaking to ensure content uniformity.

[00219] The apparent viscosities of the solutions prepared from these polymers at the specified weight ratios were found to be close to 100 mPa. (see Table 5). The concentrations for Resomer® RG 503H, Resomer® RG 504H and Resomer® RG 756 for a solution viscosity of around 100 mPa were critical, Resomer® RG 503H and Resomer® RG 504H have much lower inherent viscosities and both are derived from PLGA with amorphous character, wherein the monomer composition was around 50% D,L-lactide and 50% glycolide. These materials would be expected to degrade at a rate of 6-8 weeks for 50% of the polymer *in vivo*. Thus, the encapsulated components would have a two-three month release profile with gels prepared from Resomer® RG 503H or Resomer® RG 504H. Gels prepared from these materials would be most suited for short-term single-dose controlled release applications. Conversely, Resomer® RG 756 is a more crystalline polymer composed of 75% D,L-lactide to 25% glycolide residues. It may require from 4-6 months for 50% of the polymer to degrade *in vivo* and the release rate for encapsulated components would consequently be more protracted. Resomer® RG 756 would be expected to be more desirable for long-term single-dose controlled release applications.

Example 7: The Immunogenicity of IgE and CD4 Peptide Immunogens Formulated as Immunostimulatory complex or as W/O Emulsion or in Combinations

[00220] This Example illustrates the immunogenicity of IgE and CD4 peptide immunogens formulated as immunostimulatory complexes with CpG1 or CpG2 oligonucleotides, as a w/o-emulsion or as immunostimulatory complex dispersed in a w/o-emulsion in guinea pigs, which were immunized intramuscularly.

WO 03/068169

PCT/US03/04711

The w/o-emulsions were prepared by homogenization as described in Example 4a/4b or by extrusion as described in Example 5a/5b.

[00221] Groups of three, 6 to 8 week old female guinea pigs (Covance Research Products Inc., Denver, PA) were immunized intramuscularly (I.M.) on week 0, 3 and 6 with the following compositions: 100 µg of the IgE peptides/CpG1 immunostimulatory complex (4:1 charge ratio and 1:1 charge ratio) prepared as described in Table 4 suspended in a final volume of 250 µL PBS, pH 7.4; CD4 peptides/CpG2 immunostimulatory complexes (2:1 charge ratio and 1:2 charge ratio) prepared as described in Table 4 in 75 µL suspended in a final volume of 250 µL PBS, pH 7.4;; IgE peptides in 75 µL PBS, pH 7.4 emulsified with ISA Montanide® 720 (175 µL); CD4 peptides in 75 µL distilled deionized water emulsified with ISA Montanide® 720 (175 µL); IgE peptide/CpG1 immunostimulatory complex in 75 µL PBS, pH 7.4 prepared as described in Table 4 (4:1 charge ratio and 1:1 neutral charge ratio) emulsified with ISA Montanide® 720 (175 µL), or CD4 peptides/CpG2 immunostimulatory complexes prepared as described in Table 4 in 75 µL distilled deionized water (2:1 charge ratio and 1:2 charge ratio) emulsified with ISA Montanide® 720 (175 µL).

[00222] The guinea pigs showed no gross pathologies or behavioral changes after receiving immunostimulatory complexes, w/o emulsions containing peptide immunogens or w/o emulsions containing the immunostimulatory complexes. Sera were obtained on weeks +3, +5, +9, +11 and +17 and were evaluated for the presence of anti-IgE antibodies in the case of IgE immunogens or anti-CD4 antibodies in the case of CD4 immunogens, by immunogen-specific ELISAs.

WO 03/068169

PCT/US03/04711

Measurement of anti-IgE antibodies

[00223] Anti-IgE peptide titers were determined by IgE peptide ELISA and cross-reactivities to human IgE by human IgE ELISA. Peptide ELISAs for determination of anti-IgE peptide reactivity were conducted in microtiter plates coated with the target antigen site peptide without the T helper site, as described⁶⁴. For determination of anti-human IgE cross-reactivity, human IgE ELISAs were conducted in microtiter plates coated in a likewise fashion with a human IgE myeloma protein (American Biosystems, Inc. cat. no. A113) at 5 µg/ml.

[00224] Captured anti-peptide or anti-IgE antibodies were detected by horseradish peroxidase-labeled anti-guinea pig IgG goat antibody. ELISA titers, expressed as log₁₀ of reciprocal dilution, were calculated based on linear regression analysis of the absorbances, with cutoff A₄₉₂ set at 0.5. This cutoff value was rigorous, as the values for diluted normal guinea pig control samples run with each assay were less than 0.15. Hyperimmune guinea pig anti-IgE peptide immunogen antiserum was used as a positive control. Pre-immune sera were used as negative controls.

Measurement of anti-CD4 Antibodies

[00225] ELISAs for binding to recombinant soluble CD4 were done in 96 well microtiter plates coated with rsCD4 (American Bio-Technologies) at 0.25 µg/mL, using 100 µL per well in 10mM NaHCO₃ buffer, pH 9.5. Wells were blocked with 250 µL of 3% gelatin, washed with 0.05% TWEEN 20 in phosphate-buffered-saline (PBS) and dried. Test wells were reacted with 100 µL of diluted immune sera for 1 hour at 37 C. Wells were washed with 0.05% TWEEN 20 in PBS, reacted with 100 µL of horseradish peroxidase-labeled goat anti-mouse IgG (Pierce) diluted 1:1000 in 1% goat serum, 0.05% TWEEN® 20 in PBS, and washed. 100 µL of orthophenylenediamine (OPD) substrate at 0.04% by weight

WO 03/068169

PCT/US03/04711

(Pierce) and 0.12% H_2O_2 in sodium citrate buffer, pH 5.0, was added for 15 minutes. Reactions were stopped by addition of 100 μ L 1.0 M H_2SO_4 and A_{492} determined. Hyperimmune guinea pig anti-CD4 peptide immunogen antiserum was used as a positive control. Pre-immune sera were used as negative control.

Measurement of Functional Antigenicity by Competitive ELISA

[00226] In this competitive ELISA, functional antigenicity was quantitated for CD4 immunogens by testing the evoked antibodies for the capacity to competitively inhibit a functional monoclonal antibody, mAb B4, whose known specificity was for the CD4 complex on the host cell surface that binds HIV. This anti-binding site monoclonal antibody has been well characterized for its high affinity for the HIV binding complex, for binding to domain 1 of soluble recombinant CD4 (rsCD4), and for its ability to neutralize HIV-1 primary isolates.⁶⁵

[0001] The anti-binding site monoclonal antibody was purified by protein A affinity chromatography and conjugated to horseradish peroxidase. The mAb B4-HRP conjugate was used in the assay as a tracer, at a concentration of 0.5 μ g/ml. 96-well microtiter plates were coated with recombinant soluble CD4 protein, 1 μ g/ml in 0.1 M sodium carbonate buffer, pH 9.5, with overnight incubation. Reactions were done in the microtiter wells in 100 μ L total volume of PBS/goat serum/gelatin/TWEEN® 20, with serially diluted immune serum (guinea pig, swine, or baboon) and 30 μ L of the mAb B4-HRP working stock. Diluted serum and mAb B4-HRP were pre-incubated prior to adding the mixture to the well. The positive control for the competition ELISA was 5 μ L of unlabelled-anti-binding site mAb at 0.5 μ g/ml in normal serum, the negative control is normal serum. The serum/antibody

WO 03/068169

PCT/US03/04711

dilution mixture, 100 μ l was added to a coated well and incubated for one hour at 37°. The plates were drained and washed and bound mAb B4-HRP was detected by reaction with a chromogen. The chromogen was 3,3',5,5'-tetramethylbenzidine (TMB) and TMB-bound mAb B4 conjugate was detected at A₄₅₀. A calibration curve was obtained with purified mAb B4 serially diluted from 10 μ g/ml into normal serum of the appropriate species so as to obtain an mAb equivalent value for the dilutions of immune sera which competitively inhibit the binding to human recombinant soluble CD4 of the mAb B4-HRP.

Virus Neutralization Assay

[00228] The MT-2 microplaque assay was carried out as described⁶⁶ except that heat-inactivated sera were serially diluted in 50% high glucose DMEM with 15% FBS, antibiotics, 2% glutamine and bicarbonate buffer, and 50% pooled, defibrinated normal human plasma. In this assay, diluted serum is incubated with 20 pfu of HIV in microtiter wells. HIV-sensitive MT-2 cells are added and formed into monolayers by centrifugal force under molten agarose. Residual virus infectivity is detected by the presence of propidium iodide-stained plaques one week later. The endpoint is the serum dilution at which there was a 50% or 90% reduction in the plaque count.

Immunogenicity Results

[00229] The serum antibody titers following immunization of IgE immunogens are shown in Figure 7 (homogenized systems) and Figure 9 (extruded systems) and for CD4 immunogens are shown in Figure 8 (homogenized systems) and Figure 10 (extruded systems). Table 6 compares the competitive inhibition of a B4 monoclonal antibody assayed on sera obtained from the CD4 peptide study (homogenized and extruded w/o emulsion systems) on week 9, week 11 and week 17, respectively. Table 7

WO 03/068169

PCT/US03/04711

compares virus neutralization activity (50% and 90% inhibition respectively) assayed on sera obtained from the CD4 peptide study (homogenized and extruded w/o emulsion systems) on week 9 and week 11, respectively. Control experiments demonstrated that unadjuvanted peptide was non-immunogenic or weakly immunogenic in all cases.

[00230] For both IgE and CD4 vaccines, the results of immunizations indicated that immunostimulatory complexes were adjuvanting and titers by week 9 were slightly less than or comparable to those obtained with w/o emulsions, irrespective of whether the emulsions were prepared by homogenized or extruded techniques as shown in Figures 7-10.

[00231] The combination systems with immunostimulatory complex dispersed as w/o emulsions prepared by either method consistently provided the highest sustained immune responses.

As depicted in Figures 7-10, the antibody titers elicited from week 11 through week 17, for both IgE and CD4 immunogens were found to be on the order of a log unit or more higher than antibody titers obtained with either the immunostimulatory complex alone or the w/o emulsions with peptide alone. The sole exception to this being the CD4 w/o emulsions prepared by homogenization, where this separation is not found until week 17.

[00232] This observation is further supported by data obtained from the CD4 peptide competitive inhibition and virus neutralization studies highlighted in Tables 6 and 7, wherein the immune sera to the w/o emulsion combination systems with CD4 peptide/CpG oligonucleotides (charge ratio CD4:CpG2 = 2:1) competitively inhibited the highest level of B4 monoclonal antibody compared to the immune sera to the simple w/o emulsions or immunostimulatory complex with CD4 peptides alone. Moreover, the same formulations are shown to be the

WO 03/068169

PCT/US03/04711

most effective at eliciting neutralizing activity against infectious virus.

[00233] Small differences are noted between the homogenized or extruded preparations and include the rate with which the titers elicited to IgE or CD4 immunogens obtained by ELISA were observed to peak. The immune responses peaked earlier (wk 9) for the extruded w/o emulsions, although the duration of the responses obtained are good (essentially equivalent by week 11 and slightly reduced by week 17). The analogous homogenized system peaked a little later (week 11) and provided sustained responses as can be seen by the high titers persisting at week 17.

[00234] This trend is also supported by data obtained from the CD4 peptide/mAb B4-HRP competitive inhibition assay and the virus neutralization studies highlighted in Tables 6 and 7.

[00235] By week 9, assays on sera obtained from animals immunized by the w/o emulsion system prepared from uncomplexed CD4 peptides via homogenization (87.2%) or by extrusion (88.6%) have been shown to competitively inhibit high levels of B4 monoclonal antibody. These were found to be the same order of magnitude (within experimental error) as for sera obtained from animals immunized with the w/o emulsion combination systems of CD4 peptide/CpG2 oligonucleotides (2:1) prepared via homogenization (70.1%) or by extrusion (94.9%). By week 17, assays on sera obtained from animals immunized by the w/o emulsion system prepared from uncomplexed CD4 peptides via homogenization (11.2%) or by extrusion (42.6%) competitively inhibited dramatically lower levels of B4 monoclonal antibody. The degree of inhibition were no longer generally comparable with that obtained for sera from animals immunized with the w/o emulsion combination systems of CD4 peptide/CpG2 oligonucleotides (2:1) prepared via homogenization (85.0%) or by extrusion (77.2%) processes.

WO 03/068169

PCT/US03/04711

[00236] Moreover, the same trend is shown for sera obtained from formulations of CD4 peptides when assayed for neutralization of infectious HIV-1 virus.

[00237] By week 9, assays on sera obtained from animals immunized by the w/o emulsion system prepared from uncomplexed CD4 peptides via homogenization (73% for 50% virus neutralization or 27% for 90% virus neutralization) or by extrusion (31% for 50% virus neutralization or 12% for 90% virus neutralization) neutralized essentially the same percentages of infectious HIV-1 virus (within experimental error). Assays on sera obtained from animals immunized with the w/o emulsion combination systems of CD4 peptide/CpG2 oligonucleotides (2:1) prepared via homogenization (12% for 50% virus neutralization or < 10% for 90% virus neutralization) or by extrusion (103% for 50% virus neutralization or 33% for 90% virus neutralization) has shown that the homogenized system is significantly less effective at generating neutralizing antibodies against infectious HIV-1 virus at this time point. By week 11, assays on sera obtained from animals immunized by the w/o emulsion system prepared from uncomplexed CD4 peptides via homogenization (57% for 50% virus neutralization or 17% for 90% virus neutralization) or by extrusion (< 10% for 50% virus neutralization or < 10% for 90% virus neutralization) demonstrated that the capacity to neutralize infectious HIV-1 virus is reduced or eliminated (within experimental error). Assays on sera obtained from animals immunized with the w/o emulsion combination systems of CD4 peptide/CpG oligonucleotides (2:1) prepared via homogenization (40% for 50% virus neutralization or 30% for 90% virus neutralization) or by extrusion (120% for 50% virus neutralization or 39% for 90% virus neutralization) has clearly shown that both the homogenized and extruded systems were now effective at eliciting neutralizing antibody responses against infectious HIV. The response for the

WO 03/068169

PCT/US03/04711

homogenized system was shown to be delayed relative to the extruded composition.

[00238] One possible explanation for these trends may be that w/o emulsions prepared via low energy extrusion processes can interact or present complexed immunogens more efficiently at earlier time points to immune effector cells, whereas the high energy homogenization process, provides a more uniform emulsion and essentially acts as a more efficient depot. The immune responses obtained by such a system would be anticipated to be delayed and potentially more sustainable.

[00239] The combination of the immunostimulatory complex and residual uncomplexed peptides dispersed in w/o emulsions were found to synergistically enhance the overall titers for both the IgE and CD4 immunogens. The method of preparation can influence the kinetics and duration of the responses, with both homogenization and extrusion shown to be compatible for preparing an efficacious vaccine.

[00240] In addition, in a separate study we examined the effect of CpG dose on immune responses. For both IgE and CD4 immunogens, immunostimulatory complexes were prepared from varying doses of CpG1 or CpG2 oligonucleotides (i.e. IgE:CpG1 = 4:1 or 1:1 and CD4:CpG2 = 2:1 or 1:2) and administered in either an aqueous buffer or dispersed in a w/o emulsion. All compositions were found to be immunogenic, however, in both studies the smaller relative dose of oligonucleotide (excess of synthetic peptide immunogen to oligonucleotide) elicited the superior immune responses in terms of absolute titer and of duration. In the case of IgE peptides/CpG1 oligonucleotides the ranking follows the order 4:1 charge ratio > 1:1 neutral charge ratio whereas for CD4 peptides/CpG2 oligonucleotides the ranking follows the order 2:1 charge ratio > 1:2 charge ratio. Most often improved adjuvant activity can be correlated with increasing doses of adjuvants. In

WO 03/068169

PCT/US03/04711

these Examples, we have demonstrated the unexpected advantages of co-formulating stabilized immunostimulatory complex and uncomplexed peptide for maximum synergy of immune responses.

[00241] Thus, it can be concluded that immunostimulatory complex prepared from IgE or CD4 immunogens as described in this Example can effectively adjuvant immune responses *in vivo*. The responses obtained are comparable to those found for these same immunogens dispersed in w/o emulsions, however, it is anticipated that fewer reactogenicity issues would result from use of the fully aqueous dispersable immunostimulatory complex of synthetic immunogens as opposed to dispersing synthetic immunogens as w/o emulsions.

[00242] In this Example we have demonstrated that the delivery of IgE or CD4 immunogens as immunostimulatory complexes in combination with uncomplexed peptides dispersed within a water-in-oil emulsion vehicle provided the most effective presentation of immunogen to the immune system. The immune responses obtained for the combined system are significantly greater than the sum of the immune responses obtained for each system independently.

[00243] Furthermore, assays of sera obtained from animals immunized with combinations of immunostimulatory complex of CD4 immunogens and uncomplexed CD4 immunogens dispersed within a water-in-oil emulsion vehicle were shown to be more effective than simple w/o emulsions of uncomplexed CD4 immunogens at competitively inhibiting B4 monoclonal antibody. Moreover these same systems were shown to be the most effective at neutralizing infectious HIV-1 virus.

[00244] In the guinea pig model, the quantity and longevity of the immune responses obtained indicated that immunostimulatory complex derived from IgE/CpG1 and CD4/CpG2 combinations were preferred. It was experimentally determined that compositions

WO 03/068169

PCT/US03/04711

derived from the alternative pairings of IgE/CpG2 and CD4/CpG1 were adjuvanting, although not to the same extent.

[00245] The possibility for fewer and lower (immunogen/adjuvant) dose regimens is indicated by these results. In cases where reactogenicity is a problem the combination system opens up the possibility of administering a smaller volume of emulsion with similar or higher levels of immunogenicity.

[00246] Specifically, this Example strongly indicates the potential of these new combination based formulations for development as efficacious dosage forms.

Example 8: The Immunogenicity of IgE and CD4 Peptide Immunogens Formulated as Immunostimulatory complex or as In-situ Gelling Polymer Solutions or in Combinations

[00247] This Example illustrates the immunogenicity of IgE and CD4 peptide immunogens formulated as immunostimulatory complex with CpG1 or CpG2 oligonucleotides or as *in-situ* gelling polymers and biocompatible solvents or as immunostimulatory complex suspended in *in-situ* gelling polymers and biocompatible solvents in guinea pigs, which were immunized intramuscularly. Lyophilized peptide immunogens or immunostimulatory complex derived from peptide immunogens and CpG oligonucleotides were prepared as described in Example 3.

The *in-situ* gelling polymers were prepared as described in Example 6a/6b.

[00248] To examine the immunogenicity of IgE and CD4 peptide immunogens formulated as *in-situ* gelling polymers (Resomer® RG 504H) or as immunostimulatory complexes with CpG1 or CpG2 oligonucleotides suspended in *in-situ* gelling polymers (Resomer® RG 504H) formed in accordance with the present invention, groups of three, 6 to 8 week old female guinea pigs (Covance Research Products Inc, Denver, PA) were immunized

WO 03/068169

PCT/US03/04711

intramuscularly (I.M.) with the following amounts of immunogen on week 0: 300 µg of lyophilized IgE peptides/CpG1 immunostimulatory complex (4:1 charge ratio) reconstituted and suspended in a final volume of 200 µL PBS (pH 7.4), prepared as described in Table 4, or 300 µg of CD4 peptides/CpG2 immunostimulatory complex (2:1 charge ratio) reconstituted and suspended in a final volume of 200 µL PBS (pH 7.4), prepared as described in Table 4, or 300 µg of IgE peptides reconstituted and suspended in 200 µL of Resomer® RG 504H (20% by wt) dissolved in dimethyl sulfoxide (DMSO) or 300 µg of CD4 peptides reconstituted and suspended in 200 µL of Resomer® RG 504H (20% by wt) dissolved in dimethyl sulfoxide (DMSO) or 300 µg of lyophilized IgE peptides/CpG1 immunostimulatory complex (4:1 charge ratio), prepared as described in Table 4, reconstituted and suspended in 200 µL of Resomer® RG 504H (20% by wt) dissolved in dimethyl sulfoxide (DMSO) or 300 µg of lyophilized CD4 peptides/CpG2 immunostimulatory complex (2:1 charge ratio), prepared as described in Table 4, reconstituted and suspended in 200 µL of Resomer® RG 504H (20% by wt) dissolved in dimethyl sulfoxide (DMSO).

[00249] The guinea pigs showed no gross pathologies or behavioral changes after receiving immunostimulatory complex, *in-situ* gelling polymers in DMSO containing peptide immunogens or *in-situ* gelling polymers in DMSO containing immunostimulatory complex. Sera were obtained on weeks +3, +6, +9, +12 and were evaluated for the presence of anti-IgE antibodies in the case of IgE immunogens or anti-CD4 antibodies in the case of CD4 immunogens, by immunogen-specific ELISAs following the procedures described in Example 7.

WO 03/068169

PCT/US03/04711

Immunogenicity Results

[00250] The serum antibody titers following single-dose immunization of IgE immunogens are shown in Figure 11 and for CD4 immunogens are shown in Figure 12. Control experiments demonstrated that unadjuvanted peptide was non-immunogenic or weakly immunogenic in either case. In both studies, the results of immunizations indicated that immunostimulatory complex alone were moderately adjuvanting with the titers peaking by week 9. Conversely, uncomplexed immunogens suspended in *in-situ* gelling polymers were also weakly adjuvanted with peak responses observed at week 12.

[00251] For both IgE and CD4 immunogens, the derived immunostimulatory complexes suspended as an *in-situ* gelling polymer elicited the highest immune responses. These responses were seen to peak around week 9 and were sustainable through week 12. The quantity and duration of the immune responses obtained were not found with either the immunostimulatory complex alone or with uncomplexed immunogens administered in a composition including *in-situ* gelling polymer alone.

[00252] It is expected that small molecular weight immunogens such as peptides can easily diffuse through polymer implants and gels resulting in large quantities of burst release upon injection. The physical factors that control gelation can be adjusted to retard this process; however, the mass of peptide so released is essentially unadjuvanted and subject to the standard degradation processes that are normally experienced *in vivo*. In addition, the small amounts of material remaining encapsulated may not be expected to be sufficient for an efficient boost once the polymer degrades, necessitating much larger doses of peptide. The residual DMSO trapped within the matrix also presents stability issues, wherein sensitive amino acids contained in the peptides could be oxidized.

WO 03/068169

PCT/US03/04711

Furthermore it has been well established that water can penetrate these materials at varying rates depending on various factors such as gel micromorphology, polymer hydrophobicity and crystallinity^{45, 46}. Water penetrating the matrix will promote bulk hydrolysis, the prime degradation mechanism operating on PLG/PLGA copolymers *in vivo*. This process is known to be accompanied by dramatic local pH changes, which can essentially reduce the pH to 2 or 3⁶⁷. The free uncomplexed solubilized peptides may not be stable to such an environment, and this further limits the potential for these systems. Acid buffering agents may be employed to help to offset these problems, but cannot be considered ideal. Encapsulating a suspension of peptide immunogens in the form of an immunostimulatory complex imparts a number of stability and adjuvantation advantages for this system. Once the injection of polymer gel is made, the small amounts of complex not effectively encapsulated in the gel (presumably surface located near the gelling front) can serve to initiate or prime the immune response more effectively than uncomplexed peptide immunogen alone. The CpG oligonucleotide remains in close contact with peptide immunogen and in the form of a complex particulate may further protect and stabilize the peptide immunogen from enzymatic digestion *in vivo* or from chemical instabilities which may be due to the DMSO solvent contained within the matrix.

[00253] Furthermore, the peptide immunogens remaining entrapped in the matrix in a particulate form would be expected to be better protected against the acidification process than free uncomplexed peptides. Immunogens presented in this form can be expected to provide a more efficient boost of immunogen to the immune system eliciting stronger and longer lasting immune responses than otherwise possible in a single-dose controlled release formulation.

WO 03/068169

PCT/US03/04711

[00254] In control experiments, it was determined that solutions of uncomplexed peptide immunogens dissolved in polymer compositions of RG 504H (20% by wt) in DMSO gelled rapidly when placed in contact with solutions of PBS. Separating the solution from gel phase for these samples and analyzing the solutions by ultraviolet spectroscopy (at $\lambda = 280$ nm) revealed that sizeable amounts of uncomplexed peptide (c.a. 50-70%) were co-extracted with the DMSO.

[00255] The combination of the immunostimulatory complex and uncomplexed peptide immunogens suspended in *in-situ* gelling polymers have been found to synergistically enhance the overall titers for both the IgE and CD4 immunogens in these controlled release preparations.

[00256] A separate study examining the effect of CpG oligonucleotide dose on immune responses was not conducted in this study. It would be expected that further improvement in the absolute titers may be obtained by employing immunostimulatory complex prepared near electrical neutrality or with an excess of negative charge supplied by either CpG oligonucleotide or alternatively an additional compatible excipient. In these compositions the majority of the peptide immunogen is bound as an immunostimulatory complex and the gellation process upon injection does not result in major losses of unadjuvanted peptide by virtue of co-extraction in the biocompatible solvent.

[00257] Thus, it can be concluded that immunostimulatory complex can both stabilize peptide immunogens as immunostimulatory complex and that these compositions when combined with an *in-situ* gelling polymer can effectively adjuvant the immune responses *in vivo*. This is particularly important for these polymer systems which are intended for single-dose use. The delivery of immunogens as immunostimulatory complex suspended within an *in-situ* gelling

WO 03/068169

PCT/US03/04711

polymer vehicle provides the most efficient presentation of immunogen to the immune system. The responses obtained for the combined system are significantly greater than the sum of the immune responses obtained for each system independently and are sustainable, unlike *in-situ* gels prepared by simple reconstitution of uncomplexed peptide immunogens from polymers in biocompatible solvents.

[00258] In the guinea pig model, the quantity and longevity of the responses obtained indicated that immunostimulatory complexes derived from IgE/CpG1 and CD4/CpG2 combinations were preferred. It was experimentally determined that compositions derived from the alternative pairings of IgE/CpG2 and CD4/CpG1 were adjuvanting, although not to the same extent.

[00259] The possibility of a single-dose regimen is indicated by these results. Specifically, this Example strongly indicates the potential of these new instantly reconstituted combination-based formulations for development as efficacious controlled release dosage form.

Example 9: Preparation of Combination Immunostimulatory Complex and Mineral Salt Suspensions

[00260] This Example illustrates the process of preparing a mineral salt suspension from cationic peptides derived from LHRH peptide immunogens (SEQ ID NOS: 7-9 in a 1:1:1 molar ratio in solution) or an immunostimulatory complex derived from LHRH immunogens and CpG1 oligonucleotide in various proportions. A flow diagram illustrating the process of preparing a mixed suspension as described herein is shown in Figure 16.

[00261] All glassware, stir bars and pipette tips were autoclaved for 40 minutes at 121°C prior to use. All reagents were weighed, dispensed, transferred or added to reaction vessels in a laminar flow hood to prevent contamination.

WO 03/068169

PCT/US03/04711

[0001] To a 5.0 mL glass vial equipped with a stir bar, was added 100 µg (250 µL, 0.4 mg/mL) or 1,600 µg (534 µL, 3.0 mg/mL) of LHRH peptide immunogens dissolved in an aqueous solution. Immunostimulatory complexes with either of two charge ratios (i.e. 4:1 or 1.5:1) were prepared from LHRH immunogens and CpG1 oligonucleotides in distilled deionized water.

[00263] Specifically, the preparation of a 4:1 complex from 100 µg or 1,600 µg of LHRH immunogens required 7.3 µg or 116.8 µg of CpG1 oligonucleotide (2.0 mg/mL), whereas the preparation of a 1.5:1 complex from 1,600 µg of LHRH immunogens required 350.4 µg of CpG1 oligonucleotide (2.0 mg/mL), respectively.

[00264] Table 9 shows the calculations employed to determine the relative amount of CpG1 oligonucleotide required for complexation with LHRH peptide immunogens for a fixed final dosage of 25 µg/0.5 mL or 400 µg/0.5 mL with respect to the specified charge ratios.

[00265] To a second 5.0 mL glass vial, was added 1.0 mL of Alhydrogel® (3.2 mg Aluminum (Al)/mL) mineral salt suspension in distilled deionized water. The Alhydrogel® stock suspension employed was first pH adjusted to pH 7.1-7.4 by the addition of 0.1 N NaOH. The pH measurements were made through use of pH indicator strips with a resolution +/- 0.3 pH units.

[00266] The mineral salt suspension was added to the vial containing immunostimulatory complex and residual unbound immunogens and equilibrated with stirring over 30 minutes.

[0001] To the mixture of Alhydrogel® and immunostimulatory complex was added 90 µL of 20% NaCl for tonicity, 5.0 µL of 2-phenoxy-ethanol (2-PE) preservative (in select cases) and additional distilled deionized water to ensure the final volume of the formulation equaled 2.0 mL.

WO 03/068169

PCT/US03/04711

[00268] The final concentration of immunogens once formulated as a suspension of immunostimulatory complex combined with mineral salt as described above was 25 µg/0.5 mL or 400 µg/0.5 mL respectively. The final concentration of Alhydrogel® prepared was dependent on target species. Formulations intended for the rodents were prepared at 0.4 mg Al/0.5 mL whereas formulations intended for non-human primates were prepared at 0.8 mg Al/0.5 mL. In all cases the finished formulations were adjusted for tonicity (0.9% NaCl) and those employed for the non-human primates contained a preservative (0.25% v/v, 2-PE).

Example 10: The Immunogenicity of LHRH Peptide Immunogens Formulated as a Suspension of Immunostimulatory Complex with Mineral Salt in Rodents

[00269] This Example illustrates the immunogenicity of LHRH peptide immunogens formulated as immunostimulatory complexes with CpG1 oligonucleotides in combination with mineral salts, which were immunized intramuscularly, in male rats. The mineral salt suspensions were prepared as described in Example 9.

[0001] Groups of four, 6 to 8 week old Sprague-Dawley male rats were immunized intramuscularly (I.M.) on week 0 4 and 8 with following compositions: 25 µg of LHRH peptides was suspended in a volume of 500 µL distilled deionized water; 25 µg of LHRH peptides was suspended in a volume of 250 µL distilled deionized water and 250 µL of Alhydrogel® (1.6 mg Al/mL) was added; 25 µg of LHRH peptides/CpG1 immunostimulatory complex (4:1 charge ratio) prepared as described in Table 9 was suspended in a volume of 500 µL distilled deionized water; 25 µg of LHRH peptides/CpG1 immunostimulatory complex (4:1 charge ratio) prepared as described in Table 9 was suspended in a volume of 250 µL

WO 03/068169

PCT/US03/04711

distilled deionized water and 250 μ L of Alhydrogel[®] (1.6 mg Al/mL) was added. To each formulation was added 45 μ L of a 20% saline solution and 455.0 μ L of distilled deionized water.

The final volume of each formulation was 1.0 mL.

[00271] The rats showed no gross pathologies or behavioral changes after receiving mineral salts containing peptide immunogens or mineral salts containing the immunostimulatory complex. Sera were obtained on weeks +0, +4, +6, +8 and +12 and were evaluated for the presence of anti-LHRH antibodies by immunogen-specific ELISA and for serum testosterone by RIA immunoassay.

Measurement of anti-LHRH antibodies

[00272] Antibody activities were determined by ELISA using 96 well microtiter plates coated with the LHRH peptide⁵⁴ as immunosorbent.

[00273] Aliquots (100 μ L) of the peptide immunogen solution at a concentration of 5 μ g/mL were incubated for 1 hour at 37°C. Wells were subsequently blocked with a 3% gelatin/PBS solution for 1 hour at 37°C. The plates were then dried and used for the assay. Aliquots (100 μ L) of the test immune sera, starting with a 1:100 dilution in a sample dilution buffer and 10-fold serial dilutions thereafter, were added to the peptide coated plates. The plates were incubated for 1-1.5 hours at 37°C. The plates were washed six times with 0.05% TWEEN 20 in PBS. 100 μ L of horseradish peroxidase-labeled goat anti-rat IgG (Cappel) for assays performed on rat sera, 100 μ L of goat anti-swine horseradish peroxidase-labeled IgG (Pierce) for assays performed on swine sera or 100 μ L of horseradish peroxidase-labeled goat anti-human IgG (Anogen) for assays performed on baboon sera was added at the appropriate dilutions in conjugate dilution buffer (PBS containing 0.5M NaCl and normal goat serum). The plates were incubated for 1

WO 03/068169

PCT/US03/04711

hour at 37°C and washed as described above. Aliquots (100 µL) of orthophenylenediamine (OPD) substrate at 0.04% by weight (Pierce) and 0.12% H₂O₂ in sodium citrate buffer, pH 5.0, was added for 15 minutes. Reactions were stopped by addition of 50 µL 2N H₂SO₄ and the A₄₉₂ determined for each well.

[00274] ELISA titers were calculated based on linear regression analysis of the adsorbances, with cutoff A₄₉₂, set at 0.5. This cutoff was rigorous, as the values for diluted normal control samples run with each assay were less than 0.15.

Measurement of Serum Testosterone

[00275] Immunogens were evaluated for efficacy by RIA for serum testosterone values. Serum testosterone levels were measured using a RIA kit from Diagnostic Products (Los Angeles, Calif.) according to manufacturer's instructions. The lower detection limit for testosterone ranged from 0.01 to 0.03 nMol/L. Each sample was analyzed in duplicate.

[00276] Serum samples were scored as being at castration level when the testosterone level was below limits of detection and as "near castration" at < 0.1 nMol/L.

Immunogenicity Results

[00277] The serum antibody titers following immunization of LHRH immunogens are shown in Figure 13a. The corresponding serum testosterone levels are shown in Figure 13b.

[00278] The antibody titers determined from sera obtained from male rats in this study proved that neither the composition of LHRH peptides in buffer nor LHRH peptides in combination with the Alhydrogel® mineral salts were immunogenic. Conversely, both compositions derived from the LHRH/CpG1 immunostimulatory complex alone or in combination with the Alhydrogel® mineral salt were shown to be immunogenic as depicted in Figure 13a.

WO 03/068169

PCT/US03/04711

[00279] The antibody responses of these later two groups proved similar over the first 8 weeks. By week 12, the antibody titers found for the combined system of LHRH immunostimulatory complex and Alhydrogel® mineral salt were only marginally better (i.e. ~ 0.5 log units) than those determined for the LHRH immunostimulatory complex alone.

[00280] The corresponding serum testosterone levels determined for the compositions of LHRH peptides in buffer and LHRH peptides in combination with the Alhydrogel® mineral salts similarly demonstrated that neither the LHRH peptide nor LHRH peptide with mineral salt formulations were capable of achieving immunocastration in male rats.

[00281] Conversely, both the immunostimulatory complex derived from LHRH peptides/CpG1 alone and the combination of LHRH peptides/CpG1 oligonucleotide with Alhydrogel® mineral salt effectively immunocastrated all rats in each group as shown in Figure 13b.

[00282] Complete immunocastration for each rat in the composition derived from the LHRH immunostimulatory complex combined with the Alhydrogel® mineral salt was achieved by week 6 (2 weeks after the first boost). A similar level of immunocastration for the composition derived from the LHRH immunostimulatory complex alone was not achieved until week 10 (2 weeks after the second boost).

[00283] In this Example we have demonstrated a novel vaccination regimen to obtain effective immunocastration (as measured by serum testosterone) with either a composition prepared from LHRH immunostimulatory complex (in a 3-dose immunization strategy) or a LHRH immunostimulatory complex in combination with a mineral salt (in a two-dose immunization strategy).

WO 03/068169

PCT/US03/04711

[00284] The Alhydrogel® mineral salt administered alone with LHRH peptide immunogens proved to be an ineffective adjuvant. However, once formulated with the LHRH immunogens in the form of an immunostimulatory complex the combination yielded synergistically far superior results. The mineral salt itself may be acting in two modes. The first may be to provide a depot localizing the immunostimulatory complex at the site of injection and secondly by recruiting specialized cells of the immune system which can facilitate the presentation of immunogen to the immune system.

[00285] Concurrent experiments were conducted with alternative mineral salt, Adju-phos® (derived from Aluminum phosphate) and full immunocastration in all rats was achieved by week 8 solely for the system derived from the LHRH immunostimulatory complex in combination with the Adju-phos® mineral salt.

Example 11: The Immunogenicity of LHRH Peptide Immunogens Formulated as a Suspension of Immunostimulatory Complex with Mineral Salt in Baboons

[00286] This Example illustrates the immunogenicity of LHRH peptide immunogens formulated as immunostimulatory complexes with CpG1 oligonucleotides in various ratios in combination with mineral salts, which were immunized intramuscularly, in male baboons. The mineral salt suspensions were prepared as described in Example 9.

[0001] Groups of two, 2 year old male baboons were immunized intramuscularly (I.M.) on weeks 0, 4 and 8 with the following compositions: 400 µg of LHRH peptides/CpG1 immunostimulatory complex (4:1 or 1.5:1 charge ratio) prepared as described in Table 9 suspended in a volume of 500 µL distilled deionized water; 400 µg of LHRH peptides/CpG1 immunostimulatory complex (4:1 or 1.5:1 charge ratio) prepared as described in Table 9 suspended in a volume of 250 µL distilled deionized water and

WO 03/068169

PCT/US03/04711

250 μ L of Alhydrogel[®] (3.2 mg Al/mL) was added. To each formulation was added 45 μ L of a 20% saline solution, 2.5 μ L of 2-phenoxy-ethanol and 452.5 μ L of distilled deionized water. The final volume of each formulation was 1.0 mL.

[00288] The baboons showed no gross pathologies or behavioral changes after receiving immunostimulatory complex at either ratio or in combination with the Alhydrogel[®] mineral salt. Sera were obtained on weeks +0, +4, +6, +8, +12 and +14 (for the 1.5:1 complexes only) and were evaluated for the presence of anti-LHRH antibodies by immunogen-specific ELISA and for serum testosterone by RIA immunoassay.

Immunogenicity Results

[00289] The serum antibody titers following immunization of LHRH immunogens are shown in Figure 14a. The corresponding serum testosterone levels for each baboon are shown in Figure 14b and 14c, respectively.

[00290] The antibody titers determined from sera obtained from male baboons immunized by LHRH immunostimulatory complexes prepared in either a 4:1 or 1:5:1 charge ratio or a combination of LHRH peptide immunostimulatory complexes and Alhydrogel[®] mineral salt prepared in either a 4:1 or 1:5:1 charge ratio indicated that all compositions were immunogenic as shown in Figure 14a.

[00291] Marginally higher antibody titers were found for both systems prepared at the 4:1 charge ratio relative to the antibody titers obtained for the 1.5:1 system irrespective of whether the Alhydrogel[®] mineral salt was present or not.

[00292] The corresponding serum testosterone levels determined from sera obtained from male baboons immunized with LHRH immunostimulatory complexes prepared at the 4:1 charge ratio

WO 03/068169

PCT/US03/04711

without Alhydrogel® mineral salt proved totally ineffective for both baboons on trial as shown in Figure 14b.

[00293] The system formulated from the LHRH immunostimulatory complexes prepared at the 1.5:1 charge ratio without Alhydrogel® mineral salt was shown to more effectively downregulate the serum testosterone response for one of the baboons in the trial, however full immunocastration was not achieved as shown in Figure 14c.

[00294] For the composition prepared from a LHRH peptide immunostimulatory complex (4:1 charge ratio) in combination with Alhydrogel® full immunocastration was obtained in one baboon by week 10 and was demonstrated to be sustainable through week 14 as shown in Figure 14b. Near castration levels of serum testosterone were obtained in the other baboon in this group, although this response proved transient as shown in Figure 14b.

[00295] For the composition prepared from a LHRH immunostimulatory complex (1.5:1 charge ratio) in combination with Alhydrogel® both baboons in the study were successfully immunocastrated (one baboon achieved this by week 8 and the other by week 10) and this effect proved sustainable through week 14 as shown in Figure 14c.

[0001] For formulations derived from LHRH immunostimulatory complexes prepared at either a 4:1 or 1.5:1 charge ratio (LHRH peptide concentration = 400 µg), the actual quantity of LHRH peptide immunogens bound in the form of an immunostimulatory complex varies significantly. Table 8 shows the proportion of LHRH immunogen administered in this form as a function of varying charge ratios. Approximately 16% (~ 63 µg) of the LHRH immunogens in solution are bound in the form of an immunostimulatory complex when prepared at a 4:1 charge ratio,

WO 03/068169

PCT/US03/04711

whereas approximately 86% (~ 344 µg) are bound when prepared at the 1.5:1 ratio.

[00297] The presentation of the majority of the LHRH immunogens in the form of an immunostimulatory complex as in the 1.5:1 ratio system provided longer lasting and earlier immunocastration responses in baboons. We have experimentally determined that the Alhydrogel® mineral salt adsorbs an additional 10% of the free unbound LHRH immunogens in solution upon addition. Thus it is likely that the mechanism by which the mineral salt is improving the efficacy of the vaccine when combined with the immunostimulatory complex is probably linked to indirect immunomodulatory effects.

[00298] Concurrent experiments were conducted with an alternative mineral salt, Adju-phos® (derived from Aluminum phosphate) and full immunocastration was demonstrated in one baboon by week 10 whereas the other baboon on trial demonstrated near castration levels of serum testosterone by this time point.

[00299] In this Example we have demonstrated that a LHRH immunostimulatory complex in combination with a mineral salt is an effective vaccine to achieve immunocastration (as measured by serum testosterone) in a non-human primate.

[00300] Furthermore we have shown that the formulation kinetics of the immunocastration response is a function of the initial charge ratio of LHRH immunogens to CpG1 oligonucleotide and selection of mineral salt.

[00301] Specifically, this Example indicates the potential of these new combination based formulations for the development of safe vaccines useful for hormone ablation in animals or humans.

[00302] Moreover, this Example strongly indicates the potential of these new combination based formulations for the

WO 03/068169

PCT/US03/04711

development of safe vaccines suitable for the treatment of androgen-sensitive prostate cancer in humans.

Example 12: Preparation of Water-in-Oil Emulsions from ISA Montanide® 50v, Immunostimulatory Complex Derived from LHRH in the Presence of a IL-1 β Derived Peptide Fragment

[0001] To a 10 mL vessel, was added 1,000 μ g of LHRH peptide immunogens (SEQ ID NOS: 7-9 in a 1:1:1 molar ratio in solution), dissolved in an appropriate aqueous buffer (2,500 μ L, 0.4 mg/mL) and CpG1 oligonucleotide to prepare an immunostimulatory complex (16:1 charge ratio) or 1,000 μ g of peptide immunogens dissolved in an appropriate aqueous buffer (2,500 μ L, 0.4 mg/mL) plus a peptide derived from IL-1 β (SEQ ID NO: 14, C*VQGEESNDKIPC*-CO₂H.HCl (where C* indicates cyclization between two cysteines) in solution; or 1,000 μ g of peptide immunogens dissolved in an appropriate aqueous buffer (2,500 μ L, 0.4 mg/mL) was added to a mixture of CpG1 and IL-1 β peptide to prepare a combination of LHRH immunostimulatory complex (16:1 charge ratio) and IL-1 β peptide. Table 9 shows the calculations employed to determine the relative amount of CpG1 oligonucleotide required for complexation with LHRH peptide immunogens for a fixed final dosage of 100 μ g/1.0 mL with respect to the specified charge ratio.

[00304] Peptide-based fragments derived from IL-1 β are known to possess adjuvanting properties.⁶⁹ The IL-1 β peptide employed herein is relatively small (FW = 1421.5) and negatively charged when dissolved in standard physiological buffers. Employing the calculations described in Example 2, one nMol of IL-1 β peptide contributes 2 nMols of negative charge. As such, this molecule would not be predicted to physically interact with the LHRH immunogens and no evidence of complexation in the form of a precipitate was found upon mixing.

WO 03/068169

PCT/US03/04711

[00305] Specifically, to prepare an immunostimulatory complex from LHRH peptide immunogens at a 16:1 charge ratio of LHRH:CpG1, 18.3 µg CpG1 oligonucleotide (9.2 µL, 2.0 µg/mL) were used. To prepare a solution of LHRH peptide immunogens and IL-1β, 10 µg IL-1β (5.0 µL, 2.0 µg/mL) were added in an appropriate aqueous buffer. To prepare an immunostimulatory complex from LHRH peptide immunogens at a 16:1 charge ratio of LHRH:CpG1 plus IL-1β, 18.3 µg CpG1 oligonucleotide (9.2 µL, 2.0 µg/mL) and 10 µg IL-1β peptide (5.0 µL, 2.0 µg/mL) were mixed.

[00306] To each of the vessels additional aqueous solvent diluent was added so that the final volume of the aqueous phase was fixed at 5.0 mL for preparation of ISA Montanide® 50v w/o-emulsions respectively.

[00307] For the preparation of the placebo group, 5.0 mL of normal saline was employed for the aqueous phase.

[00308] For the LHRH peptide immunogens, normal saline was found to be suitable for complexation. The calculated IP for each peptide is greater than 9.0 (Table 1), far greater than the pH of the aqueous solvent selected.

[00309] This example demonstrates the advantages of stabilizing immunogens in solution in the form of an immunostimulatory complex. The complexation process has been shown to be compatible in the presence of additional immunomodulators.

[00310] The diluted aqueous suspensions of LHRH immunogens or placebo solution were then slowly added to a dry 25 mL reaction vessel charged with ISA Montanide® 50v (5.0 mL). The additions were made while homogenizing (High Shear Laboratory Mixer, Sealed Unit, Silverson) the mixture at low speeds (2,000-3,000 rpm) to generate a coarse emulsion. This processing speed was maintained until the aqueous sample had been completely added and was continued a full 2 minutes to

WO 03/068169

PCT/US03/04711

ensure uniform pre-mixing of the aqueous and oil phases. The homogenization speed was then ramped up (5,000-8,000 rpm) and maintained for from 5 to 10 minutes further resulting in the formation of a homogeneous white finely dispersed w/o-emulsion.

[00311] The final concentration of immunogens once formulated as water-in-oil emulsions as described above was 100 µg/mL.

Example 13: The Immunogenicity and Growth Promoting Effects of LHRH Peptide Immunogens Formulated as an Immunostimulatory Complex or with IL-1β Peptide or as a Combination of an Immunostimulatory Complex with IL-1β Peptide in a W/O Emulsion

[00312] This Example illustrates the immunogenicity of LHRH peptide immunogens formulated; as immunostimulatory complexes with CpG1 oligonucleotides in combination with a w/o emulsion or with an immunomodulator (IL-1β peptide) in combination with a w/o emulsions or as immunostimulatory complexes combined with an additional immunomodulator (IL-1β peptide) in a w/o-emulsion, which were immunized intramuscularly, in boars. The w/o-emulsions were prepared by homogenization as described in Example 4a and Example 12.

[0001] Groups of five, 8 week old boars (30 Kg each) were immunized intramuscularly (I.M.) on week 0 and 8 with following compositions: 100 µg of LHRH peptides/CpG1 immunostimulatory complex (16:1 charge ratio) prepared as described in Table 9 suspended in a final volume of 500 µL NaCl and dispersed with ISA Montanide® 50v (500 µL); LHRH peptides/IL-1β peptide (1 µg) was suspended in a final volume of 500 µL NaCl and dispersed with ISA Montanide® 50v (500 µL); or LHRH peptides/(CpG1 + IL-1β peptide (1 µg)) immunostimulatory complex (16:1 charge ratio) prepared as described in Table 9 was suspended in a final volume of 500 µL

WO 03/068169

PCT/US03/04711

NaCl dispersed with ISA Montanide® 50v (500 µL). A placebo control group of 500 µL NaCl dispersed with ISA Montanide® 50v (500 µL) was prepared and one unimmunized control group included in the study was surgically castrated.

[00314] The boars showed no gross pathologies or behavioral changes after receiving placebo w/o emulsions, w/o emulsions containing peptide immunogens in combination with IL-1β peptide or w/o emulsions containing the immunostimulatory complex or immunostimulatory complex in combinations with IL-1β peptide. Sera were obtained on weeks +0, +8, +10, +12 and +14 and were evaluated for the presence of anti-LHRH antibodies by immunogen-specific ELISAs, for serum testosterone by RIA immunoassay and for weight gain.

Immunogenicity Results

[00315] The serum antibody titers following immunization of LHRH immunogens are shown in Figure 15a. The corresponding serum testosterone levels are shown in Figure 15b. The effects of immunocastration following immunization of LHRH immunogens versus surgical castration on the weight gain over the trial period are shown in Figure 15c. Control experiments demonstrated that unadjuvanted peptide was non-immunogenic or weakly immunogenic in all cases.

[00316] The antibody titers determined from sera obtained from male boars immunized by LHRH immunostimulatory complexes, LHRH peptides adjuvanted by a cytokine, or by an LHRH immunostimulatory complex co-formulated with a cytokine administered as w/o emulsions indicated all three compositions were immunogenic. The titers obtained at all timepoints over the trial period proved comparable. The Placebo and surgically castrated negative control groups returned no titer as shown in Figure 15a.

WO 03/068169

PCT/US03/04711

[00317] The corresponding serum testosterone levels determined from sera obtained from boars immunized by LHRH immunostimulatory complex in a w/o emulsion or LHRH peptides adjuvanted by the IL-1 β peptide in a w/o emulsion or by a combination of LHRH immunostimulatory complex and the IL-1 β peptide administered as w/o emulsion indicated that male boars in these groups were effectively immunocastrated by week 12.

[00318] Notably, the compositions derived from the LHRH immunostimulatory complex in a w/o emulsion and the LHRH peptides adjuvanted by the IL-1 β peptide in a w/o emulsion failed to maintain this level of serum testosterone. By week 14, serum testosterone levels from both groups were shown to be rebounding and neither group would be described as immunocastrated.

[00319] The LHRH vaccine formulated as a combination of immunostimulatory complex and IL-1 β peptide as a w/o emulsion proved more effective maintaining the same level of immunocastration with no indication of early rebound as shown in Figure 15b.

[00320] The Placebo negative control group returned widely fluctuating serum testosterone values at the various timepoints evaluated in agreement with the expected variations in monthly hormone levels. The surgically castrated positive control groups returned negative serum testosterone levels at all timepoints over the trial period as shown in Figure 15b.

[00321] The serum testosterone level in boars prior to slaughter has been directly correlated with the quality of the meat produced. High levels of testosterone give rise to products of unappealing taste (boar taint) and thus controlling this property is an important market consideration. The standard method for ensuring negligible testosterone has been surgical castration. A viable vaccine approach must be proven effective over the interval of time

WO 03/068169

PCT/US03/04711

when boars would normally be brought to market. The point at which the boars have reached a weight between 110-130 KGs.

[00322] The growth promotion of boars immunized at 8 weeks of age in this study was tracked over 14 weeks. The boars immunocastrated by the LHRH immunostimulatory complex in a w/o emulsion or by LHRH peptides adjuvanted solely by the IL-1 β peptide in a w/o emulsion posted weight gains, that paralleled the surgically castrated group. These reached on average 110 KGs by week 14 as shown in Figure 15c.

[00323] Unexpectedly, the group immunized by the LHRH vaccine formulated as a combination of the LHRH immunostimulatory complex and IL-1 β peptide in a w/o emulsion proved considerably more effective. All boars within this group responded rapidly reporting the highest average weight gains at all timepoints evaluated in comparison to the other groups on trial. Boars from this group attained an average weight slightly below 120 KGs by week 12 and reached 130 KGs by week 14 as shown in Figure 15c.

[00324] The disparity between this group and the others on trial may be due to a synergistic combination of effects obtained when the immunostimulatory complex of LHRH/CpG1 is presented to the immune system in combination with the IL-1 β peptide and free uncomplexed LHRH peptide in a w/o emulsion.

[00325] The combination formulation proved effective with very small amounts of LHRH/CpG1 immunostimulatory complex present in suspension. In this Example a LHRH:CpG1 charge ratio of 16:1 provided significant responses in all swine.

[00326] The Placebo control group proved poorest at promoting growth over the trial period. The average weight gain for this group was significantly reduced relative to all others as shown in Figure 15c.

WO 03/068169

PCT/US03/04711

[00327] Marginal improvements in weight gain as a consequence of immunocastration relative to placebo controls have been observed in the past⁷⁰, however in this Example we have demonstrated a novel method to obtain effective immunocastration for the removal of boar taint (as measured by serum testosterone) and obtained superior growth promotion (as measured by weight gain) over the trial period with respect to the standard method of surgical castration.

[00328] Furthermore, boars immunocastrated by the LHRH vaccines formulated as a combination of an immunostimulatory complex and IL-1 β peptide in a w/o emulsion could go to market 2 weeks earlier than male boars immunized by either alternative formulation, or the present method of preference, surgical castration.

[00329] Specifically, the monetary savings in terms of avoiding losses due to surgical trauma, reduced feed and housing costs and improved turnover in terms of time to market would be significant, demonstrating the advantages of this improved method of immunocastration and growth promotion.

Example 14: Preparation of Water-in-Oil Emulsions from ISA Montanide® 50v and Immunostimulatory Complexes Derived from FMD

[00330] To a 20 mL vessel, was added 4,000 μ g of FMD peptide immunogens (SEQ ID NOS: 12-13 in solution), dissolved in an appropriate aqueous buffer (2,000 μ L, 2.0 mg/mL) or was added 4,000 μ g of peptide immunogens dissolved in an appropriate aqueous buffer (2,000 μ L, 2.0 mg/mL) and CpG1 oligonucleotide to prepare an immunostimulatory complex (4:1 charge ratio). Table 9 shows the calculations employed to determine the relative amount of CpG1 oligonucleotide required for complexation with the FMD peptide immunogens for a fixed final

WO 03/068169

PCT/US03/04711

dosage of 200 µg/1.0 mL with respect to the specified charge ratio.

[00331] Specifically, to prepare an immunostimulatory complex from FMD peptide immunogens at a 4:1 charge ratio of FMD:CpG1, 125 µg CpG1 oligonucleotide (62.5 µL, 2.0 µg/mL) were used.

[00332] To each of the vessels additional aqueous solvent diluent was added so that the final volume of the aqueous phase was fixed at 10.0 mL for preparation of ISA Montanide® 50v w/o-emulsions respectively.

[00333] For the preparation of the placebo group, 10.0 mL of normal saline was employed for the aqueous phase.

[00334] For the library of FMD peptide immunogens normal saline was found to be suitable for complexation. The average calculated IP for each peptide derived from a positional analog in the library is greater than 9.0 (Table 1), far greater than the pH of the aqueous solvent selected.

[00335] The diluted aqueous suspensions of FMD immunogens or placebo solution were then slowly added to a dry 25 mL reaction vessel charged with ISA Montanide® 50v (10.0 mL). The additions were made while homogenizing (High Shear Laboratory Mixer, Sealed Unit, Silverson) the mixture at low speeds (2,000-3,000 rpm) to generate a coarse emulsion. This processing speed was maintained until the aqueous sample had been completely added and was continued a full 2 minutes to ensure uniform pre-mixing of the aqueous and oil phases. The homogenization speed was then ramped up (5,000-8,000 rpm) and maintained for from 5 to 10 minutes further resulting in the formation of a homogeneous white finely dispersed w/o-emulsion.

[00336] The final concentration of immunogens once formulated as water-in-oil emulsions as described above was 200 µg/mL.

WO 03/068169

PCT/US03/04711

Example 15: The Immunogenicity and Protection of FMD Peptide Immunogens Formulated as an Immunostimulatory Complex in a W/O Emulsion

[00337] This Example illustrates the immunogenicity of FMD peptide immunogens formulated as a w/o emulsion or as FMD immunostimulatory complexes in combination with a w/o emulsion, which were immunized intramuscularly in cattle. The w/o-emulsions were prepared by homogenization as described in Example 4a and Example 14.

[00338] Groups of three, adult cattle were immunized intramuscularly (I.M.) on week 0 and 3 with the following compositions: 400 µg of FMD peptides suspended in a final volume of 1,000 µL NaCl and dispersed with ISA Montanide® 50v (1,000 µL); or FMD peptides/CpG1 immunostimulatory complex (4:1 charge ratio) prepared as described in Table 9 suspended in a final volume of 1,000 µL NaCl and dispersed with ISA Montanide® 50v (1,000 µL). A placebo control group of 1,000 µL NaCl emulsified with ISA Montanide® 50v (1,000 µL) was prepared.

[00339] The cattle showed no gross pathologies or behavioral changes after receiving placebo w/o emulsions or w/o emulsions containing FMD peptide immunogens or FMD immunostimulatory complexes. Sera obtained on week +5 were evaluated for the presence of FMD neutralizing antibodies and on week +6 the cattle were challenged with live virus to determine the level of protection in a trial lasting 14 days.

Measurement of anti-FMD Antibodies - Neutralization Assay

[00340] The quantitative neutralization assay (NA) for FMD antibody was performed with BHK-21 cells in flat-bottomed tissue-culture grade microtiter plates. The test is an equal volume test in 50 µL amounts. Starting from a 1:4 dilution,

WO 03/068169

PCT/US03/04711

sera were diluted in a two-fold dilution series in duplicate.

Serum samples to be tested were mixed with an equal volume of the FMDV O_{Manisa} serotype (200 TCID₅₀/0.05 mL) and incubated for one hour at 37°C. A cell suspension at 10⁶ cells/mL was prepared in a medium containing 10% bovine serum. A volume of 50 µL of cell suspension was added to each well. Plates were sealed and incubated at 37°C for 2-3 days.

[00341] Microscopic examination was feasible after 48 hours. Fixation was effected with 10% formol/saline for 30 minutes. For staining the plates were immersed in 0.05% methylene blue in 10% formalin for 30 minutes. Positive wells (where virus had been neutralized and cells remained intact) were seen to contain blue-stained cells. Negative wells are empty. Titers were expressed as the final dilution of serum present in serum/virus mixture at the 50% end-point.

Cattle Challenge Trial Protocol

[00342] On day 35, all cattle, which received vaccine or placebo controls on day 0 and day 21 were separated by groups into separate containment rooms. On day 42, each animal was challenged intradermolingually (IDL) with a total of 10⁴ BID₅₀ FMDV O injected in two sites on the dorsal surface of the tongue.

[00343] After challenge, the cattle were observed for development of clinical signs of FMD for 14 days and body temperature was recorded daily. Unprotected animals show lesions at sites other than the tongue. Control animals must develop a generalized infection as shown by lesions on at least three feet for the virus challenge to be considered valid.⁷¹

WO 03/068169

PCT/US03/04711

Immunogenicity Results

[00344] The neutralizing antibody (N.A.) titers following immunization of FMD immunogens and the corresponding protection results are shown in Table 10.

[00345] The N.A. titers determined from sera obtained from cattle (week +5) immunized by FMD peptide immunogens or by FMD immunostimulatory complexes administered as w/o emulsions indicated that both compositions were immunogenic. The titers obtained at the week 5 timepoint were highly variable, but in all cases were shown to be greater than 16. The minimum requirement for proof of potency for a *foot-and-mouth* disease vaccine as established by the Office International des Epizooties (OIE) is a N.A. titer of 16.⁷¹ Each steer in the Placebo negative control group returned negligible N.A. titers, all of which were less than 16 as shown in Table 10.

[00346] Conclusive proof for protection must be obtained by challenge of the immunized groups with live virus of specified titer. Live virus was administered intradermolingually (IDL) with a total of 10^4 BID₅₀ FMDV O injected in two sites on the dorsal surface of the tongue.

[00347] The challenge protocol was initiated on week 6, one week after the N.A. titers were established for all groups and the results in Table 10 prove that the formulation derived from FMD peptides/CpG1 immunostimulatory complexes in combination with unbound FMD peptides administered as a w/o emulsion was superior (3/3 protected) to the formulation derived from FMD peptides administered as a w/o emulsion alone (1/3 protected).

[00348] The placebo control group confirmed that the live virus employed for the challenge was sufficiently virulent as all three cattle in this group were infected and showing signs of

WO 03/068169

PCT/US03/04711

disease within 14 days after challenge (0/3 protected) as shown in Table 10.

[00349] Both of the groups formulated with FMD immunogens or an FMD immunostimulatory complex in a w/o emulsion obtained significant N.A. antibody titers by week +5.

[00350] Surprisingly, the challenge study demonstrated that the formulation of superior efficacy was derived from the formulation comprising the FMD immunostimulatory complex in the w/o emulsion. It is likely that this composition concurrently improves the N.A. responses and is more effective at upregulating a specific kind of immune response important for combating viral infections.

[00351] Specifically, the immunostimulatory complex derived from FMD and CpG1 presented in the form of a w/o emulsion may effectively augment the Th₁ arm of the immune response (e.g. IFN-gamma). This role for CpG oligonucleotides has been well established in other models and IFN-gamma itself has been shown to be an effective immunomodulator achieving immune protection against influenza virus.⁷²

[00352] The control of *foot-and-mouth* disease, once an outbreak has been identified is often managed by culling infected and neighboring herds. The economic loss of important commodities like cattle, pork and sheep is often significant. The existing vaccine strategies employ killed virus, which are in some cases locally produced and of inferior quality. The manufacturing from live virus has various issues relating to production associated with it and the products themselves represent a potential safety risk. A strategy based on immunogens derived from synthetic peptides represents an improved method for effective immunization, and should be considered low risk.

WO 03/068169

PCT/US03/04711

[00353] Specifically, this Example demonstrates that a synthetic peptide-based vaccine strategy can safely and effectively protect cattle against *foot-and-mouth* disease.

[00354] Furthermore, this Example further demonstrates the utility of this vaccine approach for the general protection of important domestic livestock susceptible to *foot-and-mouth* disease.

Table 1
Synthetic Peptide Immunogens And Oligonucleotides

Vaccine	SEQ ID No:	Sequence	IP	FW
HIV (CD4) Vaccine	4	ISITEIKGVIVHRIETILF- (6K) CNQGSFLTKGPSKLNDRADS- RRSLNDQNC	9.30	5646
	5	KKKTDRIEVLQRAAIL- (6K) CNQGSFLTKGPSKLNDRADS- RRSLNDQNC	10.30	5659
	6	ISITEIKGVIVHRIETILF- (6K) CHASIVDFGSC	6.91	3493
Prostate Cancer (LHRH) Vaccine	7	KKQYIKANSKEFIGITELEHWSYGLRPG	9.70	3164
	8	TAKSKKFPSTATYQFGGFFLLTRILLTIPOSLGEGHWSYGLRPG	9.70	5052
	9	TAKSKKFPSTATYQFGGLSEIKGVIVHRIEVLGVGGEHWSYGLRPG	9.60	4910
Allergy (IgE) Vaccine	10	KKKLIITITRIITITID- (6K) CGETYQSRVTHPHLPALMRSTTKC	10.31	5068
	11	ISITEIKGVIVHRIETILF- (6K) CGETYQSRVTHPHLPALMR STTKC	9.69	5165
Foot-in- Mouth (FMD) Vaccine	12 13	ISISEIKGVIVHRIETILF- (6K) YNGSCKYSDARVSNVRGDLQR- T RT TR GDLQVLAQKAERCLPSSFNIGAIK T	~9.39	6759- 6851
Oligonucleotide	SEQ ID No:	Sequence	Tm	FW
SEQ ID No: 1	5'-	TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT -3'	77.1°C	10,295
SEQ ID No: 2	5'-	ntc GTC GTT TTG TCG TTT TGT CGT T -3' n = phosphorothioate group	70.9°C	7,400

IP = Theoretical Ionization Potential, (ref. 68)

FW = Formula Weight, Tm = Primer to target Tm (by %GC)

Table 2
Molar Charge Calculations
Synthetic Peptide Immunogens And Oligonucleotides

Vaccine	SEQ ID No:	Net Calculated Charge ¹	% Molar Peptide Contribution In Vaccine	Avg. Total Molar Equivalents +ve Charge ²	FW	Avg. Total Peptide FW ³
CD4 Vaccine	4	4 +ve	50%	1 nmol = 4.3 nmol +ve charge	5646	5280.6
	5	7 +ve	25%		5659	
	6	2 +ve	25%		3493	
IgE Vaccine	10	7 +ve	66.6%	1 nmol = 7.7 nmol +ve charge	5068	5132.1
	11	9 +ve	33.3%		5165	
LHRH Vaccine	7	4 +ve	33.3%	1 nmol = 4.3 nmol +ve charge	3164	4543.9
	8	5 +ve	33.3%		5052	
	9	4 +ve	33.3%		4910	
FMD Vaccine	12	~ 3.5 +ve	Library Peptide ⁴	1 nmol ~ 3.5 nmol +ve charge	6759-6851	6805 ⁵

1) **Net charge:** Calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a -1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for every other amino acid within the sequence. The charges are summed for each peptide and expressed as the net average charge.

2) **Average Total Molar Equivalents Of +ve Charge From Peptides:** Estimates for the average charge of the combined peptide mixture are calculated by summing the overall molar charge contribution for each component within the mixture and taking the mean.

3) **Average Total Peptide Formula Weight (FW):** Estimates for the average Total peptide FW are calculated by summing the overall molar mass contribution for each component within the mixture and taking the mean.

4) The FMD vaccine is derived from a library of peptides. The molar contribution of each component is assumed equivalent and the average total molar equivalents of +ve charge is similarly calculated.

5) For the FMD vaccine the average total peptide formula weight is obtained by summing the lowest and highest FW found for the various FMD peptides in the library and taking the mean.

Molar Equivalents Of -ve charge From CpG Oligonucleotides: Each phosphorothioate group contributes -1 charge.

CpG1 (32 base oligomer) - 1 nmol CpG1 = 31.0 nmol -ve charge

CpG2 (24 base oligomer + phosphorothioate). - 1 nmol CpG2 = 24.0 nmol -ve charge

Table 3

**Calculated Molar Charge Ratios Used To Prepare Complexes
LHRH Peptide Immunogens And CpG1 Oligonucleotides**

Final Charge Ratio (LHRH:CpG1)	nmols of LHRH by Charge for the Final Charge Ratio of LHRH:CpG1 (LHRH of Fixed Mass) ¹ (nmols +ve charge)	Theoretical nmol of CpG1 Required ²	Actual Mass(nmols) of CpG1 Used FW = 10,295 µg/µmol (Table 1) (CpG1 – Stock A = 2.0µg/µL)
8:1	94.6/8 = 11.8 (~ 8:1 ratio)	11.8/31 = 0.38 nmols CpG1	3.6 µg (0.37 nmols)
4:1	94.6/4 = 23.7 (~ 4:1 ratio)	23.7/31 = 0.76 nmols CpG1	7.3 µg (0.84 nmols)
2:1	94.6/2 = 47.3 (~ 2:1 ratio)	47.3/31 = 1.53 nmols CpG1	14.7 µg (1.45 nmols)
1:1	94.6/1 = 94.6 (~ 1:1 ratio)	94.6/31 = 3.05 nmols CpG1	29.3 µg (2.96 nmols)
1:2	94.6/0.5 = 189.4 (~ 1:2 ratio)	189.4/31 = 6.11 nmols CpG1	58.6 µg (5.91 nmols)

1) Total calculated +ve molar charge for 100 µg of LHRH peptides:

Avg. FW = 4543.9 µg/µmol (Table 2).

Total +ve molar charge LHRH peptides = 4.3 nmol +ve charge/nmol LHRH peptide (Table 2)

In 100 µg LHRH peptides there are 100 µg /4543.9 µg/µmol = 22.0 nmol of LHRH immunogen

Total +ve molar charge = 22.0 nmol x 4.3 nmols +ve charge/nmol LHRH peptides = 94.6 nmols +ve charge

2) Sample calculation:

Final 8:1 molar charge ratio of LHRH immunogen to CpG1 oligonucleotide.

100 µg of LHRH contributes 94.6 nmols of +ve charge.

To establish an 8:1 molar charge ratio of LHRH to CpG1 in solution the required amount of LHRH that must be neutralized by CpG1 is calculated as 94.6 nmols +ve charge/8 = 11.8 nmols +ve charge.

Thus 11.8 nmols +ve charge contributed by LHRH must be neutralized by 11.8 nmols of -ve charge contributed by CpG1.

1 nmol of CpG1 = 31 nmol -ve charge (Table 2).

Thus the total nmols of CpG1 required to contribute 11.8 nmols of -ve charge = 11.8/31 = 0.38 nmols CpG1.

Table 4
Molar Charge Ratio Calculations
IgE, CD4 Peptide Immunogens And CpG Oligonucleotides

Formulation	Dose Peptide	Calculated nmols of CpG Charge Required for Specified Peptide: CpG Charge Ratio nmols IgE: nmols CpG1 (+/-) ¹ nmols CD4: nmols CpG2 (+/-) ²	Theoretical nmol of CpG1 or CpG2 (by Mass) Required ³	Actual Mass(nmols) of CpG1 or CpG2 Used (CpG1 - Stock A = 2.0 µg/µL) (CpG2 - Stock B = 2.0 µg/µL)
IgE - w/o emulsions	100 µg	150:150.0 ~ 1:1, neutral charge ratio	150/31 = 4.8 nmols CpG1	50 µg CpG1 (4.9 nmols)
	100 µg	150:37.5 ~ 4:1, +ve charge ratio	37.5/31 = 1.2 nmols CpG1	11.1 µg CpG1 (1.1 nmols)
IgE - polymer gels	300 µg	451:451 ~ 1:1, neutral charge ratio	451/31 = 14.5 nmols CpG1	150 µg CpG1 (14.6 nmols)
	300 µg	451:112.8 ~ 4:1, +ve charge ratio	112.8/31 = 3.5 nmols CpG1	33.3 µg CpG1 (3.2 nmols)
CD4 - w/o emulsions	100 µg	81.3:163 ~ 1:2, -ve charge ratio	163/24 = 6.8 nmols CpG2	50 µg CpG2 (6.7 nmols)
	100 µg	81.3:40.7 ~ 2:1, +ve charge ratio	40.7/24 = 1.7 nmols CpG2	11.1 µg CpG2 (1.5 nmols)
CD4 - polymer gels	300 µg	244.2:488.4 ~ 1:2, -ve charge ratio	488.4/24 = 20.4 nmols CpG2	150 µg CpG2 (20.2 nmols)
	300 µg	244.2:122.1 ~ 2:1, +ve charge ratio	122.1/24 = 5.0 nmols CpG2	33.3 µg CpG2 (4.5 nmols)

1) Total calculated +ve molar charge for 100 µg or 300 µg of IgE peptides:

Avg. FW = 5132.1 g/ mol (Table 2); Total +ve molar charge IgE peptides = 7.7 nmol +ve charge/nmol IgE peptides (Table 2)
 In 100 g IgE peptides there are 100 g /5132.1 g/ mol = 19.5 nmol of IgE immunogen
 Total +ve molar charge = 19.5 nmol x 7.7 nmols +ve charge/nmol IgE peptides = 150.1 nmols +ve charge
 In 300 g IgE peptides there are 300 g /5132.1 g/ mol = 58.5 nmol of IgE immunogen
 Total +ve molar charge = 58.5 nmol x 7.7 nmols +ve charge/nmol IgE peptides = 450.5 nmols +ve charge

2) Total calculated +ve molar charge for 100 µg or 300 µg of CD4 peptides:

Avg. FW = 5280.6 g/ mol (Table 2); Total +ve molar charge CD4 peptides = 4.3 nmol +ve charge/nmol CD4 peptides (Table 2)
 In 100 g CD4 peptides there are 100 g /5280.6 g/ mol = 18.9 nmol of CD4 immunogen
 Total +ve molar charge = 18.9 nmol x 4.3 nmols +ve charge/nmol CD4 peptides = 81.3 nmols +ve charge
 In 300 g CD4 peptides there are 300 g /5280.6 g/ mol = 56.8 nmol of CD4 immunogen
 Total +ve molar charge = 56.8 nmol x 4.3 nmols +ve charge/nmol CD4 peptides = 244.2 nmols +ve charge

3) # nmol of -ve charge contributed by CpG1 or CpG2:

Total calculated -ve molar charge for CpG1/CpG2 oligonucleotides

1 nmol of CpG1 = 31 nmol -ve charge, FW = 10,295 g/ mol (Table 1)

1 nmol of CpG2 = 24 nmol -ve charge, FW = 7,400 g/ mol (Table 1)

Table 5
Comparison Of Physical Properties Of PLG/PLGA Copolymers Dissolved
In DMSO As A Function Of Weight Percent In Solution

Polymer Identity (ratio D,L-lactide:glycolide)	Polymer Properties Molecular Weight (g/mol) Inherent Viscosity (dl/g)	Wt % Polymer in DMSO	Viscosity (mPa)
RG 502H (50:50)	Mw = 8,033, I.V. = 0.2	44.0%	86.7
RG 503H (50:50)	Mw = 25,760, I.V. = 0.3	30.0%	226.2
RG 503H (50:50)	Mw = 25,760, I.V. = 0.3	24.0%	99.6
RG 503H (50:50)	Mw = 25,760, I.V. = 0.3	20.0%	55.1
RG 503H (50:50)	Mw = 25,760, I.V. = 0.3	17.3%	34.0
RG 504H (50:50)	Mw = 43,110, I.V. = 0.4	30.4%	418.4
RG 504H (50:50)	Mw = 43,110, I.V. = 0.4	24.5%	187.5
RG 504H (50:50)	Mw = 43,110, I.V. = 0.4	20.5%	104.3
RG 504H (50:50)	Mw = 43,110, I.V. = 0.4	17.6%	63.3
RG 504H (50:50)	Mw = 43,110, I.V. = 0.4	15.4%	44.5
RG 756 (75:25)	Mw = 81,970, I.V. = 0.8	33.0%	-----
RG 756 (75:25)	Mw = 81,970, I.V. = 0.8	24.5%	-----
RG 756 (75:25)	Mw = 81,970, I.V. = 0.8	19.4%	252.0
RG 756 (75:25)	Mw = 81,970, I.V. = 0.8	16.0%	138.3
RG 756 (75:25)	Mw = 81,970, I.V. = 0.8	13.6%	102.2
RG 756 (75:25)	Mw = 81,970, I.V. = 0.8	11.9%	68.0
Polymer	Percentage by weight required for a solution with apparent viscosity of ~ 100 mPa		
RG-503H	~ 24%		
RG-504H	~ 20.5%		
RG-756	~ 13.6%		

Table 6
B4-HRP Inhibition Assay Of Sera Obtained From CD4 Peptides, CD4/CpG2
Immunostimulatory Complexes Or Combinations In W/O Emulsions

Formulation	% Inhibition* (week 9)	% Inhibition* (week 11)	% Inhibition* (week 17)
CD4 peptide unadjuvanted	5%	49.1%**	8.2%
CD4 /CpG2 (2:1)			
CD4 /w/o emulsion***	12.8%	2.7%	N.D.
CD4 /CpG2 (2:1)/(w/o) emulsion***	87.2%	87.5%	11.2%
CD4 /w/o emulsion****	70.1%	92.1%	85.0%
CD4 /CpG2 (2:1)/(w/o) emulsion****	88.6%	61.4%	42.6%
	94.9%	95.3%	77.2%
Positive Controls			
mAb B4, 20 µg/mL	63%	63%	48.7%
mAb B4, 2.0 µg/mL	23.5%	11.7%	11.7%

* - N.D. - samples were not assayed

** - The value of 49.1% at week 11 for unadjuvanted CD4 peptide is unexpected and likely due to experimental error.

*** - Water-in-oil emulsion prepared with ISA 720 via homogenization techniques

**** - Water-in-oil emulsion prepared with ISA 720 via extrusion techniques

Table 7

**Neutralization Of HIV-1 Strain VL135 By Immune Sera To CD4 Peptides
CD4/CpG2 Immunostimulatory Complexes Or Combinations In W/O Emulsions
(MT-2 microplaque assay)**

Formulation	HIV-1 Strain VL135 50% Inhibition* (week 9)	HIV-1 Strain VL135 50% Inhibition* (week 11)	HIV-1 Strain VL135 90% Inhibition* (week 9)	HIV-1 Strain VL135 90% Inhibition* (week 11)
CD4 peptide unadjuvanted	< 10%	< 10%	< 10%	< 10%
CD4 / (w/o) emulsion**	73%	27%	57%	17%
CD4 /CpG2 (2:1 charge ratio) / (w/o) emulsion**	12%	40%	< 10%	30%
CD4 / (w/o) emulsion***	31%	< 10%	< 10%	< 10%
CD4 /CpG2 (2:1 charge ratio) / (w/o) emulsion***	103%	120%	33%	39%
Positive Controls				
mAb B4	0.078 µg/mL	0.13 µg/mL	0.27 µg/mL	0.32 µg/mL
mAb B4	0.18 µg/mL	0.13 µg/mL	0.32 µg/mL	0.31 µg/mL

* - Reciprocal titer prior to the addition of an equal volume of virus containing 1-1.3 logs

** - Water-in-oil emulsion prepared with ISA 720 by homogenization techniques

*** - Water-in-oil emulsion prepared with ISA 720 by extrusion techniques

Table 8

**Complexation Efficiency As A Function of LHRH Peptide:CpG1
Molar Charge Ratio By RP-HPLC**

(Mass of LHRH peptide cocktail fixed @ 400 g)

LHRH Peptide/CpG1 molar charge ratio	% of each peptide bound 500:667:607E ¹	Overall % LHRH/CpG complex present in mixture ²	Effective dose of LHRH bound in the form of an LHRH/CpG Complex
~ 8:1	500 - 0.8 % 667 - 3.7 % 607E - 13.8 %	6.1 %	24.4 µg
~ 4:1	500 - 7.8 % 667 - 12.7 % 607E - 27.2 %	15.8 %	63.2 µg
~ 2:1	500 - 23.3 % 667 - 50.3 % 607E - 97.8 %	57.1 %	228.4 µg
~ 1.5:1	500 - 69.5 % 667 - 89.5 % 607E - 100 %	85.9 %	343.6 µg
~ 1:1	500 - 93.5 % 667 - 99.2 % 607E - 100 %	97.6 %	390.4 µg

1) Percentage of bound peptides are calculated by comparing the RP-HPLC peak areas relative to the control LHRH composition assayed in the absence of the CpG1 oligonucleotide.

2) Percentages for the overall amount of LHRH/CpG1 complexed peptide are calculated by summing the total RP-HPLC peak areas obtained and comparing that with total summed RP-HPLC peak areas obtained from the control composition examined in the absence of CpG1 oligonucleotide.

Table 9.
Molar Charge Ratio Calculations
LHRH And FMD Peptide Immunogens And CpG Oligonucleotides

Formulation	Dose Peptide	Calculated nmols of CpG Charge Required for Specified Peptide: CpG Charge Ratio nmols IgE: nmols CpG1 (+/-) ¹ nmols CD4: nmols CpG2 (+/-) ²	Theoretical nmol of CpG1 or CpG2 (by Mass) Required ³	Actual Mass(nmols) of CpG1 or CpG2 Used (CpG1 - Stock A = 2.0 µg/µL)
LHRH - mineral salts	25 µg	23.7:5.9 ~ 4:1, +ve charge ratio	5.9/31 = 0.2 nmols CpG1	1.83 µg CpG1 (0.2 nmols)
LHRH - w/o emulsions	400 µg	378.4:252.3 ~ 1.5:1, +ve charge ratio	252.3/31 = 8.2 nmols CpG1	87.6 µg CpG1 (8.5 nmols)
	100 µg	94.6:11.8 ~ 16:1, +ve charge ratio	5.7/31 = 0.2 nmols CpG1	1.83g µg CpG1 (0.2 nmols)
FMD - w/o emulsions	400 µg	205.8:51.4 ~ 4:1, +ve charge ratio	51.4/31 = 1.6 nmols CpG1	12.5 µg CpG1 (1.3 nmols)

1) Total calculated +ve molar charge for 25 g, 100 g or 400 g of LHRH peptides:

Avg. FW = 4543.9 g/ mol (Table 2); Total +ve molar charge LHRH peptides = 4.3 nmol +ve charge/nmol LHRH peptides (Table 2)

In 25 g LHRH peptides there are 25 g /4543.9 g/ mol = 5.5 nmol of LHRH immunogen

Total +ve molar charge = 5.5 nmol x 4.3 nmols +ve charge/nmol LHRH peptides = 23.7 nmols +ve charge

In 100 g LHRH peptides there are 100 g /4543.9 g/ mol = 22.0 nmol of LHRH immunogen

Total +ve molar charge = 22.0 nmol x 4.3 nmols +ve charge/nmol LHRH peptides = 94.6 nmols +ve charge

In 400 g LHRH peptides there are 400 g /4543.9 g/ mol = 88.0 nmol of LHRH immunogen

Total +ve molar charge = 88.0 nmol x 4.3 nmols +ve charge/nmol LHRH peptides = 378.4 nmols +ve charge

2) Total calculated +ve molar charge for 400 g of FMD peptides:

Avg. FW = 6805 g/ mol (Table 2); Total +ve molar charge LHRH peptides ~ 3.5 nmol +ve charge/nmol FMD peptides (Table 2)

In 400 g FMD peptides there are 400 g/6805 g/ mol = 58.8 nmol of FMD immunogen

Total +ve molar charge = 58.8 nmol x 3.5 nmols +ve charge/nmol FMD peptides = 205.8 nmols +ve charge

3) # nmol of -ve charge contributed by CpG1:

Total calculated -ve molar charge for CpG1 oligonucleotides

1 nmol of CpG1 = 31 nmol -ve charge, FW = 10,295 g/ mol (Table 1)

Table 10.
Neutralization Antibody Titers And Protection Data Obtained
In Cattle Immunized With FMD Vaccines.

Animal Group #	Formulation	Neutralizing Antibody Titer (5 WPT)	Virus Titer (ID ₅₀) (Challenge date 6 WPT) ¹	Number Cattle Protected (8 WPT)
1	FMD/ISA 50v	724 256 64	10 ⁴	1/3
2	FMD/CpGI (4:1)/ISA 50v	256 128 512	10 ⁴	3/3
3	Placebo (ISA 50v)	3 3 8	10 ⁴	0/3

¹ Challenge intradermally (IDL) with a total of 10⁴ BID₅₀ FMDV O injected in two sites on the dorsal surface of the tongue.

What we claim is:

1. A stabilized immunostimulatory complex comprising a cationic peptide immunogen and anionic CpG oligonucleotide wherein the cationic peptide immunogen has a net positive charge at a pH in the range of 5.0 to 8.0 calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a -1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for all other amino acids in the peptide immunogen and wherein the anionic CpG oligonucleotide has a net negative charge at a pH in the range of 5.0-8.0 and is a single-stranded DNA comprising 8 to 64 nucleotide bases with a repeat of a cytosine-guanidine motif and the number of repeats of the CpG motif is in the range of 1 to 10.
2. The immunostimulatory complex of claim 1, wherein the cationic peptide immunogen is a synthetic peptide.
3. The immunostimulatory complex of claim 2, wherein the peptide immunogen comprises a target B cell or a CTL epitope, and a T helper cell epitope.
4. The immunostimulatory complex of claim 1, wherein the net positive charge of the cationic synthetic peptide immunogen is at least +2.
5. The immunostimulatory complex of claim 1, wherein the net negative charge of the anionic oligonucleotide is at least -2.
6. The immunostimulatory complex of claim 1, wherein the CpG oligonucleotide is a single-stranded DNA molecules with

WO 03/068169

PCT/US03/04711

18-48 nucleotide bases and the number of repeats of CpG motif therein in the range of 3 to 8.

7. The immunostimulatory complex of claim 1, wherein the CpG oligonucleotide has the formula: 5' X¹CGX² 3' wherein C and G are unmethylated; and X¹ is selected from the group consisting of A (adenine), G (guanine) and T (thymine); and X² is C (cytosine) or T (thymine).
8. The immunostimulatory complex of claim 1, wherein the CpG oligonucleotide has the formula: 5' (X³)₂CG(X⁴)₂ 3' wherein C and G are unmethylated; and X³ is selected from the group consisting of A, T or G, and X⁴ is C or T.
9. The immunostimulatory complex of claim 1, wherein the CpG oligonucleotide is modified with a phosphorothioate.
10. The immunostimulatory complex of claim 9, wherein CpG oligonucleotide is selected from a group consisting of 5' TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3' (CpG1) SEQ ID NO: 1, a 32 base length oligomer, and 5' nTC GTC GTT TTG TCG TTT TGT CGT T 3' (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus an phosphorothioate group designated as n.
11. The immunostimulatory complex of claim 10, wherein CpG oligonucleotide is 5' TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3' (CpG1) SEQ ID NO: 1.
12. The immunostimulatory complex of claim 10, wherein CpG oligonucleotide is 5' nTC GTC GTT TTG TCG TTT TGT CGT T 3' (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus an phosphorothioate group designated as n.

WO 03/068169

PCT/US03/04711

13. The immunostimulatory complex of claim 10, wherein the cationic peptide immunogen is a synthetic peptide derived from HIV CD4.
14. The immunostimulatory complex of claim 13, wherein the synthetic peptide derived from HIV CD4 is selected from the group consisting of SEQ ID NO:4, 5, and 6 and a mixture thereof.
15. The immunostimulatory complex of claim 14, wherein the mixture is a mixture of SEQ ID NO:4, 5, and 6.
16. The immunostimulatory complex of claim 10, wherein the cationic peptide immunogen is a synthetic peptide derived from LHRH.
17. The immunostimulatory complex of claim 16, wherein the synthetic peptide derived from LHRH is selected from the group consisting of SEQ ID NO:7, 8 and 9 and a mixture thereof.
18. The immunostimulatory complex of claim 17, wherein the mixture is a mixture of SEQ ID NO:7, 8, and 9.
19. The immunostimulatory complex of claim 10, wherein the cationic peptide immunogen is a synthetic peptide derived from IgE.
20. The immunostimulatory complex of claim 19, wherein the synthetic peptide derived from IgE is selected from the group consisting of SEQ ID NO:10 and 11 and a mixture thereof.

WO 03/068169

PCT/US03/04711

21. The immunostimulatory complex of claim 20, wherein the synthetic peptide derived from IgE is a mixture of SEQ ID NO:10, and 11.
22. The immunostimulatory complex of claim 10, wherein the cationic peptide immunogen is derived from FMD selected from the group consisting of SEQ ID NO:12 and 13.
23. The immunostimulatory complex of claim 11, wherein the peptide immunogen derived from FMD is a mixture of SEQ ID NO:12 and 13.
24. A process for preparing a stabilized immunostimulatory complex according to claim 1 comprising the steps of:
 - (a) dissolving or dispersing the cationic peptide immunogen in an aqueous phase selected from the group consisting of distilled deionized water, saline, PBS and a mixture thereof with the proviso that the pH of the aqueous phase is lower than the ionization point of the peptide immunogen;
 - (b) Dissolving the anionic CpG oligonucleotide in an aqueous phase selected from the group consisting of distilled deionized water, saline, PBS and a mixture thereof;
 - (c) Adding the CpG oligonucleotide in the aqueous phase dropwise to the solution or dispersion of the cationic peptide immunogen in an amount to form a stabilized immunostimulatory complex of the peptide immunogen and the CpG oligonucleotide in a charge ratio of the cationic immunogen peptide to the CpG oligonucleotide in the range of 16:1 to 1:1.

WO 03/068169

PCT/US03/04711

25. The process of claim 24, further comprising the step of removing the aqueous phase of the suspension of the immunostimulatory complex obtained.
26. The process of claim 25, wherein the aqueous phase is removed by lyophilization, or spray-drying.
27. The process of claim 24, wherein the immunostimulatory complex has an average particle size in the range of 1 to 50 μ M.
28. The process according to claim 24 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 16:1 of the cationic immunogen peptide to the CpG nucleotide.
29. The process according to claim 25 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 16:1 of the cationic immunogen peptide to the CpG nucleotide.
30. The process according to claim 24 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 4:1 of the cationic immunogen peptide to the CpG nucleotide.
31. The process according to claim 25 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 4:1 of the cationic immunogen peptide to the CpG nucleotide.
32. The process according to claim 24 wherein the amount of the immunogen peptide and the CpG oligonucleotide added

- is in a charge ratio in the range of 2:1 of the cationic immunogen peptide to the CpG nucleotide.
33. The process according to claim 25 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 2:1 of the cationic immunogen peptide to the CpG nucleotide.
34. The process according to claim 24 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 1.5:1 of the cationic immunogen peptide to the CpG nucleotide.
35. The process according to claim 25 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 1.5:1 of the cationic immunogen peptide to the CpG nucleotide.
36. The process according to claim 24 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 1:1 of the cationic immunogen peptide to the CpG nucleotide.
37. The process according to claim 25 wherein the amount of the immunogen peptide and the CpG oligonucleotide added is in a charge ratio in the range of 1:1 of the cationic immunogen peptide to the CpG nucleotide.
38. A process for preparing a water-in-oil emulsion comprising an immunostimulatory complex of claim 1, comprising the steps of:
- (a) Preparing an immunostimulatory complex in aqueous phase selected from the group consisting of

WO 03/068169

PCT/US03/04711

distilled deionized water, saline and phosphate buffered saline;

- (b) Adding the immunostimulatory complex in the aqueous phase into a continuous oil phase selected from the group consisting of a synthetic oil, a vegetable oil, a mineral oil, a metabolizable animal oil and a mixture thereof;
 - (c) Dispersing under mechanical shear the immunostimulatory complex in the aqueous phase into the continuous oil phase to form a homogeneous water-in-oil emulsion
39. A process for preparing a water-in-oil emulsion according to claim 38, wherein step (c) comprises:
- (a) Loading a first syringe with the aqueous phase containing an immunostimulatory complex;
 - (b) Loading a second syringe with the oil phase having an inherent viscosity of less than 1,500 mPa;
 - (c) Connecting the first and second syringes through a narrow bore tube to a membrane support housing a membrane of controlled pore size (0.05-20 μM);
 - (d) Extruding the aqueous phase into the oil phase by repeated exchanges through the membrane until the homogeneous w/o-emulsion is formed.
40. The process of claim 38, wherein the oil phase is selected from the group consisting of a metabolizable or non-metabolizable oil selected from the group consisting of Montanide® ISA 720, Montanide® ISA 51, Montanide® ISA 50v or a mixture thereof..
41. The process of claim 39, wherein the oil phase is selected from the group consisting of a metabolizable or

WO 03/068169

PCT/US03/04711

non-metabolizable oil selected from the group consisting of Montanide® ISA 720, Montanide® ISA 51, Montanide® ISA 50v or a mixture thereof..

42. The process of claim 38, wherein the aqueous phase may further comprise a surfactant, an emulsion stabilizer, or a combination thereof.
43. The process of claim 39, wherein the aqueous phase may further comprise a surfactant, an emulsion stabilizer, or a combination thereof.
44. The process of claim 42 wherein the emulsion stabilizer is selected from the group consisting of a mannide-oleate and a derivative thereof.
45. The process of claim 43 wherein the emulsion stabilizer selected from the group consisting of a mannide-oleate and a derivative thereof.
46. The process of claim 38 wherein the oil phase further comprises an adjuvant selected from the group consisting of MPL, MDP, DDA, Avridine, BAY-1005, DC-Chol, Murapalmitine and a derivative thereof.
47. The process of claim 39 wherein the oil phase further comprises an adjuvant selected from the group consisting of MPL, MDP, DDA, Avridine, BAY-1005, DC-Chol, Murapalmitine and and a derivative thereof.
48. The process of claim 38, wherein the aqueous phase further comprises an aqueous soluble adjuvant selected from the group consisting of PCPP, a saponin, a Cholera

WO 03/068169

PCT/US03/04711

Toxin, a heat labile Enterotoxin from *E. Coli* and a cytokine, selected from the group consisting of IL-1 β , IL-2, IL-12, IFN- γ and a derivative thereof.


49. The process of claim 48, wherein the cytokine derivative is an IL-1 β derived peptide fragment, SEQ ID NO:14.
50. The process of claim 39, wherein the aqueous phase further comprises an aqueous soluble adjuvant selected from the group consisting of PCPP, a saponin, a Cholera Toxin, a heat labile Enterotoxin from *E. Coli* and a cytokine selected from the group consisting of IL-1 β , IL-2, IL-12, IFN- γ and a derivative thereof.
51. The process of claim 50, wherein the cytokine derivative is IL-1 β derived peptide fragment, SEQ ID NO:14.
52. A process of claim 25 further comprising the steps:
 - (a) Preparing a solution of an *in-situ* gelling polymer selected from the group consisting of poly-D,L-lactide-coglycolide copolymer, poly-D,L-lactic acid-co-glycolic acid copolymer, polycaprolactone, polyanhydride, polyorthoester, and poly(α -hydroxybutyric acid) in a biocompatible solvent selected from the group consisting of dimethyl sulfoxide (DMSO), N-methyl pyrrolidine (NMP), triacetin and glycerin;
 - (b) Reconstituting the immunostimulatory complex in dry form in the solution of the *in-situ* gelling polymer in the biocompatible solvent.
53. The process of claim 52 wherein in step (b) the immunostimulatory complex in dry form used was obtained

WO 03/068169

PCT/US03/04711


by lyophilization.

54. The process of claim 52 wherein the biodegradable polymer is



wherein R1 is OH or alkoxy having 1 to 5 carbons and R2 is H; x:y is the ratio of each monomer unit of the copolymer with x+y=1.

55. The process of claim 54 wherein said biodegradable polymer is



wherein R1 is OH or alkoxy having 1 to 5 carbons and R2 is H; x:y is the ratio of each monomer unit of the copolymer with x+y=1.

56. The process of claim 55 wherein the copolymer has a molecular weight in the range of 2,000-100,000 daltons and an inherent viscosity of 0.1-1.0 dl/g.

WO 03/068169

PCT/US03/04711

57. The process of claim 56 wherein the copolymer has a molecular weight in the range of 2,000-100,000 daltons and an inherent viscosity of 0.1-1.0 dl/g.
58. The process of claim 52 wherein the weight of the biodegradable *in situ* gelling polymer dissolved in the biocompatible solvent is in the range of 5 w/w% to 50 w/w%.
59. The process of claim 53 wherein the weight of the biodegradable *in situ* gelling polymer dissolved in the biocompatible solvent is in the range of 5 w/w% to 50 w/w%.
60. The process of claim 52, wherein step (c) further comprises dissolving an oil soluble adjuvant selected from the group consisting of 3-O-desacyl-4'-monophosphoryl lipid A (MPL), N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), Dimethyldioctadecylammonium bromide (DDA), N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)propanediamine (Avridine), N-(2-Deoxy-2-l-leucylamino- β -D-glucopyranosyl)-N-octadecyl-dodecanoylamide hydroacetate (BAY-1005), 3 β -[N-(N,N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol), NAc-Mur-L-Thr-D-isoGln-sn-glycerol dipalmitoyl (Murapalmitine) and a cytokine selected from the group consisting of IL-1 β , IL-2, IL-12, IFN- γ and a derivative thereof in the biocompatible solvent.
61. The process of claim 53, wherein step (c) further comprises dissolving an oil soluble adjuvant selected from the group consisting of 3-O-desacyl-4'-monophosphoryl lipid A (MPL), N-acetyl-muramyl-L-alanyl-

D-isoglutamine (MDP), Dimethyldioctadecylammonium bromide (DDA), *N,N*-dioctadecyl-*N',N'*-bis(2-hydroxyethyl)propanediamine (Avridine), *N*-(2-Deoxy-2- β -leucylamino- β -D-glucopyranosyl)-*N*-octadecyl-dodecanoylamide hydroacetate (BAY-1005), 3β -[*N*-(*N,N'*-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol), NAc-Mur-L-Thr-D-isoGln-sn-glycerol dipalmitoyl (Murapalmitine) and a cytokine selected from the group consisting of IL-1 β , IL-2, IL-12, IFN- γ and mixtures and derivatives thereof in the biocompatible solvent.

62. A process for preparing a suspension comprising an immunostimulatory complex comprising the steps of:
- (a) Preparing an immunostimulatory complex of claim 1 in an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline;
 - (b) Preparing a suspension of a mineral salt selected from the group consisting of aluminum hydroxide, aluminum phosphate, and calcium phosphate, in an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline;
 - (c) Adding the immunostimulatory complex in the aqueous phase into an aqueous phase containing the mineral salt suspension;
 - (d) Mixing the immunostimulatory complex with the mineral salt suspension to form a mixed suspension.
63. A process for preparing a suspension comprising an immunostimulatory complex comprising the steps of:
- (a) Preparing a solution of a peptide immunogen selected from the group consisting of SEQ ID NOs: 3-13 in

- an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline; buffered saline;
- (b) Preparing a suspension of a mineral salt selected from the group consisting of aluminum hydroxide, aluminum phosphate and calcium phosphate in an aqueous phase selected from the group consisting of distilled deionized water, saline and phosphate buffered saline;
 - (c) Adding the peptide solution to the suspension of the mineral salt with mixing;
 - (d) Adding a CpG nucleotide selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2 with mixing to form a mixed suspension of an immunostimulatory complex and a mineral salt.
64. The process of claim 62, wherein the mineral salt is selected from the group consisting of Alhydrogel®, Adju-phos® and a mixture thereof.
65. The process of claim 63, wherein the mineral salt is selected from the group consisting of Alhydrogel®, Adju-phos® and a mixture thereof.
66. The process of claim 62, wherein the aqueous phase may further comprise a surfactant, a tonifier, a preservative or any combination thereof.
67. The process of claim 63, wherein the aqueous phase may further comprise a surfactant, a tonifier, a preservative or any combination thereof.
68. The process of claim 66 wherein the aqueous phase

comprises a tonifier selected from the group consisting of a PBS or saline and a mixture thereof.


69. The process of claim 67 wherein the aqueous phase comprises a tonifier selected from the group consisting of a PBS or saline and a mixture thereof.
70. The process of claim 66 further comprising adding to the aqueous phase a preservative selected from the group consisting of 2-phenoxy-ethanol and a derivative thereof.
71. The process of claim 67 further comprising adding to the aqueous phase a preservative selected from the group consisting of 2-phenoxy-ethanol and a derivative thereof.
72. The process of claim 62 further comprising adding to the aqueous phase an adjuvant selected from the group consisting of MPL, MDP, DDA, Avridine, BAY-1005, DC-Chol, Murapalmitine, PCPP, a saponin, a Cholera Toxin, a heat labile Enterotoxin from *E. Coli* and a cytokine selected from the group consisting of IL-1 β , IL-2, IL-12, IFN- γ and a derivative thereof.
73. The process of claim 63 further comprising adding to the aqueous phase an adjuvant selected from the group consisting of MPL, MDP, DDA, Avridine, BAY-1005, DC-Chol, Murapalmitine, PCPP, a saponin, a Cholera Toxin, a heat labile Enterotoxin from *E. Coli* and a cytokine selected from the group consisting of IL-1 β , IL-2, IL-12, IFN- γ and a derivative thereof.
74. A pharmaceutical composition comprising a suspension of an immunostimulatory complex of any one of claim 1 to 23

in an aqueous solvent selected from the group consisting of distilled deionized water, saline and phosphate buffered saline.

75. A pharmaceutical composition comprising a water-in-oil emulsion of an immunostimulatory complex of any one of claim 1 to 23.
76. A pharmaceutical composition according to claim 74 further comprising an adjuvant selected from the group consisting of MPL, MDP, DDA, Avridine, BAY-1005, DC-Chol, Murapalmitine, PCPP, a saponin, a Cholera Toxin, a heat labile Enterotoxin from *E. Coli* and a cytokine selected from the group consisting of IL-1 β , IL-2, IL-12, IFN- γ and a derivative thereof.
77. A pharmaceutical composition comprising a gel of an immunostimulatory complex of any one of claim 1 to 23 wherein the gel is formed *in situ* by adding the immunostimulatory complex in dried form to a solution of an *in-situ* gelling biocompatible polymer selected from the group consisting of poly-D,L-lactide-coglycolide copolymer, poly-D,L-lactic acid-co-glycolic acid copolymer, polycaprolactone, polyanhydride, polyorthoester, and poly(α -hydroxybutyric acid) in a biocompatible solvent selected from the group consisting of dimethyl sulfoxide (DMSO), N-methyl pyrrolidine (NMP), triacetin and glycerin.
78. The pharmaceutical composition of claim 77 wherein the biodegradable polymer is

WO 03/068169

PCT/US03/04711



wherein R1 is OH or alkoxy having 1 to 5 carbons and R2 is H; x:y is the ratio of each monomer unit of the copolymer with x+y=1.

79. The pharmaceutical composition of claim 78 wherein the biodegradable polymer has a molecular weight in the range of 2,000-100,000 daltons and an inherent viscosity of 0.1-1.0 dl/g.
80. A pharmaceutical composition comprising an aqueous suspension of a mineral salt and an immunostimulatory complex of any one of claim 1 to 23 wherein the mineral salt is selected from group consisting of aluminum hydroxide, aluminum phosphate, aluminum sulphate, calcium phosphate.
81. The pharmaceutical composition of claim 80 wherein the aluminum hydroxide is selected from the group consisting of Alhydrogel® and Adju-phos®.
82. The pharmaceutical composition of claim 80 wherein the aqueous phase is selected from the group consisting of distilled deionized water, saline, PBS and a mixture thereof.
83. The pharmaceutical composition of claim 80 further

comprising a preservative selected from the group
consisting of 2-phenoxy-ethanol and a derivative thereof
in the aqueous phase.

WO 03/068169

PCT/US03/04711

SEQUENCE LISTING

<110> Sokoll, Kenneth K.
Sokoll, Kenneth K.

<120> Stabilized Synthetic Immunogen Delivery System

<130> Immunogen Delivery System

<150> US 10/076674

<151> 2002-02-14

<160> 13

<170> PatentIn version 3.1

<210> 1

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide

<400> 1
tcgtcgtttt gtcgttttgt cgttttgtcg tt
32

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n indicates phosphorothioate group

<400> 2
tcgtcgtttt gtcgttttgt cgtt
24

14 August 2006

WO 03/068169

PCT/US03/04711

<210> 3
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 3
tcgtcgtttt gtcgttttgt cggt
24

<210> 4
<211> 50
<212> PRT
<213> Human

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa indicates epsilon-Lys

<400> 4

Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
1 5 10 15

Ile Leu Phe Xaa Cys Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser
20 25 30

Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly
35 40 45

Asn Cys
50

<210> 5
<211> 50
<212> PRT
<213> Human

<220>

14 August 2006

WO 03/068169

PCT/US03/04711

<221> misc_feature
<222> (20)..(20)
<223> Xaa indicates epsilon-Lys

<400> 5

Lys Lys Lys Thr Asp Arg Val Ile Glu Val Leu Gln Arg Ala Gly Arg
1 5 10 15

Ala Ile Leu Xaa Cys Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser
20 25 30

Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly
35 40 45

Asn Cys
50

<210> 6
<211> 31
<212> PRT
<213> Human

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa indicates epsilon-Lys

<400> 6

Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
1 5 10 15

Ile Leu Phe Xaa Cys His Ala Ser Ile Tyr Asp Phe Gly Ser Cys
20 25 30

<210> 7
<211> 27
<212> PRT
<213> Human

14 August 2006

WO 03/068169

PCT/US03/04711

<400> 7

Lys Lys Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu
1 5 10 15

Leu Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
20 25

<210> 8

<211> 45

<212> PRT

<213> Human

<400> 8

Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gln Phe
1 5 10 15

Gly Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu
20 25 30

Glu Gly Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
35 40 45

<210> 9

<211> 45

<212> PRT

<213> Human

<400> 9

Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gln Phe
1 5 10 15

Gly Gly Leu Ser Glu Ile Lys Gly Val Ile Val His Arg Leu Glu Gly
20 25 30

Val Gly Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
35 40 45

14 August 2006

WO 03/068169

PCT/US03/04711

<210> 10
<211> 44
<212> PRT
<213> Human

<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa indicates epsilon-Lys

<400> 10

Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile Thr Ile Ile Thr Thr
1 5 10 15

Ile Asp Xaa Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro His
20 25 30

Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
35 40

<210> 11
<211> 45
<212> PRT
<213> Human

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa indicates epsilon-Lys

<400> 11

Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
1 5 10 15

Ile Leu Phe Xaa Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro
20 25 30

His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys

WO 03/068169

PCT/US03/04711

35

40

45

<210> 12
 <211> 65
 <212> PRT
 <213> Foot-and-mouth disease virus

<400> 12

Ile Ser Ile Ser Glu Ile Lys Gly Val Ile Val His Lys Ile Glu Thr
 1 5 10 15

Ile Leu Phe Lys Tyr Asn Gly Ser Cys Lys Tyr Ser Asp Ala Arg Val
 20 25 30

Ser Asn Cys Arg Gly Asp Leu Gln Arg Gly Asp Leu Gln Val Leu Ala
 35 40 45

Gln Lys Ala Glu Arg Cys Leu Pro Ser Ser Phe Asn Tyr Gly Ala Ile
 50 55 60

Lys
 65

<210> 13
 <211> 65
 <212> PRT
 <213> Foot-and-mouth disease virus

<400> 13

Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Lys Ile Glu Thr
 1 5 10 15

Ile Leu Phe Lys Tyr Asn Gly Ser Cys Lys Tyr Ser Asp Ala Arg Val
 20 25 30

Ser Asn Val Arg Gly Asp Leu Gln Arg Gly Asp Leu Gln Val Leu Ala
 35 40 45

14 August 2006

WO 03/068169

PCT/US03/04711

Gln Lys Ala Glu Arg Cys Leu Pro Thr Ser Phe Asn Tyr Gly Ala Ile
50 55 60

Lys
65